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1 List of abbreviations 
APC  Antigen Presenting Cell 
AJCC  American Joint Committee on Cancer 
CA  Carbonic anhydrase 
CD  Cluster of Differentiation 
CFSE  Carboxyfluorescein succinimidyl ester 
COX-2 Cyclooxygenase-2 
CTLA-4 Cytotoxic T Lymphocyte Antigen-4 
ER  Estrogen receptor 
ESTDAB European Searchable Tumour Line Database 
FoxP3 Forkhead box P3 
GDF-15 Growth/differentiation factor-15 
GM-CSF Granulocyte-Monocyte Colony Stimulation Factor 
gp100  Glycoprotein 100 
HER2  Human epidermal growth factor receptor-2 
HIF-1 Hypoxia inducible factor-1  transcription factor 
HLA-DR Human leukocyte antigen-DR 
HSP  Heat Shock Protein 
ICS  Intracellular cytokine staining 
IDO  Indolamin – 2,3 - Dioxygenase 
IL-  Interleukin- 
IFN-  Interferon-gamma 
LDH  Lactate dehydrogenase 
mDC  Myeloid Dendritic Cell 
MDSC Myeloid-derived suppressor cell 
MUC1  Mucin 1 
NK cell Natural Killer cell 
NKT cells Natural Killer T cells  
NO  Nitric oxide 
NY-ESO-1 New York Esophageal Squamous Cell Carcinoma-1 
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PBMC Peripheral Blood Mononuclear Cell 
pDC  Plasmacytoid Dendritic Cell 
PD-1  Programmed Cell Death-1 
PD-L1  Programmed Cell Death Ligand-1 
PGE2  Prostaglandin E2 
PR  Progesterone receptor 
ROS  Reactive Oxygen Species 
STAT3 Signal transducer and activator of transcription 3 
SUR  Survivin 
TAA  Tumour-associated antigen 
TSCN  Stem memory T cells 
TEMRA Terminally differentiated effector memory cells  
TGF- Transforming growth factor-beta 
TNF  Tumour Necrosis Factor 
Treg  Regulatory T cell 
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2 Abstract 
In addition to conventional surgery, chemotherapy and radiotherapy, 
immunotherapy holds a great deal of promise as an effective form of cancer 
treatment. This utilises the patient’s own immune system to control tumour growth 
and thus relies on the presence of immune cells which can recognise and 
subsequently kill or otherwise control cancer. This notion is supported by many 
studies showing that the presence of T cells recognising tumour-associated 
antigens (TAAs) is associated with superior survival in a number of cancer types. 
In contrast, cancer patients with high levels of immune suppressor cells experience 
worse survival and respond more poorly to therapy. These studies demonstrate 
that the balance between different immune populations is closely associated with 
clinical outcome. Therefore, the aim of the work in this thesis was to identify new 
blood- and tissue-based prognostic markers that more accurately predict patient 
outcome. Monitoring patients for their possession of TAA-reactive T cells may be 
important for this, but standardising such biological assays is challenging. 
Therefore, the first part of this work attempted to identify surrogate markers that 
may more easily identify patients with beneficial T cell responses. To achieve this, 
T cells reactive to the shared TAAs MUC1, survivin and HER2 were measured in a 
cohort of breast cancer patients and were investigated for association with a broad 
set of immunological parameters. Considering HLA type, serum cytokines, tumour-
infiltrating leukocytes and blood leukocyte populations, the latter were found to be 
the most informative for identifying patients with such antigen-reactive T cells. 
Moreover, by constructing composite immune profiles, we were able to achieve a 
sensitivity and specificity of up to 100 % for the identification of patients possessing 
these antigen-reactive T cells. In addition to predictive immune markers in the 
periphery, a number of studies has shown that the immune status within the 
tumour plays a major role in cancer progression. Therefore the second part of this 
work investigated immune features in the tumour microenvironment which may 
serve as prognostic markers for patient survival. Unlike in the majority of prior 
studies which only considered one type of immune feature, for example only 
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leukocytes or only cytokines, this study assessed a combination of diverse immune 
parameters in the tumour microenvironment including lymphoid and myeloid cells, 
secreted cytokines and transcription factors. This investigation showed that 
patients whose tumours had high relative levels of putatively suppressive CD15+ 
cells had shorter overall survival. Furthermore, by combining the assessment of 
CD3+ and CD15+ cells, it was observed that patients with high levels of CD3+ T 
cells and low levels of CD15+ cells survived the longest. Other studies have 
yielded similar results regarding the impact of the state of the immune system on 
clinical outcome. These studies have shown that one of the mechanisms employed 
by melanoma to escape anti-tumour immunity is the induction of 
immunosuppressive myeloid-derived suppressor cells (MDSCs), the levels of 
which correlate with clinical outcome. The mechanisms by which tumour cells 
induce MDSCs remain unknown, but knowledge thereof may pave the way for new 
forms of cancer therapy. Therefore, an in vitro co-culture model was developed to 
uncover tumour-immune interactions, with the aim of identifying pathways that 
allow the induction of such suppressive cells to be prevented. The implementation 
of a three-way co-culture system employing melanoma cells, activated T cells and 
monocytes (precursors of MDSCs) allowed the re-creation of MDSC-induced 
immune suppression in vitro. Subsequent targeting of specific molecular pathways 
in melanoma cells revealed that proteins involved in cellular stress pathways (heat 
shock proteins) are involved in triggering the differentiation of normal monocytes 
into MDSCs. These studies show that the levels of immune populations in the 
periphery and in the tumour can be used to monitor the clinical course of cancer 
patients. Furthermore, this work identifies new mechanisms of immune 
suppression by revealing novel pathways used by tumour cells to suppress the 
immune system. 
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3 Zusammenfassung 
Bei der Behandlung solider Tumore gilt die Immuntherapie zurzeit als einer der 
vielversprechendsten Therapieansätze. Hierbei macht man sich die Fähigkeit von 
patienteneigenen Immunzellen zu Nutze, Tumorzellen nach Stimulation zu 
erkennen und anschließend zu eliminieren. So konnte bereits bei mehreren 
Entitäten eine längere Überlebenszeit bei denjenigen Patienten festgestellt 
werden, deren Tumore antigen-reaktive T-Zellen aufweisen. Da es sich bei der 
Erfassung solcher T-Zell vermittelten Reaktionen jedoch um kosten- und vor allem 
arbeitsintensive Verfahren handelt, haben diese Untersuchungen noch keinen 
Einzug in die klinische Routine gehalten. Im Fokus dieser Arbeit stand daher unter 
anderem die Suche nach Biomarkern, welche die Identifizierung derjenigen 
Patienten erlaubt, die solch klinisch relevanten Antigen-reaktive T Zellen besitzen. 
Im ersten Screening wurden HLA Typen, Serumzytokine, Tumor-infiltrierende 
Leukozyten und Blutleukozyten gemessen, wobei sich Blutleukozyten als am 
geeignetsten für die Identifizierung von Patienten mit solchen Antigen-reaktiven T 
Zellen erwiesen. Durch die Kombination verschiedener Parameter konnte darüber 
hinaus eine 100-prozentige Sensitivität und Spezifität bei der Identifizierung von 
Patienten mit reaktiven Zellen erreicht werden. Jedoch scheinen nicht nur die 
Immunzellen der Peripherie allein eine wichtige Rolle für den Tumor zu spielen, 
zusätzlich scheint die zelluläre Zusammensetzung des Tumorgewebes selbst 
maßgeblich dessen Wachstum zu beeinflussen. Die Identifizierung von zellulären 
und löslichen Faktoren innerhalb des Tumors, welche eine prognostische Rolle in 
Melanom Patienten haben, war daher ein weiterer Schwerpunkt der vorliegenden 
Arbeit. Hier zeigte sich, dass Patienten mit einer starken Infiltration von potentiell 
suppressiven CD15+ Zellen, als auch Patienten mit schwacher Infiltration von 
CD3+ und starker Infiltration von CD15+ Zellen ein geringeres Gesamtüberleben 
aufwiesen. 
Ein weiterer Hinweis für die Relevanz des Immunsystems hinsichtlich des 
Überlebens zeigten weitere Studien, in denen ein erhöhtes Level an 
immunsuppressiven MDSCs mit einem verkürzten Überleben der Patienten 
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assoziiert war. So ist von Melanom Zellen bekannt, dass sie die Fähigkeit besitzen 
immunsuppressive MDSCs zu induzieren, wobei allerdings wenig über den 
zugrunde liegenden Mechanismus bekannt ist. Wir untersuchten daher in einem 
Zellkulturmodel die Wechselwirkungen zwischen Tumor und Immunzellen mit dem 
Ziel, die Induktion immunsuppressiver Zellen zu blockieren. Hierbei zeigte sich, 
dass molekulare Signalwege, welche in Stresssituationen relevant sind, für die 
Differenzierung von MDSCs verantwortlich sind. Durch die Hemmung dieser 
Signalwege lässt sich die Differenzierung von immunsuppressiven Zellen 
blockieren, womit sich Möglichkeiten für vielversprechende therapeutische Ansätze 
ergeben. 
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7 Introduction 
Cancer is a leading cause of death worldwide where it accounts for approximately 
16 % of all deaths. This equates to 8.8 million people who died from cancer in 
2015, with 70 % of deaths in low- or middle-income countries 1. The main 
characteristic of cancer is the uncontrolled growth of abnormal cells resulting in: 
repression of normal cells, invasion into adjacent tissue, the spread to distant 
organs and metastasis being the major cause of death from cancer 2. Normally, 
cell proliferation and function is strictly regulated. However, in cancer this 
regulation is lost due to the accumulation of genetic mutations. However, mutation 
in a single gene does not usually cause cancer, which requires multiple steps 
typically consisting of genetic mutations in a number of different genes that include 
gain of function mutations in proto-oncogenes and loss of function mutations in 
tumour suppressor and DNA repair genes 3. Such mutations can be caused by a 
diverse range of factors, including physical or chemical carcinogens such as 
irradiation or components of tobacco smoke but also by biological factors such as 
infections with certain viruses 1. With the accumulation of such mutations a normal 
cell transforms into a precancerous cell which eventually leads to cancer. During 
this process, cancer cells acquire traits including sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
reprogramming energy metabolism, evading immune destruction, inducing 
angiogenesis and activating invasion and metastasis 4,5. 
7.1 Breast cancer  
All forms of cancer resulted in 14.1 million cases being diagnosed in 2012, with the 
majority being cancer of the lung, breast and colon. Breast cancer represents the 
second most common form, account for 12 % of all cancers. In women, it is the 
most common cancer, representing with 25 % of all cancer types 6. Over the past 
few decades the incidence of breast cancer increased, while the death rate has 
significantly decreased. This is attributed to earlier discovery and subsequent 
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improvements in therapy 7. Despite this, it is still the most leading cause of death in 
women, with approximately 522 000 deaths in 2012 6.  
Breast cancer is heterogeneous genetically and clinically, with several histological 
and molecular subtypes being identified. The subtype classification is of great 
importance for prognosis and prediction of response to chemotherapy and 
endocrine therapy 8. It can be broadly categorised into in situ carcinoma and 
invasive carcinoma. The in situ breast carcinoma most commonly begins in the 
lining of the milk ducts or in the lobules of the breast and are therefore referred to 
as ductual or lobular carcinoma. If the cancer cells then spread into surrounding 
tissue of either breast ducts or lobules, it is then referred to as invasive ductal 
carcinoma or invasive lobular carcinoma 9. In addition to traditional 
clinicopathological variables, including tumour size, tumour grade and nodal 
involvement, immunohistochemistry markers such as the hormone receptors, 
estrogen (ER) and progesterone (PR) as well as the expression of human 
epidermal growth factor receptor-2 (HER2) are analysed in order to further 
characterise breast cancer. Based on this, breast tumours can be further 
categorised into at least three major subtypes: luminal, HER2+ and basal like 10,11. 
This is of great importance, as each subtype has different risk factors for incidence, 
response to treatment, risk of disease progression and different preferential organ 
sites of metastasis. Based on this knowledge, treatment can be customised in 
order to improve disease-specific survival 12. Thus, luminal tumours positive for the 
hormone receptors ER and PR consequently often respond well to hormone 
therapies. HER2+ tumours have an amplification of the ERBB2 oncogene and 
overexpress HER2. This subtype can be treated with anti-HER2 therapies. In 
contrast, basal-like tumours neither express hormone receptors nor do they 
express HER2 and are therefore known as triple-negative breast cancer. These 
properties result in triple negative tumours being insensitive to some of the most 
effective therapies available for breast cancer including anti-HER2 and endocrine 
therapies. Although only a minority of breast cancer is categorised as triple-
negative, it is an aggressive form whereby only 20 % of patients respond to 
chemotherapy 13. Therefore, there is a need to develop better therapies and to 
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identify biomarkers that can be used to select which patients should receive which 
treatment in order to improve disease outcome.  
7.2 Malignant melanoma 
In contrast to breast cancer, melanoma is relatively rare with 232 000 newly 
diagnosed cases throughout the world in 2012, only representing 1.7 % of all 
cancer types. However, according to the US National Cancer Institute, the 
incidence rate of melanoma has more than doubled since 1975 – with 7.5 new 
cases per 100 000 in 1975 versus 25 per 100 000 in 2014 14. This is a more rapid 
increase in the incidence rate compared to any other solid tumour type 14,15. The 5-
year survival rate for primary melanoma of the skin is about 92 %. However, 
looking at late stage melanoma, the 5-year survival rate drops dramatically to 15 % 
- 20 % 1. As with many other cancers, patient outcome depends on the tumour 
stage at diagnosis. According to the American Joint Committee on Cancer (AJCC), 
melanoma can be classified into stages I – IV by characteristics of the primary 
tumour (T) (thickness, ulceration, mitotic rate), involvement of locoregional lymph 
nodes and soft tissue metastases (N) (microscopic vs macroscopic lesions) and 
the presence of distant metastases (M) (serum concentration of lactate 
dehydrogenase and localization of metastases) 16. In stage I melanoma, the 
tumour is restricted to the dermal layer with a 5-year survival rate of 90 – 95 %. 
With progressing disease, tumour size increases, loco-regional metastases 
develop and finally the tumour spreads into distant organs, typically accompanied 
by high serum LDH levels. The latter is defined as stage IV melanoma with a 5-
year survival probability of 15 – 20 % 16–18. However, with the introduction of new 
treatment approaches such as immunotherapies or targeted therapies, 5-year 
survival of metastatic melanoma patients may rise to as high as 35 % 19.  
7.3 Immune system and Cancer 
The role of the immune system in cancer has been discussed for more than a 
century, starting with Paul Ehrlich who first proposed the idea that the immune 
system could repress carcinomas, which would otherwise occur at higher 
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frequencies. Burnet and Thomas then further postulated a protective role of the 
immune system according to the theory of cancer immune surveillance, suggesting 
that lymphocytes can recognise and eliminate continuously arising transformed 
cells 21,22. However, despite the notion that the host immune system can provide 
protection from cancer, it has been shown that it may also be involved in tumour 
progression. Therefore, the hypothesis of cancer immune surveillance was 
modified into the concept of immunoediting, dividing the process from immune 
surveillance to tumour escape into three phases (Elimination, Equilibrium and 
Escape) 20. Immune surveillance occurs during the elimination process. In the 
equilibrium phase, the immune system prevents tumour growth as well as 
promotes tumour cell variants with reduced immunogenicity. These cells are then 
able to develop mechanisms to escape immune control and enter the last “escape” 
phase in which cancer cells grow in an uncontrolled manner 20.  
7.4 Immunosuppression 
Immunosuppression by cancer cells can be mediated by multiple mechanisms in 
order to avoid being recognised or attacked by the immune system. Blocking these 
mechanisms of immunosuppression and understanding components and the 
mechanisms responsible for suppression of anti-tumour immune response are of 
great interest in order to increase the efficacy of immunotherapies.  
One mechanism used by tumours to avoid T cell recognition is changing the 
antigenic profile. This occurs during immune selection against tumour cells 
expressing immunologically relevant epitopes, therefore leaving those behind 
which are not recognised by T cells of the adaptive immune system 23. This leads 
to a selection of tumour cells highly resistant to T cell responses, thus supporting 
tumour growth. In addition, tumours can down-regulate and mutate their antigen 
processing machinery resulting in impaired antigen presentation and thus immune 
evasion from T-cell responses 24. Furthermore, immunosuppressive cytokines, 
chemokines and growth factors are either synthesised by tumour or stromal cells. 
For example, TGF- is a cytokine capable of inhibiting T-cell activation, 
proliferation and differentiation 25 and high serum levels are associated with poor 
clinical outcome in several types of cancer 26–29. Several other cytokines have been 
Introduction 
17 
 
identified that impair anti-tumour immune response by directly acting on T cells or 
by recruiting or expanding regulatory cells like regulatory T cells (Tregs) or myeloid 
derived suppressor cells (MDSCs). Although Tregs were originally described as 
regulators for preventing organ-specific autoimmune disease, several studies 
suggest an important role in anti-tumour immune responses and their involvement 
in tumour growth and progression. In multiple malignancies, including breast and 
skin cancer, an accumulation of Tregs has been shown in either the circulation or 
the tumour itself 30–33, the levels of which are associated with poor overall survival 
34. Supporting the role of Tregs in preventing anti-tumour immune responses, 
studies targeting these cells have been shown to improve the efficacy of 
immunotherapy 35–37. More recently, another regulatory cell type, the MDSC, has 
gained great attention due to its pro-tumoural and immunosuppressive activity 38,39.  
7.5 Myeloid derived suppressor cells (MDSCs) 
Myeloid cells may be terminally differentiated cells including dendritic cells, 
macrophages and granulocytes, however, in the case of cancer a typical high 
inflammatory environment induces a higher than normal level of immature myeloid 
cells which have immunosuppressive properties. Due to their suppressive nature 
and myeloid origin, these cells are called myeloid-derived suppressor cells 40,41. 
Regarding their characterisation, in humans no definite phenotype has been 
identified so far, although a combination of different markers has been reported to 
mark these cells. They are negative for the lineage markers of T cells (CD3), B 
cells (CD19) and natural killer cells (CD56) and always positive for myeloid 
markers including CD11b and CD33 with low expression of human leukocyte 
antigen-DR (HLA-DR) 42,43. In addition to these markers, MDSCs can be further 
distinguished based on the expression of CD14 and CD15 - granulocytic MDSCs 
express CD15 and lack CD14 while monocytic MDSCs can be defined by their 
CD14 expression.  
Recently, MDSCs gained a great deal of attention for their role in cancer. Due to 
their suppressive activity, MDSCs represent a major barrier in effective cancer 
therapy. In support of this, melanoma patients with high relative levels of MDSCs 
experience shorter overall survival and respond more poorly to immunotherapy 
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with the anti-CTLA-4 antibody ipilimumab 44,45. Mechanisms of MDSC-mediated 
immunosuppression include (1) depletion of nutrients required for T cell activation, 
(2) generation of oxidative stress (3) cleavage of L-selectin on naïve T cells 
required for homing and activation of T cells and (4) induction of Tregs. These 
mechanisms of immunosuppression might represent potential targets for 
therapeutic intervention. Studies targeting pathways associated with MDSC-
mediated immunosuppression (including arginase, ROS, COX-2 and STAT3) may 
restore T cell proliferation in co-culture experiments. In addition to blocking the 
suppressive activity of MDSCs, it might also be possible to prevent the 
differentiation of myeloid cells into MDSCs or to induce the differentiation of 
MDSCs into non-suppressive cells. Recently, Mao et al. have shown that co-
culturing CD14+ monocytes from healthy individuals with melanoma cells results in 
the induction of monocytes with an MDSC-like phenotype possessing suppressive 
activity 46. These data suggest that either cell-cell contact or soluble factors 
produced by melanoma cells are able to induce the differentiation of MDSCs. 
Several soluble factors have already been identified to be involved in the 
differentiation of monocytes into suppressive MDSCs, including GM-CSF, IL-6 and 
PGE2 47–53. In addition, upstream signalling pathways like COX2 and STAT3 have 
also been identified to be involved in the differentiation and suppressive function of 
MDSCs 46–48. Targeting these pathways resulted in restored T cell proliferation 
after treating melanoma-educated monocytes or patient-derived MDSCs with 
different inhibitors. These data suggest that combining agents that block the 
differentiation or suppressive function of MDSCs with current immunotherapeutic 
strategies may be a useful approach that could result in more efficacious 
treatment. 
7.6 Tumour microenvironment 
The tumour microenvironment consists of tumour cells, fibroblasts, myofibroblasts, 
blood and lymph vessels as well as tumour-infiltrating immune cells, chemokines 
and cytokines, with each component contributing to either tumour suppression or 
tumour development and progression 55. Among non-immune components, 
tumour-associated fibroblasts are involved in the formation and remodelling of the 
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extracellular matrix as well as in the supply of factors which promote the growth of 
cancer cells 54. With increasing tumour mass, the formation of new blood vessels is 
required to supply sufficient oxygen and nutrition, and this also provides routes for 
local invasion and distant metastases. Especially the role of immune factors in 
tumour progression and control has gained more and more attention recently. 
Analysis of the tumour microenvironment of several cancer types revealed that 
many or most tumours are infiltrated by T cells. In colorectal cancer, intra- and 
peritumoural infiltration with CD8+ T cells has been shown to have greater 
prognostic power than the standard clinical staging system for predicting post-
operative survival 56–58. Such associations between the level of tumour-infiltrating 
lymphocytes and clinical outcome have been also shown in several other cancer 
types 59–62. Although high infiltration with T lymphocytes is generally associated 
with good prognosis, tumour progression is still frequently seen despite the 
presence of high levels of such intra-tumoural immune cells. This suggests that 
factors such as suppressive cells within the tumour microenvironment impair the 
function of these beneficial immune cells. Indeed, studies have shown that 
infiltration by MDSCs or regulatory T cells promotes tumour progression via 
multiple suppressive mechanisms. These cells dampen beneficial anti-tumour 
immune responses by both innate and adaptive immune cells. In addition to 
cellular components of the tumour microenvironment, soluble factors may also alter 
anti-tumour immune responses. In support of this, studies have shown that soluble 
immune molecules in the tumour microenvironment such as PGE2 or IL-6, 
correlate with patient survival 63,64 and influence the migration, differentiation and 
functional state of infiltrating immune cells 67. As well as providing prognostic 
information relating to patient survival, the assessment of the intra-tumoural 
immune context can also assist in predicting which patients will respond to certain 
forms of therapy, something of great importance in clinical patient management. 
Consistent with this, analysis of the tumour microenvironment revealed an 
association between the density of tumour-infiltrating T cells and clinical response 
to PD-1 antibodies 65. 
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7.7 Immunotherapy 
Based on the current knowledge of the immune system and its role in tumour 
defence, an approach in cancer therapy, referred to as immunotherapy, was has 
been established. This form of therapy aims to boost the host’s immune system, 
re-enabling it to effectively target and destroy malignant cells. Numerous studies 
have been conducted to develop treatment approaches with different mechanisms 
of action including monoclonal antibodies, adoptive immunotherapies or cancer 
vaccines targeting different tumour-associated antigens. Encouraging results were 
observed in breast cancer when HER2-positive patients were treated with the 
monoclonal antibody trastuzumab targeting HER2. Until then, HER2-positive 
breast cancer patients had the worst overall survival and recurrence-free survival 
compared to all other types including triple-negative breast cancer 66. With the 
introduction of trastuzumub the median survival of HER2-positive breast cancer 
patients was increased up to 25.1 months compared to 20.3 months in the group of 
patients receiving chemotherapy alone 68. However, as a passive immunotherapy, 
therapeutic effect will be achieved only during the administration of the antibody. In 
contrast active immunotherapy strategies potentially induce long-term immune 
activation even after treatment has been completed. Breakthrough results were 
achieved in metastatic melanoma patients treated with a monoclonal antibody 
called ipilimumab, which targets cytotoxic T lymphocyte antigen-4 (CTLA-4) 
expressed on T cells. In patients with unresectable metastatic melanoma 
vaccinated with the tumour-associated antigen glycoprotein 100, an improved 
overall survival of 10.1 months was achieved with ipilimumab, compared to 6.4 
months in the group of patients treated with vaccine alone 69. Later studies 
targeting another “checkpoint” molecule, programmed death-1 (PD-1) or 
programmed death-ligand 1 (PD-L1) have demonstrated superior clinical 
responses compared with ipilimumab in melanoma. There are also promising 
results in other cancer types 70–75. Similarly, cancer vaccines also aim to prime or 
boost immune responses against tumour cells, and both approaches have been 
shown to stimulate T cell responses resulting in clinical tumour regression or 
prolonged patient survival 76,77.  
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Despite these encouraging advances in cancer therapy, not every patient is equally 
likely to benefit from a certain form of therapy. The effectiveness of such 
treatments is presumably based on T cell responses against tumour-associated 
antigens (TAAs) expressed by cancer cells, allowing these T cells to kill or 
otherwise inhibit tumour cells and induce tumour regression.  
7.8 Antigen-reactive T cells 
The immune system can distinguish non-transformed cells from cancer cells by 
differential recognition of certain proteins. However, these targets for the immune 
system are not necessarily cancer cell-specific and as such can also be found on 
normal tissue. Therefore, molecules that are more commonly found on cancer cells 
give rise to so-called tumour-associated antigens (TAA). These proteins can be 
products of (1) aberrantly expressed genes such as HER2, which is also 
expressed in non-transformed cells but at lower levels (2) genes encoding viral 
products like the human papillomavirus proteins (3) mutated cellular genes such as 
p53, (4) molecules that are expressed during certain stages of development like 
melanocyte antigen (Melan-A) or (5) molecules that are expressed in germ cells of 
the testis and ovary but are silent in non-transformed somatic cells, like NY-ESO-1. 
One of the most extensively studied TAAs in breast cancer is HER2. This protein is 
overexpressed in approximately 20 – 30 % of breast carcinomas and is correlated 
with greater tumour aggressiveness and poor prognosis 78. Since HER2 is a cell 
surface molecule, it represents a good target for cancer therapy with antibodies. 
Indeed, as noted above, treatment with anti-HER2 monoclonal antibody was 
associated with longer time to progression, higher response rate, longer response 
duration and improved overall survival 68. Because antibody-based therapies rely 
on the expression of the targeted molecule at a certain expression level on the 
relevant cell type, vaccination that induces or stimulates pre-existing anti-HER2 
immune responses might result in superior therapeutic response. In support of this, 
Bailur et al. observed that breast cancer patients who possessed HER2-reactive 
CD8+ T cells experienced improved overall survival 79. In Phase I/II clinical trials 
aiming to elicit T cell responses to HER2 vaccines in breast cancer patients, partial 
clinical responses were observed 80,81. 
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8 Thesis aims  
The primary aims of this thesis were 1) to identify new blood or tissue-based 
prognostic markers in melanoma and breast cancer, and 2) to develop a better 
understanding of interactions between tumour cells and cells of the immune 
system, with the aim of understanding mechanisms of tumour-induced immune 
suppression and identifying potential therapeutic targets in melanoma. In breast 
cancer patients, the presence of HER2-reactive CD8+ T cells had previously been 
shown to be associated with superior overall survival. Therefore, the current project 
investigated whether T cells which recognise other tumour-associated antigens 
may also act as prognostic markers. This project increased the number of 
candidate antigens tested to include the tumour-associated antigens MUC1 and 
Survivin, in addition to attempting to validate the previous results for HER2. 
Because the measurement of antigen-reactive T cells is costly, time intensive and 
technically challenging they are not used as a part of routine clinical monitoring. 
Therefore, this study sought to identify surrogate markers which may more easily 
be used to indicate the presence of these cells. The identification of surrogate 
markers may also provide a better understanding of the immune states favourable 
to the presence of these cells, thus improving our understanding of breast cancer 
immunobiology. While this project in breast cancer was especially focused on the 
immune profile in peripheral blood, the project in melanoma was focused on 
identifying immune features in the tumour microenvironment which may serve as 
prognostic markers. Here, diverse immune parameters covering both soluble and 
cellular features in the tumours of melanoma patients were assessed. Using 
immunofluorescence, protocols for the detection of T cells, myeloid cells and a 
panel of soluble immune factors were established. These factors were then 
quantified in tumour tissue and investigated for relationship with patient clinical 
features.  
It is being ever more appreciated that immune suppressive cells are of great 
clinical importance in melanoma, for example they have been shown to correlate 
with patient survival and to impair the efficacy of immunotherapy. Melanoma cells 
Thesis aims 
23 
 
have been shown to induce such myeloid cells with immune suppressive activity in 
vitro, but little is known regarding how melanoma cells convert healthy cells into 
immune suppressive cells. Therefore, unlike in the prior observational studies, a 
subsequent project in melanoma involved the development of an in vitro model to 
investigate interactions between melanoma and immune cells, with the aim of 
identifying potential new therapeutic targets that can prevent tumour-induced 
suppression of the immune system, which may have the additional benefit of 
enhancing the efficacy of immunotherapy. 
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9 Results and Discussion  
9.1 Publication 1 
Peripheral T cell responses to tumour antigens are associated with molecular, 
immunogenetic and cellular features of breast cancer patients 
 
Previously, our group demonstrated an association of peripheral HER2-reactive T 
cells with superior survival in breast cancer patients 79. The present study analysed 
patient features associated with the presence of such T cell responses to tumour 
antigens, with the goal of identifying biomarkers that may be routinely used to 
select breast cancer patients with responses to tumour antigens. Surrogate 
markers for antigen-reactive T cells may be more easily implemented into routine 
clinical practice compared to the complex and expensive protocol required to 
measure them directly. The introduction of routine detection of such tumour-
antigen reactive T cells may improve therapeutic management of breast cancer 
patients. This study included analysis of (1) the type of reactive T cell (CD4+ or 
CD8+) and (2) the produced cytokine pattern (interferon- (IFN-), TNF-α, IL-2, IL-
4, IL-10 and IL-17 was simultaneously measured in the same cell) of T cells 
reactive to HER2, MUC1 and Survivin antigens using intracellular cytokine staining 
(ICS) (3) immunogenetic factors (HLA type), (4) soluble signalling molecules in 
serum using Luminex-based technology, as well as immune cells (5) in the 
peripheral blood using immunophenotyping (monocytes, MDSCs, pDCs, mDCs, T 
cells and NK cells) and (6) within the tumour using immunohistochemistry (CD4, 
CD8, FoxP3 and CD163). 
Cryopreserved PBMCs from 50 patients with non-metastatic invasive carcinoma 
were collected at the St. Savas Cancer Hospital in Athens between February 2014 
and May 2015, one day prior to surgery. The study included women with an age 
range of 27–78 (median age 56 years) with early stage non-metastatic invasive 
ductal carcinoma. Patients with AJCC stages 1, 2A, 2B, 3A and 3C were included, 
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while patients with tumours extending to the chest wall as well as AJCC stages 3B 
and 4 were excluded.  
Although only 30 % of patient tumours overexpressed HER2, almost every patient 
possessed T cells responding to HER2 (96 %) (Fig. 1a). These results are in line 
with studies indicating the benefit of HER2 vaccines in HER2-“negative” patients 
82–84 . In terms of MUC1 and SUR, data on tumour expression are not available. 
Here, were observed antigen-reactive T cells in 80 % and 72 % of patients (Fig. 
1a). Consistent with previous studies of our group, we found that CD4+ T cells 
responses were more common compared to CD8+, and also produced a larger 
number of different cytokines (Fig. 1C) 79. Furthermore these two different 
compartments were associated with different clinical characteristics. According to 
Mann-Whitney U testing, patients with more advanced disease (higher tumour 
grade) had weaker CD4+ T cell responses to MUC1 (p = 0.045) (Fig. 2a) while 
those patients with oestrogen receptor (ER)-positive tumours had stronger CD8+ T 
cell responses to HER2 (p = 0.031) (Fig. 2b). In contrast, patients with SUR-
reactive T cells showed no associations with any clinical parameters including T, N 
or AJCC stage, total lymph node involvement as well as expression of Ki67, HER2 
or progesterone receptor in the tumour.  
In order to identify immune parameters associated with the presence or absence of 
antigen-reactive T cells, immune features including serum cytokines, HLA type and 
tumour leukocyte infiltration were analysed for correlations with T cells responding 
to HER2, MUC1 and SUR. However, these analyses revealed only a few 
correlations with T cell responses. Here, the presence of HLA-A*01 was associated 
with a lack of T cell response to MUC1 (p = 0.045), while HLA-A*02+ patients were 
more likely to possess MUC1-reactive T cells (p = 0.0001) (Fig. 3a). In terms of 
serum cytokines, high levels of IL-10 were associated with HER2-reactive (Fig. 3b) 
and SUR-reactive CD8+ T cells. Interestingly, no association between tumour 
leukocyte infiltration and in vitro T cell responses were observed for HER2-reactive 
T cells (Fig. 4a), but high infiltration of CD163+, CD4+ T cells (Fig. 4b) as well as 
combined cell counts for both CD4+ and CD8+ T cells was associated with the 
presence of T cells responding to the MUC1 antigen. In contrast, patients with low 
numbers of tumour-infiltrating CD8+ T cells had more frequent CD8+ T cells 
Results and Discussion 
26 
 
responding to the SUR antigen (Fig. 4c). Interestingly, no correlations for these 
particular cell types in tissue were found for the same cell type in blood. These 
differences between blood and tissue and their association with TAA-reactive T 
cells suggest that cellular location and phenotype are both relevant for their impact 
on T cell responses to tumour-associated antigens in blood. Therefore, unless 
location-specific markers are found, the identification of marker proteins which 
accurately reflect cellular function remains difficult.  
Analysing peripheral blood leukocytes for their association with TAA-reactive T 
cells, only a few correlations were observed between T cell responses and 
potential suppressive cells like Tregs and MDSCs, although the presence of such 
suppressive cells is one mechanism dampening beneficial antigen-reactive T cell 
responses. This suggests that (a) either these potential suppressive cells are not 
suppressive in breast cancer patients or (b) that these cells are not able to 
suppress antigen-reactive T cells in blood or (c) circulating suppressive cells are 
not relevant for the activity of antigen-reactive T cells. Notably, several inverse 
relationships between TAA reactive T cells and blood leukocytes were observed. 
For example, high levels of blood monocytes was associated with absent or 
weaker CD4+ and CD8+ T cells responsive to HER2 and MUC1. Comparable 
inverse relationships were observed for the HLA-DR-negative fraction within 
monocytes, NK cells, mDCs and CD4+ and CD8+ T cells expressing markers of 
proliferation (Fig. 5), while several other populations were positively associated 
with antigen-reactive T cells (Table 2). These data suggest that blood leukocytes 
are able to suppress T cell responses to tumour antigens, but remain imperfectly 
defined on a phenotypic level.  
Notably, combining different immune parameters resulted in increased specificity 
and sensitivity in identifying patients with TAA-reactive T cells as well as in 
identifying patients with a strong or weak response (Fig. 6a). Thus, patients with 
below median levels of monocytes and NK cells identified a group in which all 
patients possessed HER2-reactive T cells with an average stimulation index of 
14.5, compared to patients with above median levels of these cells who had an 
average of stimulation index of 2.3 (Fig. 6b, left panel). In addition, combining 
multiple immunological parameters like tumour-infiltrating cells and blood 
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leukocytes resulted in superior prediction of patients responding to TAAs. For 
example, high levels of T cell infiltration and low levels of blood CD16+ mDCs were 
associated with an improved accuracy in identifying patients with MUC1-reactive T 
cells as well as identifying those with a stronger response (Fig. 6b, middle panel). 
Recent studies have shown an association between the clinical benefit of 
immunomodulatory antibodies and the presence of anti-tumour T cells. These 
findings suggest that patients with pre-existing TAA-reactive T cells may be more 
likely to respond to such therapies 85,86. Therefore, identifying biomarkers 
associated with T cells responding to TAAs may provide the basis for selecting 
breast cancer patients more likely to benefit from such treatments. Furthermore, 
patients lacking TAA-reactive T cells but who exhibit an immune profile associated 
with T cells responding to TAAs may also benefit from treatment with 
immunomodulatory drugs due to these patients having an “immune environment” 
that is favourable for facilitating such anti-tumour responses. The same principle 
may be applied for the use of cancer vaccines; patients with an immune profile 
associated with the presence of anti-tumour immune responses may be more likely 
to generate an immune response to the vaccine and benefit clinically 76,77,91–93. 
Furthermore, previous studies highlighted that not only the presence of TAA-
reactive T cells per se is relevant for patient survival, but also the production of 
certain cytokines. These results allow the selection of patients with TAA-reactive T 
cells that produce specific cytokines, and as such, may allow better prediction of 
patients most likely to respond to therapy or have a favourable prognosis according 
to the immune profiles identified here.  
In order to validate whether the composite set of biomarkers identified here will 
allow superior survival prediction, patient clinical follow-up will need to be analysed. 
Furthermore, selecting patients using these biomarker combinations may allow 
more personalised treatment management and prevent unnecessary treatment for 
patients with a favourable prognosis or the administration of more aggressive 
therapies for patients with a poorer prognosis.  
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9.2 Publication 2 
Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by 
melanoma cells 
 
Recent findings by Mao et al. showed that melanoma cells induce the 
differentiation of monocytes into immune suppressive myeloid-derived suppressor 
cells (MDSCs) which may resemble a mechanism of immune suppression that 
could also occur in vivo in melanoma patients 46. Based on these observations, we 
aimed to investigate pathways in melanoma cells responsible for the induction of 
MDSCs. We ultimately aimed to prevent the induction of MDSC-mediated immune 
suppression by targeting specific molecular pathways in tumour cells. Therefore, 
established melanoma cell lines were pre-treated with a panel of different inhibitors 
tested for their potential to alleviate T cell suppression by preventing MDSC 
differentiation. In brief, melanoma cells were co-cultured with isolated CD14+ 
monocytes and autologous CD3+ T cells. Suppressive activity of MDSCs was 
assessed by measuring CD4+ and CD8+ T cell proliferation using CFSE dilution. In 
addition, monocytes were analysed phenotypically for CD14 and HLA-DR 
expression in order to investigate their differentiation into MDSC-like cells. Before 
co-culturing melanoma cells with isolated immune cells, they were pre-treated with 
inhibitors targeting known pathways involved in the differentiation and suppressive 
function of MDSCs, such as geldanamycin (inhibition of Heat Shock Protein (HSP) 
90), methylene blue (an HSP70/NO Synthase inhibitor), U-104 (Carbonic 
anhydrase (CA) inhibitor), acetylsalicylic acid (cyclooxygenase (COX) inhibitor) and 
AG490 (a JAK/STAT inhibitor).  
 
To understand tumour-immune cell interactions we first cultured monocytes and T 
cells together with a melanoma cell line and observed changes to the monocyte 
phenotype and T cell proliferation over time. To this end we co-cultured the 
established tumour cell line EST-200 with monocytes and T cells for 24, 48, 72, 96 
or 120 hrs in vitro. This revealed that after 72 hrs T cell proliferation started to 
decrease when T cells were co-cultured with monocytes and melanoma cells 
compared to the control cultures consisting of T cells and monocytes alone. We 
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found that CD4+ T cell suppression continued to increase until 96 hrs, while 
suppression of CD8+ T cells continued to increase up until the final measurement 
point of 120 hrs (Fig. 2A). T cell proliferation was not inhibited when T cells were 
co-cultured with melanoma cells alone, suggesting T cell suppression in the co-
culture experiment (together with monocytes and melanoma cells) is due to 
interactions between monocytes and melanoma cells. As low levels of HLA-DR 
have been used as a marker for suppressive myeloid cells and MDSCs, we next 
investigated whether T cell suppression was associated with changes in monocyte 
phenotype, which may indicate their differentiation towards immunosuppressive 
MDSCs. We observed a decrease in HLA-DR expression on monocytes cultured 
with melanoma cells and T cells compared to the control monocytes cultured just 
with T cells (Fig. 2B). This decrease in HLA-DR indicates that the cells have 
differentiated towards suppressive MDSCs, which is in line with observations of 
greater T cell suppression over time. Thus, this in vitro model has shown that 
melanoma cells are able to induce differentiation of monocytes into cells that 
phenotypically and functionally resemble myeloid-derived suppressor cells.  
 
Similar results were observed when performing these experiments with additional 
donors and more melanoma cell lines. Six healthy donors were tested with a 
greater number of established cell lines (EST-41, EST-83, EST-145, EST-152 and 
EST-200); all cell lines resulted in suppression of T cell proliferation when cultured 
with monocytes compared to control cultures consisting of monocytes cultured with 
T cells but without melanoma cells. Comparing the degree of suppression, we 
observed that EST-145, EST-152 and EST-200 induced the greatest degree of 
suppression with between 90 – 70 % of T cell suppression compared to control 
cultures without melanoma cells (Fig. 3, top panel). This was accompanied by 
phenotypic changes on monocytes that are in line with changes previously 
reported to be associated with differentiation towards MDSCs, namely down-
regulation of HLA-DR and up-regulation of CD14 expression (Fig. 3, bottom panel). 
Interestingly, we observed different degrees of T cell suppression comparing co-
cultures with melanoma cell lines tested here, suggesting that different melanoma 
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cell lines vary in their capacity to induce immunosuppression via MDSCs, and 
which thus may employ different mechanisms of immune suppression.  
Several soluble factors have been identified as being involved in the differentiation 
of monocytes into suppressive MDSCs, including GM-CSF, IL-6 and COX-2/PGE2 
51 (53). Neutralizing GM-CSF, IL-6 and IL-1beta in tumour cell line- PBMC co-
cultures abolished the induction of CD33+ suppressor cells, and reduced their 
suppressive activity towards T cells to a degree comparable to controls 53 (55). 
Despite these advances in the understanding of MDSC biology, the molecular 
pathways in tumour cells responsible for inducing the differentiation of MDSCs 
remain to be elucidated. In order to identify pathways in melanoma cells 
responsible for the induction of suppressive MDSCs, we pre-treated melanoma 
cells for 18 hrs with a panel of different inhibitors including those against heat 
shock proteins (hsps) which act as molecular chaperones (geldanamycin: HSP90; 
methylene blue: HSP70), pH regulatory proteins (U-104: Carbonic anhydrase 
inhibitor) and inhibitors of COX (acetylsalicylic acid) and JAK/STAT signaling 
(AG490).  
Assessing this panel of inhibitors for their ability to prevent immune suppression in 
this in vitro model showed no significant effect on restoring T cell proliferation for 
acetylsalicylic acid or AG490. In contrast, geldanamycin was the most effective at 
restoring T cell proliferation, followed by methylene blue. Occasionally we also 
observed an effect for U-104, however this was less consistent. Interestingly, the 
effect of the inhibitors differed according to the cell line tested. Geldanamycin 
alleviated T cell suppression in 3 of 4 tested melanoma cell lines (EST-145, EST-
152, EST-200), which was followed by methylene blue and U-104 in terms of 
strength of effect (Fig. 4B – D). However, for EST-41 we observed a different trend. 
Here, methylene blue was the most effective in alleviation of T cell suppression, 
followed by geldanamycin and U-104 (Fig. 4A). In accordance with this functional 
analysis assessing T cell proliferation, reduced T cell suppression was associated 
with an increase in HLA-DR expression on monocytes compared with monocytes 
in cultures without inhibitor (Fig. 4, bottom panel). Interestingly, EST-41 was an 
exception also in terms of phenotypic analysis; no association between HLA-DR 
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expression on melanoma-educated monocytes and degree of T cell suppression 
was observed with this cell line.  
In order to exclude a direct effect of the drugs on T cell proliferation, T cells were 
directly cultured with pre-treated melanoma cells. This showed T cell proliferation 
to be comparable to the culture where melanoma cells had not been pretreated 
with an inhibitor. This suggests that due to the thorough washing protocol 
employed, no drugs remained, or that the levels were too low to have an effect on 
T cell proliferation. Because the inhibitor might affect the viability of melanoma cells 
and therefore may result in impaired induction of T cell suppression, we performed 
the experiment with double the number of melanoma cells to compensate for any 
potential effect on cell viability. Because we observed no differences in T cell 
suppression with twice the number of melanoma cells, this suggests that alleviation 
of T cell suppression is not related to the number of melanoma cells and thus 
occurs through blocking molecular pathways in melanoma cells.  
Collectively, these results show that targeting HSP70 and HSP90 prevents the 
differentiation of monocytes into suppressive cells on both a functional and 
phenotypic level 87–90. Both molecules belong to the family of molecular 
chaperones and play essential roles in maintaining the integrity of intracellular 
proteins 99. With the help of co-chaperones, they are responsible for the correct 
folding, function and degradation of a large number of cellular proteins. Particularly 
in the case of cancer, the harsh tumour microenvironment results in the up-
regulation of such molecules in order to sustain the function of cancer cells. This is 
partly achieved through chaperones maintaining the function of key signaling 
molecules required for aberrant cell division 94. Therefore, results showing restored 
T cell proliferation upon blocking HSP70 or HSP90 suggest that there are 
overlapping networks between pathways involved in cancer maintenance and 
those involved in immune suppression. This idea is supported the action of 
chemotherapeutic drugs which have been shown to exert their beneficial effect 
partly through immunomodulatory mechanisms 95. 
As geldanamycin was shown to be the most effective in alleviating T cell 
suppression, we next investigated the time-dependent effect of this drug on 
preventing the induction of suppressive cells. For this, we pre-treated established 
Results and Discussion 
32 
 
melanoma cell line EST-200 with geldanamycin and co-cultured these cells with 
monocytes and T cells for 24, 48, 72, 96 or 120 hrs. This revealed a decrease in T 
cell suppression over time compared to co-cultures with melanoma cells that had 
not been pretreated (Fig. 5). In accordance with functional analysis, we observed 
higher HLA-DR expression on melanoma-educated monocytes over time 
compared to control cultures not pretreated with geldanamycin. It was interesting 
that although melanoma cells were treated only for a duration of 18 hrs, alleviation 
of T cell suppression could be observed even 5 days post-exposure, suggesting 
that a single dose of this drug is sufficient for a long-lasting effect. In addition, we 
analysed GM-CSF production in a co-culture experiment consisting of melanoma 
cells and monocytes, as GM-CSF has been shown to be involved in the 
differentiation of suppressive MDSCs. Here, we observed decreased GM-CSF 
expression when melanoma cells were pre-treated with geldanamycin, suggesting 
HSP90 to be involved in the production of GM-CSF. Collectively, these results 
suggest that blocking HSP90 by pre-treating melanoma cells with geldanamycin 
prevents the conversion of healthy monocytes into immune suppressive cells.  
The tumour mass has distinctive features when compared to the surrounding 
tissue, including lowered oxygen tension and acidic pH, which contributes to the 
up-regulation of heat-shock proteins like HSP70 and HSP90, or the induction of the 
transcription factor hypoxia inducible factor 1 (HIF-1a) 96. Although 
chemotherapeutic drugs are typically less effective under these conditions 95,97, the 
inhibitors tested here target molecules which are up-regulated in response to 
cellular stress such as hypoxic tolerance and may not suffer from reduced efficacy 
under these conditions. On the contrary, they may even be more effective under 
conditions of the tumour microenvironment 98. Therefore we repeated the previous 
experiments under conventional (20 % O2) conditions and compared these results 
obtained under hypoxia (2 % O2). Pre-treating melanoma cells with geldanamycin 
resulted in a greater alleviation of T cell suppression under hypoxia compared to 
the conventional condition (20 %). A similar trend was observed for methylene blue 
being equally effective under hypoxia and hyperoxic conditions (Fig. 6). These 
results suggest that the efficacy of drugs targeting HSP90 is not diminished in a 
hypoxic environment in vitro. Furthermore an even greater effect was observed 
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when inhibiting HSP90, suggesting that melanoma cells are even more dependent 
on these molecules under hypoxic conditions.  
This study identified novel mechanisms in tumour cells responsible for the 
conversion of healthy monocytes into immune suppressive cells. Especially 
interesting for potential clinical application is that a single sub-lethal dose of these 
drugs was sufficient to alleviate T cell suppression. Furthermore, in contrast to 
common chemotherapeutic agents, the activity of these drugs was not diminished 
under hypoxic conditions, which may better represent the tumour 
microenvironment. Further investigations are necessary to validate the clinical role 
of hsps.  
9.3 Manuscript 1 
High levels of blood T cells identify breast cancer patients with HER2, MUC1 and 
SUR-reactive T cells. (manuscript under revision in biomarkers) 
 
Recent findings from our group, showed that (1) the presence of peripheral HER2-
reactive T cells is associated with patient survival in breast cancer and (2) 
compared with tumour-infiltrating leukocytes, HLA type and serum cytokines, blood 
leukocytes are the most informative immune parameter for the identification of 
patients possessing TAA-reactive T cells. We therefore greatly expanded the panel 
tested focusing mainly on blood leukocytes, with the aim of identifying markers that 
can more accurately select patients who possess T cells responding to tumour-
associated antigens. These markers may then be used as part of routine patient 
monitoring, in turn avoiding the complex and extended duration of directly testing 
for these antigen-reactive T cells. 
Using intracellular cytokine staining we assessed (1) T cells (CD4 or CD8) reactive 
to HER2, MUC1 and Survivin and their produced cytokine pattern (measuring 
interferon- (IFN-), TNF-α, IL-2, IL-4, IL-10 and IL-17 simultaneously in the same 
cell) (3) cellular components in the blood including T cells, NK cells and B cells 
using extracellular staining in the blood of breast cancer patients. For this study, 
cryopreserved PBMCs from 50 patients with non-metastatic invasive ductal 
carcinoma were collected at the St. Savas Cancer Hospital in Athens between 
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February 2014 and May 2015, one day prior to surgery. The study included women 
with an age range of 27–78 (median age 56 years). Patients of AJCC stages 1, 2A, 
2B, 3A and 3C were included, while patients with tumours extending to the chest 
wall as well as AJCC stages 3B and 4 were excluded. 
In this study we observed that all leukocyte types, but particularly T cells, were 
associated with clinical parameters including tumour grade, AJCC stage, Ki67 
tumour expression and lymph node infiltration. Here, higher AJCC stage and 
higher tumour grade was related to low levels of CD4+ T cells (AJCC stage: p = 
0.02, tumour grade: p = 0.03) (Fig. 2a) and high levels of CD3hiCD56dim cells that 
may resemble NKT cells (AJCC stage: p = 0.06, tumour grade: p = 0.003,) (Fig. 
2B). Interestingly, no such associations were observed for Tregs, suggesting that 
reduced levels of CD4+ T cells are due to a reduction in helper CD4+ T cells with 
disease progression. However, in terms of the number of tumour-infiltrated lymph 
nodes the same trend was observed for both CD4+ T cells and regulatory T cells; 
patients with a greater number of infiltrated lymph nodes had lower levels of both 
CD4+ T cells (p = 0.02) (Fig. 2C) and CD4+ regulatory T cells (p = 0.04). 
Furthermore, low levels of NK cells were related to higher stage and higher 
percentage of tumour cells expressing Ki67 (AJCC stage: p = 0.01, Ki67: p = 0.04), 
while the opposite trend was observed for B cells; high levels of B cells were 
associated with higher tumour grade and Ki67 tumour expression (tumour grade: p 
= 0.02; Ki67: p = 0.06) (Fig. 2D). Several other leukocyte populations were also 
observed to correlate with clinical parameters. Next, we examined the relationships 
between the major types of leukocyte populations. Here we observed only one 
significant correlation between B cells and T cells; this showed that high 
frequencies of CD20+CD40+ B cells were associated with high levels of CD4+ 
regulatory T cells (CD4+CD25+FoxP3+) (p = 0.02) (Additional File 8). 
Although previous studies have shown that tumour antigen-reactive T cells are 
predictive of patient prognosis, the generation and detection of such cells requires 
time- and resource-intensive culture protocols and thus limits their use as part of 
routine clinical monitoring. Hence, identifying immune parameters that select 
patients possessing TAA-reactive T cells may improve patient monitoring and 
clinical patient management. Having shown that blood leukocytes, compared to 
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serum cytokines, HLA type or tumour-infiltrating lymphocytes, are the most 
informative immune parameters for identifying patients possessing antigen-reactive 
T cells, in this study we expanded the panel of blood leukocytes tested to identify 
biomarkers that can more accurately select patients with response to tumour 
antigen. Thus, these blood-based biomarkers can be more easily implemented into 
clinical routine compared to the complex and expensive protocols required for 
detecting antigen-reactive T cells. 
Accordingly, we have increased the number of populations tested to include 302 
different blood leukocyte populations: 213 for T cells, 19 in the case of B cells, and 
70 NK cell populations (Additional File 9). We observed NK cells to be associated 
with T cell responses to MUC1 and SUR but not with HER2 (full set of correlations 
in Additional File 10). Here, both, low or high levels of different NK cell populations 
were shown to correlate with MUC1- and SUR- reactive T cells. For example, 
presence of CD4+ T cells responding to the MUC1 antigen was associated with 
relative high levels of CD27+ NK cells (p = 0.04) (Fig. 3A), while another population 
of NK cells (CD56dimCD16-NKG2D+) was found to be lower in patients with 
MUC1-reactive T cells (p = 0.04) (Fig. 3A). In contrast to NK cells, B cells were 
found to be associated only with T cell responses to HER2. Here, only one 
correlation between CD8+ HER2-reactive T cells and B cells was found; patients 
possessing CD8+ T cells responding to HER2 had higher levels of CD19+CD38-
CD27+CD20- B cells (p = 0.04) (Fig. 3B). Although we were able to select patients 
with TAA-reactive T cells using different B and NK cell populations, we could only 
identify selected T cell responses to certain antigens. In contrast, blood T cells 
were found to be associated with both CD4+ and CD8+ T cells responding to all 
three antigens tested. Here, compared to NK cells and B cells, T cells were found 
to be most informative for selecting patients with T cell responses to HER2, MUC1 
or SUR. Interestingly, the T cell populations found to be associated with TAA-
reactive T cells did not share any common features and covered various 
differentiation stages, including naïve as well as late-differentiated T cells. For 
example, patients with T cells responding to the SUR antigen had higher levels of 
CD8+ CD27- T cells (p = 0.0007) (Fig. 3C), while patients with MUC1-reactive T 
cells had higher levels of CD8+ TEMRA T cells (p = 0.01) (Fig. 3C). Noteworthy 
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was that the majority of patients possessing TAA-reactive T cells had higher levels 
of blood T cells, suggesting that these phenotypes may directly contribute to the 
generation of antigen-reactive T cells. This is further supported by the observation 
that, unlike B and NK cells, T cells were relevant for every type of response and 
accounted for the vast majority of all correlations with TAA-reactive T cells. 
Underlining these findings and their clinical importance, T cells were found to be 
the most informative for patient clinical parameters. These data suggest that 
altering the immune system of patients lacking TAA-reactive T cells so that it more 
closely mirrors the immune system of patients with TAA-reactive T cells might 
result in improved anti-tumour immune responses and thus superior clinical 
outcome. 
Our previous study revealed that combining multiple immune parameters can more 
accurately identify patients with TAA-reactive T cells. For example, combining 
parameters such as tumour-infiltrating leukocytes and blood leukocytes, as well as 
combining different blood leukocyte populations resulted in improved specificity 
and sensitivity in the identification of patients with TAA-reactive T cells (84). Based 
on these results, the present study aimed to identify markers that can predict 
patients possessing TAA-reactive T cells even more accurately by testing a 
markedly increased number of leukocyte populations. Indeed, in this study we were 
able to achieve specificity and sensitivity of up to 100 % in selecting patients with 
TAA-reactive T cells by combining multiple blood leukocyte populations. For 
example, by stratifying patients according to median levels of stem memory T cells 
(TSCM) and CD3-CD56- cells, we were able to identify a group of patients who all 
possessed MUC1-reactive CD4+ T cells (Fig. 4). Similarly, a group of patients with 
above median levels of NK cells (CD3-CD56hiCD16-CD27+) and NKT cells 
(NKG2D+ CD3+CD56dim) all possessed CD8+ T cells responding to the Survivin 
antigen (Fig. 4). 
This study identified populations of blood leukocytes that allow the accurate 
identification of breast cancer patients with functional TAA-reactive T cells. The 
identification of such markers could replace the direct measurement of antigen-
reactive T cells, which requires a time consuming, expensive and labour intensive 
in vitro protocol, as well as additional expertise in order to analyse and interpret the 
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results. Furthermore, difficulties in standardising culture protocols, due to user- or 
manufacturer-dependent differences, plus the limited availability of material from 
cancer patients limits the routine implementation of this approach into the clinical 
setting. Thus, identifying blood-based surrogate markers that can more easily be 
measured but still select patients with TAA-reactive T cells may represent an 
alternative to allow patient clinical monitoring and thus allow more personalised 
treatment. Especially in light of recent advances in immunotherapy, which 
presumably relies on the generation and amplification of already existing antigen-
reactive T cells, identifying patients possessing such TAA-reactive T cells, or 
identifying patients with an immune profile favourable to generating such an 
immune response, may improve the selection of patients more likely to respond the 
immunotherapy. Furthermore, identifying immune profiles of patients lacking TAA-
reactive T cells might represent therapeutic targets, whereby immune parameters 
may be altered in order to better resemble the immune profile of patients with TAA-
reactive T cells, potentially creating a more favourable environment to generate 
anti-tumour immune responses. 
These findings are intended as the first step towards replacing the time-consuming 
and costly procedure of detecting TAA-reactive T cells. By using a directly and 
more easily measured parameter such as blood leukocytes, this approach may 
more easily be integrated into routine monitoring in order to select patients with 
antigen-reactive T cells and thus identify patients with a more or less favourable 
prognosis. Ongoing clinical follow-up of these prospectively recruited patients will 
reveal which of the biomarkers identified here are relevant to patient survival 
compared with the assessment of antigen-reactive T cells. 
9.4 Manuscript 2 
Intra-tumoural immune features as prognostic markers in metastatic melanoma. (in 
preparation) 
 
Recently, investigation on the topic of the tumour microenvironment has revealed 
that the state of the immune system within the tumour plays a major role in cancer 
progression, patient clinical outcome and response to therapy. To date, prior 
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studies have been largely focused on investigating lymphocytes, typically T cells, in 
the tumour mass. In contrast, other populations of leukocytes, transcription factors 
and soluble mediators of immune response (such as cytokines) have been 
relatively neglected. Therefore, this study was designed to identify immune 
parameters including soluble factors and cellular components in the tumour 
microenvironment in order to assess which of these are most relevant for patient 
outcome. 
This study assessed T cells (CD3+) and myeloid cells (CD15+) in addition to a 
panel of soluble immune factors (IL-6, GM-CSF, TNF, IL-1Ra, IL-2, IL-10, GDF15, 
PGE2) as well as the transcription factor STAT3 in metastatic melanoma tissues of 
76 patients using fluorescence microscopy. Slide-mounted formalin-fixed paraffin-
embedded tissue sections (5 µm thick) from metastatic melanoma patients were 
collected at the Dermatology Department of Tübingen University Hospital. The 
study population consisted of 44 men and 32 women with a median age of 63 
(range 35 – 89 years). Patients of AJCC stages 3, 4A, 4B and 4C were included in 
this study. 
The analysis of soluble factors as well as immune cells within the tumour 
microenvironment revealed that the majority of melanoma tissues were positive for 
most molecules tested (Fig. 1A). However, the levels of expression as well as the 
number of infiltrating cells varied across melanoma patients, with IL-6, GM-CSF 
and IL-1Ra showing the greatest range (Fig. 1B). Overall, CD15+ granulocytic cells 
were less commonly found compared to CD3+ T cells (Fig. 1C and 1D), although 
no significant difference were observed comparing the relative distribution of T and 
granulocytic cells between the center and margin of the tumour (Fig. 1E). In 
addition to T cells and granulocytic cells, we also attempted to analyse CD14+ cell 
infiltration. Although we tested two commercially-available antibodies (goat 
polyclonal anti-CD14 from Novus Biologicals and mouse monoclonal anti-CD14 
from Santa Cruz (clone 5A3B11B5)) and a number of different staining protocols, 
unfortunately we were not able to establish a staining protocol which enabled us to 
quantify CD14+ cells. 
Soluble molecules often act in concert and may generate an environment that 
either enhances or suppress infiltration of immune cells into the tumour. Therefore, 
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we examined whether the presence of certain soluble molecules is associated with 
higher infiltration of immune cells into tumour tissue. Indeed, we found that high 
CD15+ infiltration is associated with low relative expression of PGE2 (p = 0.02) 
(Fig. 2A), but no other association between immune cell infiltration and soluble 
molecules was observed. Furthermore, analyzing the relationship between different 
soluble molecules revealed several correlations between their expression levels. 
For example, expression of IL-6 and GM-CSF (p < 0.0001, r = 0.7), TNF and 
STAT3 (p < 0.0001, r = 0.7), IL-2 and IL-10 (p < 0.0001, r = 0.5) (Fig. 2B), plus 
other combinations of these cytokines were found to be positively correlated 
(Supplementary Data 1). 
Several studies have shown that the state of the immune system plays a major role 
in patient outcome. However, the majority of those studies mainly focus on tumour-
infiltrating cells and miss analysis of soluble factors, although they have been 
shown to influence anti-tumour immune responses and thus patient survival. 
Therefore we investigated whether immune parameters tested here are associated 
with clinical features including disease stage, progression time (stage III to stage 
IV), age and gender as well as patient survival. In terms of clinical parameters, only 
stage and age were found to correlate with the immune features tested here. We 
observed that patients with stage IV disease had higher levels of TNF compared to 
patients with less advanced stage III disease (p = 0.02) (Fig. 3A). Furthermore, we 
observed age to be associated with CD15+ cell infiltration; older patients were 
found to have lower numbers of CD15+ cells in the margin of the tumour (p = 
0.046) (Fig. 3B). In order to investigate the role of immune parameters tested here 
on patient survival, we first stratified patients according to the conventional method 
of using the median values to split the cohort into relative high and low values for a 
particular parameter. Using this approach, Kaplan-Meier survival analysis revealed 
that none of the immune parameters tested here (neither soluble nor cellular 
factors) was associated with patient survival (data not shown). These results are in 
contrast to several other studies showing superior overall survival in patients with 
high CD3+ infiltration in several types of cancer 56–58,100–106. However, in 
melanoma, the role of tumour-infiltrating T cells remains to be elucidated due to 
inconsistent results from different investigators. While Hillen et al. reported a 
Results and Discussion 
40 
 
negative association with the level of intra-tumoural T cells on overall survival 67, 
other studies report a positive relationship - patients with high levels of intra-
tumoural T cells, or one study considering peri-tumoural T cell activation markers, 
were found to have longer survival 107,108. Another study, in accordance with the 
results presented here, reported no significant association between the level of 
intra- or peri-tumoural CD3+ cells and overall survival 109. Such discrepancies 
between these studies might be explained by the great diversity of cells that are 
detected when using only CD3 to identify T cells; sub-populations of CD3+ cells 
may vary considerably in functional properties or activities. For example, CD3+ T 
cells include helper cells, cytotoxic cells but also regulatory T cells or exhausted 
and anergic cells. Therefore, combining multiple markers to more accurately 
characterise their phenotypes, as well as including markers representing their 
functional state, may increase the accuracy of predicting patient prognosis. In 
support of this, one study highlighted the prognostic difference with different T cell 
populations in a cohort of melanoma patients. In that study, high T cell infiltration 
per se was associated with poorer survival, but prolonged survival was found when 
the degree of cells expressing the T cell activation marker CD69 was considered 
67. 
However, in contrast to the results showing no association between the intra-
tumoural immune parameters investigated here and patient survival, we observed 
that several immune parameters were associated with patient survival when using 
a different method to analyse the experimental data. In this approach, we grouped 
patients according to relative high and low values using different cut-off values to 
determine the threshold with the minimum p-value and thus the greatest difference 
in survival. Here, we observed that patients who had low relative levels of GM-CSF 
or IL-10 (p=0.035 and p=0.043 respectively), or high relative levels of PGE2 
showed longer survival (p=0.03) (Fig. 4A and B). In addition, higher levels of 
infiltrating T cells or low levels of infiltrating granulocytic cells were associated with 
better patient survival (p = 0.028 and p = 0.0006, respectively) (Fig. 4C). Because 
this approach requires an additional number of statistical tests, we adjusted the 
significance threshold accordingly. Considering this, only the association between 
low relative levels of intra-tumoural CD15+ cells and improved patient survival 
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remained significant (p = 0.0006, adjusted significance threshold p = 0.0009) (Fig. 
4C). 
Recent studies have shown that high numbers of tumour-infiltrating immune cells 
are associated with superior survival in many types of cancer 56,57. However, 
despite the presence of such tumour-infiltrating immune cells, tumour progression 
is still frequently seen, suggesting that there are factors in the tumour 
microenvironment inhibiting an effective anti-tumour response by these cells. 
Indeed, several mechanisms have been identified that induce T cell dysfunction by 
either directly inhibiting T cell function, for example the expression of inhibitory 
ligands like PD-L1 on tumour cells or APCs, or indirectly via the induction of 
regulatory cells such as Tregs or MDSCs 24,110. High levels of IDO and PGE2 have 
been demonstrated to inhibit T cell function while IL-6 and several other factors 
have been shown to convert monocytes into immunosuppressive MDSC. These 
mechanisms have the potential to impair T cell function within the tumour 
microenvironment and as such may limit the prognostic value of tumour-infiltrating 
leukocytes due to changing the immunological context which influences the 
functional state of these cells. To better consider the immunological context of the 
immune parameters investigated here, we assessed combinations of these 
features as potential prognostic markers. Thus, by combining immune features we 
could demonstrated that patients with high levels of infiltrating CD3+ T cells and 
low levels of CD15+ cell infiltration had better survival compared to patients without 
these combinations (p = 0.03) (Fig. 5A). Furthermore, we observed a trend for a 
survival advantage in patients with high relative levels of CD3 infiltration in 
combination with low relative levels of the potentially suppressive cytokine IL-10 (p 
= 0.1), as well as for patients with low relative levels of infiltrating CD15+ cells and 
low IL-10 expression (p = 0.08) (Fig. 5B). These results suggest that the interaction 
between different intra-tumoural leukocytes as well as between leukocytes and 
soluble factors in the tumour microenvironment are important for their functional 
state. This hypothesis is supported by a study showing that high levels of tumour-
infiltrating CD8+ T cells are associated with the recruitment of regulatory T cells 
into the tumour microenvironment, which might represent a negative feedback 
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mechanism following infiltration by cytotoxic T cells. Therefore, assessing cytotoxic 
T cells only might limit their prognostic accuracy 111. 
These results, especially in light of the increasing clinical use of immunotherapies, 
indicate the importance of a more comprehensive analysis of the tumour 
microenvironment. Supporting this notion, immune features of the tumour 
microenvironment have been shown to be associated with response to 
immunotherapies 57,112–119. For example, Tumeh et al. observed an association 
between the density of tumour-infiltrating T cells and clinical response to PD-1 
antibodies 65. Thus, there is an urgent need to understand the constitution of the 
tumour microenvironment in order to optimize personalized treatment management 
or for the identification of novel therapeutic targets.  
Collectively, these preliminary results show that intra-tumoural immune parameters 
either individually or in combination may act as potential prognostic markers in 
metastatic melanoma. Unlike in many other cancer types, tumour infiltration by T 
cells was not associated with patient survival, but granulocytic cells may be a more 
promising marker for predicting patient survival. These results require validation in 
an independent cohort of patients and should be considered preliminary until then.  
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Abstract
Purpose Breast cancer is a leading cause of cancer deaths
in women, but despite steady improvements in therapies,
treatment is still suboptimal. Immunotherapy holds pro-
mise as a more effective therapy for breast cancer; sup-
porting this, our prior study showed that patients
possessing HER2-reactive CD8? T cells in blood experi-
ence survival superior to patients without these cells. Here,
we define a composite set of biomarkers that identify
patients with T cell responses to tumour antigens.
Methods We assessed T cell responses following in vitro
stimulation with the HER2, MUC1 and SUR tumour-as-
sociated antigens (TAA) by flow cytometry and intracel-
lular cytokine staining in 50 breast cancer patients. We also
measured HLA type, serum cytokines, tumour-infiltrating
leukocytes and blood leukocyte populations.
Results We found few correlations between TAA-reactive
T cells and HLA type, serum cytokines and tumour-infil-
trating leukocytes, whereas blood leukocyte phenotypes
broadly correlated with TAA responses. This showed
monocytes, natural killer cells, dendritic cells and T cells to
be inversely associated with both CD4? and CD8? T cells
reactive to tumour antigens. Moreover, combining multiple
parameters improved the accuracy in predicting patients
with TAA-responsive T cells.
Conclusion This study therefore defines composite immune
profiles that identify patients responding to TAAs which
may allow better personalisation of cancer therapies.
Keywords Tumour-associated antigen ! Blood
leukocytes ! Breast cancer ! HER2 ! Survivin ! MUC1
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Introduction
Breast cancer is the most common cancer in women (http://
globocan.iarc.fr), but mainstay treatments are still subop-
timal for most patients. To address this, there is a growing
interest in using immunotherapy to treat breast cancer.
Immunotherapy can take many forms including mono-
clonal antibodies targeting tumour antigens expressed on
cancer cells, so-called checkpoint inhibitors, cancer vac-
cines or other treatments that aim to boost the immune
system. Of these, immunomodulatory antibodies that target
T cell suppressor ligands or receptors have shown highly
encouraging results in several types of cancer [1–3]. The
effectiveness of such treatments is presumably based on T
cell immune responses against tumour-associated antigens
(TAAs) expressed by cancer cells, allowing these cells to
kill or otherwise inhibit tumour cells and induce tumour
regression. Similarly, cancer vaccines also aim to prime or
boost immune responses against tumour cells, and it has
been shown that both of these approaches result in stimu-
lated T cell responses and clinical tumour regression or
prolonged patient survival [4–6].
One of the most widely investigated TAAs in breast
cancer is the human epidermal growth factor receptor 2
(HER2). Our previous study showed that breast cancer
patients whose peripheral blood mononuclear cells
(PBMCs) mounted in vitro CD8? T cell responses to
HER2 peptides experienced prolonged survival relative to
patients without such responses [7]. Consistent with this,
HER2 vaccination has also resulted in clinical therapeutic
responses [8, 9] and tumour regression [10]. These studies
closely link T cells specific for TAAs with improvements
in patient clinical status. As with most types of immune
responses, TAA-reactive T cells are governed by immune
regulatory factors such as regulatory T cells (Tregs) or
myeloid-derived suppressor cells (MDSCs), which can
dampen anti-tumour immune responses including those
against TAAs [11–19]. Tregs and MDSCs induce immune
suppression through a range of processes including cytol-
ysis via granzyme B and perforin, production of inhibitory
signalling molecules such as IL-10, transforming growth
factor-b (TGF-b) or prostaglandin 2, or induction of T cell
dysfunction through arginine depletion [20, 21]. This may
offer the possibility of targeting these cells to enhance anti-
tumour immunity [22]. Because many of these effector
molecules are soluble, the activity of such regulatory cells
may be reflected by systemic levels of suppressive factors
that they produce. Indeed, serum cytokines have been
associated with patient outcome [23, 24], supporting their
potential as markers reflective of patient immune status.
Considering the emerging role of tumour antigen-reac-
tive T cells and the results of our prior study which
demonstrated a survival advantage for patients possessing
T cells reactive to HER2, we aimed to pinpoint the patient
features associated with T cell responses to tumour anti-
gens in breast cancer. We reasoned that multiple different
factors could potentially influence whether a patient pos-
sesses T cells responsive to tumour antigens and thus
clinical outcome. To increase the predictive utility of such
biomarkers, here, we measured broad features including
immunogenetic factors, soluble signalling molecules in
serum as well as cellular components in the blood and also
within the tumour, with the goal of defining a composite set
of biomarkers predictive of TAA responses which may
better correlate with clinical outcome than tumour antigen
immune responses alone, and which may also allow more
effective personalised application of cancer therapies.
Materials and methods
Patients
Blood samples from 50 patients with invasive carcinoma
were collected at the St. Savas Cancer Hospital in Athens
between February 2014 and May 2015, one day prior to
surgery. The study includes women with an age range of
27–78 (median age 56 years). Peripheral blood mononu-
clear cells were isolated from blood using Ficoll–Hypaque
gradient and stored in liquid nitrogen before being shipped
to the Tu¨bingen University Hospital for analysis. Written
informed consent was approved by the Review Board at St.
Savas Cancer Hospital. The patients all had non-metastatic
invasive ductal carcinoma. Patients who had tumours of
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any size but without extension to chest wall were included,
i.e. patients were all of AJCC stages 1, 2A, 2B, 3A, 3C but
not 3B and 4. None of these patients were treated with
neoadjuvant chemotherapy or were enrolled to other
research protocols, nor did they have any history of cancer
or other serious health problems. Tumour expression of
hormone receptors [progesterone (PR) and oestrogen
receptors (ER)], the HER2 oncoprotein and the marker of
cell proliferation Ki67 was available for all patients
(Table 1).
Detection of antigen-reactive T cells
T cell responses to HER2, Mucin1 (MUC1) and Survivin
(SUR) were measured after 12 days of in vitro culture. This
procedure, including the detection of reactive T cells with
flow cytometry, was performed as in our prior study [7]
(see Online Resource 1 for full list of antibodies
employed). Cytometer setup and tracking beads (BD Bio-
science) were run before and after each sample measure-
ment to ensure consistency in machine performance. The
inclusion of a positive biological control (stimulation with
influenza peptides) assured consistency in sample quality
and the prevention of false-negative results.
Phenotypic analysis of myeloid cells, T cells
and Natural Killer cells
For characterisation of myeloid cells [including monocytes,
MDSCs, plasmacytoid Dendritic Cells (pDCs) and myeloid
DCs (mDCs)], T cells (including regulatory T cells) and
Natural Killer cells (NK cells), PBMCs were thawed and
stained as previously described [7], using the antibody
panels in Online Resource 1. Antibody panels were
established using fluorescence minus one controls.
Cytometer setup and tracking beads were run before and
after each sample measurement to ensure consistency in
machine performance. The limited nature of patient mate-
rial did not permit multiple testing of the same sample, but
we performed multiple independent measurement of a
healthy control donor (n = 9) in order to ensure consis-
tency in measurement conditions.
Flow cytometry data analysis
Data were analysed with FlowJo software version 10.07
(immunophenotyping) or version 7.2.5 (antigen-reactive T
cells). Flow cytometry data were analysed first by
excluding events not part of the main acquisition popula-
tion using a time-vs-side scatter gate. Cell doublets were
then removed before the exclusion of dead cells (EMA-
positive events) and cell debris with the use of a morpho-
logical gate (Online Resource 2). The assessment of T cell
responses to tumour-associated antigens was performed
using the same method as in our prior study [7]; we
compared control (unstimulated) and peptide-stimulated
cultures as described in the methods section ‘‘Detection of
antigen-reactive T cells’’ and assigned a positive response
when the frequency of T cells producing any cytokine in
the stimulated sample was at least twice that of the control
sample (Online Resource 4). Additionally, each response
was visually assessed to ensure the presence of a clearly
distinguishable population of positive events. T cell
responses were considered categorically (present or absent)
in addition to a quantitative assessment of the strength of
response by calculating the ratio of the frequency of pos-
itive events in the stimulated sample by comparison with
the unstimulated sample to give a stimulation index (SI).
This method allows the detection of multiple cytokines
from each patient, but does not directly assess whether
production is from the same or different population of
Table 1 Characteristics of the breast cancer patients
Patient clinicopathological parameters (n = 50)
Median age (range in years) 56 (27–78)
AJCC staging
1 15
2A 10
2B 12
3A 12
3C 1
Receptor status
Triple negative 5
ER? 42
PR? 33
HER2? 15
Ki67
\10% 7
10–20% 21
[20% 22
T stage
1 21
2 26
3 3
N stage
0 21
1 17
2 11
3 1
Grade
1 0
2 26
3 24
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cells. Antibody-stained leukocyte populations, including
the assessment of T cell responses to TAAs, were gated
according to the approaches shown in Online Resources
2–4.
Assessment of tumour-infiltrating leukocytes
Haematoxylin–Eosin-stained tumour slides were reviewed
by two breast pathologists (M.S. and N.A.) to select the most
representative slide of each tumour. Sections (4–5 lm) were
stained individually with antibodies to CD4 (4B12, 1:40;
Biogenex), CD8 (SP16, 1:80; Thermo Scientific), CD163
(10D6, 1:400; Biocare) and FoxP3 (236A/E7, 1:100;
Abcam). Staining protocols for all antibodies were opti-
mised using sections of tonsil tissues. Immunostaining was
performed using the Leica Bond III automation (Leica
Biosystems, Melbourne, Australia) and Leica detection kit
(Leica Biosystems, Newcastle, UK). The staining protocol
included a 30-min high pH epitope retrieval in the case of
CD4, CD163 and FoxP3 antibodies, and a low pH retrieval
for CD8, which was followed by a 30-min incubation with
the primary antibody. Reactions were developed with
diaminobenzidine, and sections were counterstained with
haematoxylin.
Micrographs (3840 9 3072 pixels) of each slide stained
with CD4, CD8, FoxP3 and CD163 were captured with a
Nikon DXM-1200 Camera on a Nikon Eclipse E800
microscope with E Plan Achromat Objectives using Auto-
matic Camera Tamer (ACT-1) Version 2 software. White
balance was calibrated before image capture. The images
were saved as JPG at 95% quality without image process-
ing. Quantification of infiltrating cells was performed using
Adobe Photoshop CS6 (used to select the exact colour of
positive cells for eachmarker whichwas then converted to a
grey scale image) and ImageJ (used to analyse the per-
centage of the surface covered by the stained cells). The
surface coverage of stained cells was then converted to
absolute number of infiltrating cells per mm2. For each
infiltrating subpopulation, we performed visual enumera-
tion in ten representative regions by two independent
researchers.
Patient HLA typing
DNA from peripheral blood cells was extracted using the
automated Maxwell" 16 Blood DNA Purification Kit
(Promega, Madison, WI, USA), according to the manu-
facturer’s protocol. HLA genotyping was performed using
rSSO-Luminex (LIFECODES" HLA SSO Typing—
RAPID, Immucor Transplant Diagnostics, INC, Stamford,
CT, USA), and the results were analysed with the MATCH
IT! DNA software (Immucor Transplant Diagnostics, INC,
Stamford CT).
Measurement of serum cytokines
Frozen sera from patients were thawed at 37 #C and sub-
sequently mixed well. Measurement of IL-1Ra, IL-9 and
IL-10 was simultaneously performed by Luminex using the
human premixed multi-analyte kit (R&D systems)
according to manufacturer’s instructions. RANTES/CC-
chemokine ligand 5 and TGF-b determinations were per-
formed by separate Luminex-based kits (R&D systems).
The full panel of cytokines investigated additionally
included IL-1beta, IL-2, IL-4, IL-5, IL-8, IL-12 p70, IL-15,
IL-17A, TNF, IFNc and GM-CSF, but levels of these
cytokines could not be detected.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 (GraphPad Software Inc., San Diego, CA, USA). Two
independent groups were compared using the Mann–
Whitney U test. Relationships across four grouping vari-
ables were assessed with Fisher’s exact test. Correlations
were assessed using Spearman correlation analysis. A
value of p\ 0.05 was considered statistically significant.
Because this was an exploratory study we aimed to reduce
the chance of obtaining false-negative results. For this
reason, statistical analyses were not corrected using the
Bonferroni method, and the results should be interpreted as
such.
Results
Breast cancer patients frequently show in vitro
responses to HER2, MUC1 and SUR
T cells reactive to the HER2, MUC1 and SUR tumour
antigens were detected in the PBMC of 50 non-metastatic
breast cancer patients using an established 12 day in vitro
expansion protocol. Reactive T cells were found to be
common in patients, with a high frequency of responses to
HER2 (96%), MUC1 (80%) and SUR (72%) (Fig. 1a).
Examining CD4? and CD8? T cell responses separately
showed that CD4? reactive T cells were more common
(Fig. 1b) and produced a larger number of different
cytokines than CD8? cells (Fig. 1c).
T cell responses to tumour antigens are associated
with clinical parameters in breast cancer
We investigated if T cell responses to HER2, MUC1 and
SUR were associated with patient clinical features. This
analysis showed that patients with a higher tumour grade
had weaker CD4? T cell responses to MUC1 (p = 0.045)
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(Fig. 2a), but those with oestrogen receptor (ER)-positive
tumours had stronger CD8? T cell responses to HER2
(p = 0.031) (Fig. 2b). No associations with SUR-re-
sponding T cells were found, nor were correlations with
other clinical parameters including T, N or AJCC stage,
total lymph node involvement as well as expression of
Ki67, HER2 or progesterone receptor in the tumour.
Serum cytokines and patient HLA type are
associated with T cell responses to TAAs
Immune features associated with responses to tumour
antigens were sought in the form of serum cytokines and
HLA type. We reasoned that a particular cytokine milieu or
due to immunoediting, T cell responses to tumour antigens
might be favoured or suppressed which might result in high
frequencies of certain HLA types possessing TAA-reactive
T cells. To this end, we measured serum levels of IL-1Ra,
IL-9, IL-10, TGF-b1 and RANTES and performed HLA
typing. We found that only in selected cases were these
features related to responses to tumour antigens; a high
proportion of HLA-A*01? patients lacked T cells
responsive to MUC1, whereas HLA-A*02? patients were
more likely to possess T cells reactive to this antigen than
HLA-A*02-negative patients (Fig. 3a). Considering serum
cytokines, we found higher serum IL-10 levels in patients
who had CD8 HER2-(Fig. 3b) and SUR- (p = 0.02, data
not shown) responsive T cells compared to those who did
not have these cells. Aside from these associations no other
relationships between T cell responses and serum cytokines
or HLA type were found.
Relationships between tumour leukocyte infiltration
and in vitro T cell responses to tumour antigens
Based on the notion that TAA-reactive T cells are active
against tumour cells in situ, we investigated if they were
associated with tumour leukocyte infiltration, namely by
CD4?, CD8?, FoxP3? and CD163? cells, which may act
as local regulators of tumour immunity. These analyses
revealed that there was no association between tumour
leukocyte infiltration and in vitro T cell responses to HER2
Fig. 1 T cell responses to tumour-associated antigens in breast
cancer patients. CD4? and CD8? T cell responses measured by IL-
2, IL-5, IL-10, IL-17, TNF and IFNc production were detected in the
PBMC of 50 breast cancer patients after stimulation with HER2,
MUC1 or SUR TAAs. CD4? and CD8? T cells were considered
responsive to an antigen if they showed a positive signal for any of the
six measured cytokines. a Across these 50 breast cancer patients,
HER2-reactive T cells were observed to be more common than
MUC1- or SUR-reactive T cells. b Responses to all TAAs were more
commonly seen for CD4? than CD8? T cells. c Differences in the
cytokine production profile were observed for CD4? but not for
CD8? T cells when comparing their responses to HER2, MUC1 and
SUR. The percentage for each cytokine was calculated only
considering patients who responded to HER2, MUC1 or SUR. NR
non-responder; R Responder; TAA tumour-associated antigen; HER2
human epidermal growth factor receptor 2; MUC1 Mucin 1; SUR
Survivin
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(Fig. 4a), but patients whose tumours were more densely
infiltrated by CD163? , CD4? T cells (Fig. 4b) as well as
combined cell counts for both CD4? and CD8? T cells
(data not shown) more commonly possessed CD4? T cells
responding to the MUC1 antigen. Conversely, patients who
showed less tumour infiltration by CD8? T cells more
commonly had CD8? T cells responding to SUR (Fig. 4c).
No other associations between TIL and antigen-reactive T
cells were found.
Blood leukocyte populations as surrogate markers
for anti-tumour T cell responses
The immunogenetic, molecular and cellular features investi-
gated so far were only occasionally associated with in vitro T
cell responses to tumour antigens, which led us to pursue
more robust markers of tumour antigen responses in the form
of blood leukocytes. To this end, 30 different myeloid and 23
lymphoid populations comprising T cells, monocytes, den-
dritic cells, natural killer cells, regulatory T cells and mye-
loid-derived suppressor cell phenotypes were tested for
association with T cell responses to the HER2, MUC1 or
SUR antigens (see Online Resource 5 for a complete list of
tested phenotypes). We were particularly interested in
exploring these relationships for leukocytes with suppressor
phenotypes, namely Tregs and MDSCs. Furthermore, to
account for potential location-dependent differences, we also
re-tested a number of cell types that were investigated in
tissue. This analysis revealed that many blood leukocyte
populations were associated with T cell responses to HER2
and MUC1 and SUR. It was surprising that compared with
phenotypically non-suppressive leukocyte populations, we
found relatively few correlations for Tregs (two correlations)
and MDSC phenotypes (nine correlations) (Table 2). Note-
worthy was that patients with higher levels of blood mono-
cytes presented with absent or weaker CD4? and CD8? T
cells responsive to HER2 and MUC1 than patients with lower
levels of monocytes. Similar inverse relationships were also
observed for NK cells, mDCs and CD4? and CD8? T cells
expressing markers of proliferation (Fig. 5), whereas other
populations were positively associated with antigen-reactive
T cells (Table 2). Interestingly, we observed that within
monocytes, the HLA-DR? fraction positively correlated with
Fig. 2 T cell responses to MUC1 and HER2 correlate with tumour
grade and ER receptor expression. T cell responses to the HER2,
MUC1 or SUR TAAs were measured in 50 breast cancer patients
following 12 days of in vitro expansion. The SI (ratio of cytokine
positive cells between peptide-stimulated and unstimulated T cells) of
responding CD4? or CD8? T cells were correlated with the patient
clinical parameters grade, T, N, AJCC stage, total lymph node
involvement as well as tumour expression of Ki67, HER2, ER and
PR. a Patients with more advanced tumour grade showed weaker
responses to MUC1. b ER-positive patients responded more strongly
to HER2 than ER-negative patients. SI stimulation index; ER
oestrogen receptor; HER2 human epidermal growth factor receptor
2; MUC1 mucin 1; *p\ 0.05 (Mann–Whitney U test)
Fig. 3 Patient HLA type and serum cytokine levels correlate with T
cell responses to tumour antigens. Patients with or without HER2-,
MUC1- or SUR-reactive T cells were compared in terms of HLA type
and serum cytokines (n = 50). a HLA-A*01 (p = 0.045) and HLA-
A*02 (p = 0.0001) status was associated with MUC1-reactive T cells
(Fisher’s exact test). CD8? T cells were considered responsive to an
antigen if they showed a positive signal for any of the six measured
cytokines. b Serum IL-10 levels were higher in patients who had
IFNc producing CD8 HER2-reactive T cells (Mann–Whitney U test)
compared to patients without these cells. R responder; NR non-
responder; **p\ 0.01; NS not significant; HER2 human epidermal
growth factor receptor 2; MUC1 mucin 1; SUR survivin
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tumour antigen-reactive T cells, while the HLA-DR- frac-
tion was negatively associated with TAA-reactive T cells,
indicating that the balance between monocyte maturation
states may be relevant for the presence of anti-tumour T cells.
The location of these leukocytes, whether in tissue or in
blood, was also relevant to their relationship with tumour
antigen-reactive T cells; correlations for a particular cell type
in blood were not found when the same cell type was present
in tissue and vice versa (Fig. 4; Table 2), thereby demon-
strating location-dependent differences. Figure 5 shows rep-
resentative relationships between blood leukocyte frequencies
and TAA T cell responses, and Table 2 provides an overview
of all correlations identified. Similar relationships were
obtained whether considering the strength of T cell response
(stimulation index) or categorically comparing patients who
had reactive T cells for each cytokine with those who did not.
Combining immune parameters improves
the accuracy of predicting patients with TAA-
reactive T cells
We sought to improve upon the accuracy of the
parameters found to be associated with TAA-reactive T
cells by analysing multiple immunological features. By
combining different immune parameters, we were able to
achieve superior prediction in the specificity and sensi-
tivity in identifying patients possessing T cells reactive
to HER2, MUC1 or SUR (Fig. 6a, selected results
shown). Furthermore, these combinations of immune
features allowed us to better stratify patients by the
strength and frequency of T cell responses, i.e. into sub-
groups with stronger and more frequent T cell responses
or with weaker and less frequent responses (Fig. 6b,
selected results shown). For example, the group of
patients with below median levels of monocytes and NK
cells only contained HER2 responders, with an average
SI of 14.5. In comparison, the group with above median
levels of these cells was made up of roughly equal
numbers of responding and non-responding patients and
had an average SI of 2.3 (Fig. 6b, left panel). We
observed that combining different types of immunolog-
ical parameters, for example, tumour-infiltrating cells
and blood leukocyte populations, also resulted in better
prediction of TAA responses. Patients with high levels
of tumour infiltration by T cells and low levels of
CD16? mDCs in peripheral blood were more likely to
have T cells reactive to MUC1 compared with patients
without this profile (Fig. 6b, middle panel).
Discussion
This study was conducted to identify composite immuno-
logical features including tumour-infiltrating leukocytes,
HLA type as well as peripheral immune cell types and
cytokines, with the goal of identifying biomarkers which
can accurately select breast cancer patients with responses
to tumour antigens, predict clinical outcome or facilitate
improved therapeutic customisation to individual patients.
Fig. 4 Tumour-infiltrating leukocytes are associated with peripheral
T cell responses to TAAs. The level of tumour leukocyte infiltration
was compared for patients possessing T cells reactive to the HER2,
MUC1 or SUR TAAs with those not possessing antigen-reactive T
cells (n = 50). a Patients with HER2-responsive T cells showed no
difference in their level of TILs. b Patients with MUC1-reactive T
cells showed greater tumour infiltration by CD4? T cells and
CD163? cells. c Patients with T cells reactive to the SUR antigen
had less tumour infiltration by CD8? T cells. Groups were divided
according to patients who possessed the indicated T cell response and
those who lacked these cells. NR non-responder; R responder; TIL,
tumour-infiltrating leukocytes; ***p\ 0.001; **p\ 0.004;
*p\ 0.04; NS not significant (Mann–Whitney U test); TAA tumour-
associated antigen; HER2 human epidermal growth factor receptor 2;
MUC1 mucin 1; SUR survivin
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We assessed T cells responding to HER2, MUC1 or SUR
in 50 breast cancer patients and found certain associations
between T cell responses with HLA type, serum cytokines
and tumour-infiltrating leukocytes. In contrast to these
limited associations, a number of different leukocytes in
blood, including monocytes, natural killer cells, dendritic
cells and T cells broadly correlated with tumour antigen-
reactive T cells. Moreover, accuracy in selecting patients
with tumour antigen-reactive T cells was improved when
considering multiple patient parameters. The cluster of
biomarkers identified here reveal immune profiles corre-
lating with the presence of TAA-reactive T cells that may
allow for the selection of patients with immune systems
most capable of mounting an anti-tumour response, thus
potentially identifying patients who possess a wider
repertoire of TAA-reactive T cells not limited to those
which can be feasibly measured. Ongoing clinical follow-
up of these prospectively recruited patients will reveal
whether the composite set of biomarkers identified here,
including TAA-reactive T cells, will allow superior sur-
vival prediction. Selecting patients using these biomarker
combinations may allow personalised tailoring of patient
treatments, for example, sparing patients with a favourable
prognosis from otherwise unnecessary treatment, or the
Table 2 Correlations between
blood leukocytes and T cell
responses to HER2, MUC1 and
SUR
T cell response Leukocyte population p value r value
CD4 IL-2 Monocytes 0.0001 -0.54
NK cells 0.004 -0.42
CD4? Ki67?, CD8? Ki67? 0.04, 0.02 -0.29, -0.33
CD4 IFN Monocytes 0.0005 -0.49
CD14? CD124? 0.024 0.33
CD4 IL-5 Monocytes 0.0002 -0.53
CD14? CD124? 0.007 0.39
mDCs 0.010 -0.37
NK cells 0.026 -0.33
CD4 TNF Monocytes \0.0001 -0.60
CD14? CD124? 0.0009 0.47
mDCs 0.045 -0.30
NK cells 0.024 -0.33
CD8 TNF Monocytes 0.038 -0.30
pDCs 0.016 -0.35
CD4 IFN CD14? HLA-DR- 0.013 -0.36
CD14? CD124? 0.049 0.29
CD4? CD25? FoxP3? Ki67? CD45RA? 0.033 0.33
CD4 IL-2 CD16? mDCs 0.036 -0.31
CD4 IL-5 Monocytes 0.0005 -0.49
CD14? CD124? 0.006 0.40
mDCs 0.027 -0.32
CD8? Ki67?, CD4? Ki67? 0.002, 0.04 -0.42, -0.29
CD8 IFN CD4? CD25? FoxP3? Ki67? CD45RA? 0.049 -0.31
mDCs 0.028 -0.32
CD4?, CD8? 0.015, 0.017 -0.34, 0.34
ratio CD4/CD8 0.0093 -0.36
CD8 IL-2
CD8 IL-2 Lin-CD14? HLA-DR; \0.05,\0.05 -0.29, 0.29
CD8 TNF Monocytes 0.02 -0.34
mDCs, pDCs 0.024, 0.038 -0.33, -0.30
CD4 IL-2 CD8? Ki67? 0.012 -0.35
CD8 IFN Lin-CD14? HLA-DR; 0.022, 0.015 -0.34, 0.35
CD8 TNF Lin-CD14? HLA-DR; 0.021, 0.017 -0.34, 0.35
Lin, lineage markers CD3 CD19 and CD56. Correlations were assessed using the SI
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administration of more aggressive therapies for patients
with a poorer prognosis.
The results from this study may also have implications
for the treatment of breast cancer patients with
immunotherapies. The clinical benefit of immunomodula-
tory antibodies (so-called check point inhibitors) relies on
the presence or emergence of anti-tumour T cells, sug-
gesting that patients with pre-existing tumour immunity in
the form of TAA-reactive T cells may be more likely to
respond to these drugs [25, 26]. As such, the results pre-
sented here may provide a basis for the selection of breast
cancer patients more likely to benefit from treatment with
immunomodulatory antibodies. Furthermore, patients
without TAA-reactive T cells but who show similar
immune profiles to patients with them may also benefit
from treatment with these drugs due to the existence of
conditions more permissible to the presence TAA-reactive
T cells. These results may also extend to the use of cancer
vaccines, whereby patients who have immune profiles
favourably associated with the presence of anti-tumour T
cells may also be more likely to develop an immune
response to the vaccine and to benefit clinically
[5, 6, 27–29]. Furthermore, our results allow the selection
of patients with antigen-reactive T cells producing specific
cytokines. Because our prior study found that not only the
general presence of TAA-reactive T cells but also the
production of certain cytokines by these cells to be relevant
for patient survival [7], the immune profiles identified here
therefore allow a high degree of specificity in identifying
those most likely to respond to immunotherapy or to have a
favourable prognosis.
Despite numerous associations between blood leuko-
cytes and TAA-reactive T cells, it was surprising that few
correlations were found for populations of cells with sup-
pressor phenotypes, namely Tregs and MDSCs. This sug-
gests that cells corresponding to these putatively
Fig. 5 Correlations between blood leukocytes and TAA-reactive T
cells. Levels of human blood leukocytes correlate with T cells
responding to the HER2, MUC1 or SUR TAAs (n = 50). Fig-
ure shows representative examples for monocytes, natural killer cells,
myeloid dendritic cells and CD8? T cells, which were inversely
associated with TAA-reactive T cells (Spearman correlation). The SI
(ratio of cytokine positive cells between peptide-stimulated and
unstimulated T cells) of responding CD4? or CD8? T cells were
correlated with the frequency of blood leukocytes. TAA tumour-
associated antigen; HER2 human epidermal growth factor receptor 2;
SI stimulation index
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suppressive phenotypes are not suppressive in breast cancer
patients, or if they are suppressive, that they do not exert
suppression against antigen-reactive T cells in blood.
However, the frequencies of a number of cell populations
related to MDSCs and Tregs, namely monocytes and
CD4? T cells, were found to be inversely related to the
presence of TAA-reactive T cells. These observations sug-
gest that there are leukocyte populations in blood which
suppress T cell responses to tumour antigens, but that they
remain imperfectly defined on a phenotypic level. A precise
set of phenotypic markers capable of accurately identifying
suppressive cells may in turn allow more accurate
biomarkers for the identification of patients with tumour
antigen-responsive T cells, but such markers remain elusive
[21]. One obstacle to the identification of such specific
markers is highlighted by the observation in this study that
there are differences in the association with TAA-reactive T
cells and leukocyte populations that are dependent on the
location of the cell population in question (whether in tissue
or blood). This suggests that cellular location and phenotype
are both relevant to the function of any given leukocyte
population, and unless location-specific markers are found,
may further limit the identification of marker proteins which
accurately reflect cellular function.
Conclusion
This study identified composite sets of immune features
which predict patients with TAA-reactive T cells. Con-
sidering that T cell responses to tumour antigens correlate
with breast cancer patient survival, the biomarkers identi-
fied here which include HLA type, serum cytokines,
tumour-infiltrating and blood leukocytes in addition to
in vitro TAA-reactive T cells may allow superior predic-
tion of patient survival or more personalised therapeutic
management of breast cancer patients.
Fig. 6 Combining multiple
immunological parameters
improves the accuracy of
predicting patients with anti-
tumour reactive T cells.
a Greater specificity and
sensitivity in identifying
patients with tumour antigen-
reactive T cells was achieved by
combining immune parameters.
The sensitivity and specificity
was calculated based on the
presence or absence of the
following T cells: CD8 IFNc
(‘‘CD8 SUR’’), CD4 IL-2
(‘‘CD4 MUC1’’) and CD4 IL-2
(‘‘CD4 HER2’’). b Combining
multiple immune parameters
also allowed the sorting of
patients into groups who have
stronger or weaker T cell
responses to HER2, MUC1 or
SUR. Representative examples
shown (Mann–Whitney U test).
The SI was used to represent the
strength of T cell responses to
HER2, MUC2 or SUR. SI
stimulation index; HER2 human
epidermal growth factor
receptor 2; MUC1 mucin 1;
SUR survivin; n = 50;
***p\ 0.0005; *p\ 0.02
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A B S T R A C T
Metastatic melanoma is the most dangerous form of skin cancer, with an ever-increasing incidence worldwide.
Despite encouraging results with immunotherapeutic approaches, long-term survival is still poor. This is likely
partly due to tumour-induced immune suppression mediated by myeloid-derived suppressor cells (MDSCs),
which were shown to be associated with response to therapy and survival. Thus, identifying pathways re-
sponsible for MDSC differentiation may provide new therapeutic targets and improve efficacy of existing im-
munotherapies. Therefore, we’ve analysed mechanisms by which tumour cells contribute to the induction of
MDSCs. Established melanoma cell lines were pre-treated with inhibitors of different pathways and tested for
their capacity to alleviate T cell suppression via MDSC differentiation in vitro. Targeting HSP70/90 in melanoma
cells resulted in reduced induction of immune suppressive cells on a phenotypic and functional basis, for which a
more potent effect was observed when HSP90 was inhibited under hypoxic conditions. This initial study suggests
a novel mechanism in tumour cells responsible for the induction of MDSC in melanoma.
1. Introduction
Melanoma is the most dangerous form of skin cancer with an ever
increasing incidence worldwide. Despite the recent introduction of
promising immunotherapies, the majority of patients with metastatic
disease still face a poor prognosis. Relapse or non-response to these
drugs is likely or at least partly due to tumour-induced immune sup-
pression, mediated by myeloid derived suppressor cells (MDSCs) and
regulatory T cells. MDSCs in particular represent one of the major
barriers preventing effective cancer treatment. These cells dampen
beneficial anti-tumour immune responses by both innate and adaptive
immune cells [1,2]. Supporting their relevance for cancer im-
munotherapy, MDSCs are elevated in the blood of melanoma patients
compared with healthy individuals [3,4], and patients with high re-
lative levels experience shortened survival [5,6] and respond more
poorly to immunotherapy with the anti-CTLA-4 antibody ipilimumab
[7]. In addition to in vitro studies which show that melanoma-induced
MDSCs suppress activated T and NK cells [1,2], a lower proportion of
melanoma patients with high MDSC levels exhibits anti-tumour antigen
T cell reactivity [8]. That in vitro model suggested that the negative
association between high MDSC levels and patient prognosis may be
through suppression of tumour immunity. Several mechanism of MDSC-
mediated immnunosuppresion have already been identified including
the induction of regulatory T cells, impairing NK cell function [9] and
inhibition of T cell activation [10–12]. On a molecular level, T cell
suppression by MDSCs can occur through a variety of secreted factors
such as reactive oxygen species (ROS), arginase and iNOS, TGFb and
indoleamine 2,3.dioxygenase (IDO) [10–12].
Factors that are involved in the expansion and activation of MDSCs,
in addition to cell-cell contact, could either be secreted by tumour cells
themselves, or by stromal cells present in the tumour microenviron-
ment, such as activated T cells. These interactions have been shown to
result in an elevation of MDSCs in melanoma patients compared with
healthy individuals [3,4]. These observations are complemented by in
vitro co-culture experiments with tumour cell lines which show the
induction of MDSC-like cells from healthy human monocytes mediated
by tumour cells [13]. Although several soluble factors including GM-
CSF, IL-6 and PGE2 have been shown to be involved in the differ-
entiation of monocytes into suppressive MDSCs [2,3,14–18], the precise
molecular pathways responsible for their differentiation as well as
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pathways in tumour cells responsible for this remain to be elucidated.
The identification of these mechanisms could reveal novel therapeutic
targets because they contribute to the maintenance of im-
munosuppressive pathways. As such, MDSCs have been proposed as a
major barrier to effective immunotherapy and thus drugs which aim to
affect tumour cells and block their ability to cause differentiation of
myeloid cells into MDSCs may improve the efficacy of other forms of
immunotherapy. Notably, both Obermayer et al. and Mao et al. de-
monstrated the importance of COX2/PGE2 and STAT3 in the differ-
entiation and suppressive function of MDSCs [1,2,14]. Treating T cell/
monocyte cultures with inhibitors targeting the COX2/PGE2 and STAT3
pathway resulted in alleviation of T cell suppression by such melanoma-
induced MDSC-like cells differentiated from normal monocytes. Those
studies focused on the immune-suppressive pathways in monocytes,
whereas the present study was designed to better understand the mo-
lecular pathways in tumour cells responsible for re-programming
normal monocytes to become suppressive MDSCs. Furthermore, few
prior studies have addressed physical characteristics of the tumour
microenvironment that might influence these processes. The tumour
mass has distinctive features when compared with surrounding healthy
tissue. These typically include reduced oxygen tension, acidic pH and
aberrant angiogenesis which contribute to limited oxygen and nutrient
delivery [19–22]. One of the major responses to cellular stress such as
hypoxia is the up-regulation of heat shock proteins (hsps) and induction
of the hypoxia inducible factor 1 α (HIF-1α) transcription factor. HIF-
1α has been shown to regulate the expression of hsps and to be involved
in the differentiation of MDSCs [23], while hypoxia itself has been
linked to aberrant cytokine expression that may support MDSC differ-
entiation. Considering this, the present study was designed to in-
vestigate the role that hsps, pH regulatory proteins as well as other
molecular pathways may play in the differentiation of MDSCs in mel-
anoma, with the aim of identifying pathways in tumour cells which are
responsible for inducing the differentiation of MDSCs.
To investigate MDSC induction by tumour cells, we developed an in
vitro co-culture model which allowed us to reconstruct melanoma-
monocyte interactions (Fig. 1). To consider the distinctive features
found in the tumour mass, we also considered the influence of low
oxygen tension in our in vitro model. To pin-point the molecular path-
ways in tumour cells responsible for inducing immune suppression, we
pre-treated melanoma cells with a panel of inhibitors including those
against molecular hsps, pH regulatory proteins and inhibitor of COX
and JAK/STAT signaling. The primary goal of this study was to uncover
mechanisms in tumour cells responsible for causing the differentiation
of monocytes into MDSCs. We identified inhibitors preventing the in-
duction of MDSCs by targeting certain molecular pathways in mela-
noma cells, and tested whether this inhibition would be effective under
hypoxic conditions, in order to give a better indication of the efficacy of
such approaches in vivo. The identification of suppressive pathways in
melanoma cells may point to new therapeutic targets and improve the
efficacy of existing immunotherapies by alleviating tumour-induced
immune suppression.
2. Materials and methods
2.1. Cell isolation and patient materials
Peripheral blood mononuclear cells were isolated from consenting
healthy donors of whole-blood leukoreduction filters (“Kegel”,
Tübingen University Hospital) using Ficoll-Hypaque gradient cen-
trifugation and stored in freezing medium containing 10% DMSO, 20%
FCS and 70% RPMI in liquid nitrogen until use. Monocytes were iso-
lated using magnetic bead separation with a CD14+ monocyte isola-
tion kit using LS separation columns (Miltenyi Biotech, Teterow,
Germany). Autologous T cells were isolated from the negative fraction
of the monocyte isolation by CD3+ T cell isolation kit according to the
manufacturer’s protocol (Miltenyi Biotech).
2.2. Tumour cell line culture
The EST human melanoma cell lines were sourced from the
European Searchable Tumor Line Database (ESTDAB; http://www.ebi.
ac.uk/ipd/estdab). They are currently also available from the European
Collection of Animal Cell Cultures (ECACC, see https://www.phe-
culturecollections.org.uk/products/celllines/generalcell/estdab-cell-
lines-introduction.aspx). These cell lines have been tested for myco-
plasma and verified with DNA finger printing. For melanoma-monocyte
co-culture experiments 2.0× 105 melanoma cells were cultured in 2ml
IMDM medium supplemented with 10% FCS per well in a 6-well plate
and allowed to rest overnight before being treated with either 5 µM
geldanamycin (an HSP90 inhibitor, Invitrogen, San Diego, USA), 4 µM
methylene blue (inhibition of HSP70/NO synthase, which affects pro-
tein function and ubiquitination as well as modulation of polyglutamine
protein degradation, Sigma-Aldrich), 750 µMa acetylsalicylic acid (COX
inhibitor, Sigma-Aldrich, Steinheim, Germany), 35 µM AG490 (JAK/
STAT inhibitor), 300 µM U-104 (CA inhibitor, Sigma-Aldrich) for 18 h.
The concentration of each drug was titrated so that melanoma cell line
viability and growth was not impaired (data not shown). Melanoma
cells were additionally left untreated as a control. Following the 18 h
treatment, inhibitors (or medium in the case of control wells) were
removed by three gentle washes with Hank’s Balanced Salt Solution
(HBSS) (Sigma-Aldrich). Treated and control melanoma cells were
subsequently cultured in IMDM with 10% FCS until the addition of
isolated CD3+ and CD14+ cells (typically 3 h). To further reduce the
chance that the inhibitors could directly interact with the isolated
Fig. 1. In vitromodel of immune suppression by melanoma cells. Established melanoma cell lines were cultured overnight in IMDM with 10% FCS before being treated for 18 h with either
GA, MB, U-104, acetylsalicylic acid, AG490 or left untreated as a control. Inhibitors were removed after 18 h and melanoma cells were subsequently co-cultured with isolated CD14+ and
activated CFSE-labelled CD3+ cells at a ratio of 5:1 for 5 days. Cells were then harvested and stained for CD3, CD4, CD8 (T cells) or CD14 and HLA-DR (monocytes) and analysed using
flow cytometry. GA: Geldanamycin (HSP90 inhibitor); MB: methylene blue (HSP70/NO synthase inhibitor), U-104 (CA inhibitor); acetylsalicylic acid (COX inhibitor); AG490 (JAK/STAT
inhibitor).
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CD3+ and CD14+ cells, melanoma cultures were washed once more
with HBSS before the addition of CD3+ and CD14+ cells. Isolated
CD3+ and CD14+ cells were added to melanoma cells at a ratio of 1:5
T cells : monocytes (5.0× 105 T cells to 2.5×106 monocytes). Isolated
T cells and monocytes were added to 6 well plates and co-cultured for
5 days under the following conditions: 1) pre-treated melanoma cells
(Fig. 1), 2) non-treated melanoma cells (Figs. 1 and 3) without mela-
noma cells (positive control).
2.3. T cell proliferation
T cell proliferation was used to estimate the degree of immune
suppression in melanoma-monocyte co-culture experiments. Isolated
(CD3+) T cells were labelled with carboxyfluorescein succinimidyl
ester (CFSE, Invitrogen) at a concentration of 1.4 µmol/L in 1ml PB
buffer for 5min at room temperature. Non-bound CFSE was removed by
three rounds of washing (X-Vivo 15, Lonza, Verviers, Belgium) followed
by centrifugation at 300g for 5min. 5.0× 105 CFSE-labelled T cells
were added to 6 well plates either with monocytes as a positive control
(2.5× 106 monocytes giving a ratio of 1:5) or with monocytes and
melanoma cells (2.0× 105) to investigate suppressive effects of mela-
noma-educated monocytes. Additional controls consisting of melanoma
cells only and T cells only were included in selected cases. All co-culture
experiments were performed for 5 days in 6 well plates with 7ml IMDM
containing 10% FCS unless otherwise stated. T cells were activated with
anti-CD3/CD28 mAb coated beads (2 µL per well). After 6 days of cul-
ture, the degree of T cell proliferation by CD4+ and CD8+ T cells was
measured by flow cytometry.
2.4. Phenotypic analysis of T cells and monocytes
Co-cultured T cells and monocytes were removed from 6 well plates
by gentle resuspension and aspiration of the culture medium followed
by washing with HBSS. Cells were then stained for cell surface markers
as previously described [24], but without exposure to light. Details
relating to the panel of antibodies appear in Supplementary data S1.
Antibody panels were established using fluorescence minus one con-
trols. Cytometer setup and tracking beads were run before and after
each sample measurement to ensure consistency in machine perfor-
mance.
2.5. Flow cytometry data analysis
Flow cytometry data were analysed by first excluding events not
part of the main acquisition population using a time-vs-side scatter
gate. Cell doublets were then removed before the exclusion of cell
debris with the use of a morphological gate. The full gating strategy
employed to assess T cell proliferation and to identify T cells and
monocytes is shown in Supplementary data S2.
3. Results
Mao et al. has previously shown that MDSC-like cells can be induced
by culturing monocytes from healthy individuals with melanoma cells
[1]. Based on this observation, here we established a model of tumour-
induced immune suppression that allows interactions between three
cell types to be studied: tumour cells, monocytes and T cells. Pre-
liminary experiments determined the optimum ratio of these different
cell types (data now shown), and thereafter we sought to characterise
how these cells interact across time. For these experiments, we cultured
peripheral monocytes from a healthy donor with autologous CFSE-la-
beled T cells and the EST-200 melanoma cell line for 24, 48, 72, 96 or
120 h in vitro. We observed that CD4+ T cell suppression plateaued
after 96 h, whereas CD8+ T cell suppression increased with time
(Fig. 2A, left panel). An example of inhibited proliferation of CD8+ T
cells according to CFSE dilution assay is shown in Fig. 2A (right panel).
These results suggest that interactions between melanoma cells and
monocytes result in T cell suppression, because T cell proliferation was
not inhibited when T cells were cultured directly with melanoma cells
(Supplementary data S3 and S4). To investigate these observations in
more detail we tested if T cell suppression was associated with changes
in monocyte phenotype over time. Low levels of HLA-DR have been
proposed as a marker for suppressive myeloid cells, thus we tested the
expression of this molecule in our in vitro culture model (Fig. 2B). In
accordance with the observation of greater T cell suppression over time,
we found that HLA-DR expression on monocytes cultured with mela-
noma cells was also reduced with time when compared to HLA-DR
expression on monocytes cultured only with T cells. Collectively, these
results suggest that melanoma cells cause monocytes to differentiate
into cells that phenotypically and functionally resemble myeloid-de-
rived suppressor cells.
To validate these initial results obtained in our in vitro model of
MDSC differentiation using the EST-200 melanoma cell line, we tested 6
healthy donors with a greater number of established melanoma cell
lines (EST-41, EST-83, EST-145, EST-152 and EST-200). We observed
similar results with these cell lines as with EST-200 – T cell proliferation
was suppressed when monocytes from healthy donors were co-cultured
with melanoma cells compared to T cells and monocytes without mel-
anoma cells. Of the cell lines tested, EST-145, EST-152 and EST-200
were found to induce the greatest degree of suppression with between
90 and 70% T cell suppression compared to T cells and monocytes
cultured without melanoma cells (Fig. 3, top panel). Generally
speaking, these results are in accordance with the changes previously
reported to occur when monocytes undergo differentiation into immune
suppressive cells (Fig. 3, bottom panel) [2], namely HLA-DR down-
regulation and CD14 up-regulation. To exclude direct effects of mela-
noma cells on T cells, we co-cultured T cells with melanoma cells
without monocytes; T cell proliferation was not inhibited under these
conditions (n=2, data not shown). It should be noted that some
melanoma cell lines (n= 3, data not shown) failed to induce monocytes
to become suppressive for T cell proliferation, suggesting that there is
heterogeneity in the induction of immunosuppressive capacity or in the
immune suppressive mechanisms employed by melanoma cells. Fur-
thermore, this observation demonstrates that the observed immune
suppressive effects in our co-culture model are not caused by non-
specific interactions between monocytes and the presence of any type of
cell.
Having developed a model that allowed us to generate MDSC-like
cells in vitro, we then attempted to identify molecular pathways in
melanoma cells responsible for converting normal monocytes into im-
mune suppressive cells. To achieve this, we pre-treated melanoma cells
for 18 h with a panel of inhibitors targeting a range of different mole-
cular pathways including geldanamycin (HSP90 inhibitor), methylene
blue (inhibitor of HSP70/NO synthase), acetylsalicylic acid (COX in-
hibitor), AG490 (JAK/STAT inhibitor) and U-104 (CA inhibitor). Prior
to the addition of isolated monocytes and T cells, pre-treated melanoma
cultures were thoroughly washed several times, allowed to rest and
washed once more. This was performed to minimise the potential for
direct contact between soluble drugs and the isolated immune cells. In
order to test the effect of the remaining drug on T cell proliferation, T
cells were directly cultured with melanoma cells (i.e. without mono-
cytes). Here, proliferation was found to be comparable whether the
melanoma cells had been treated with inhibitors or not, suggesting that
either no traces of the drugs remained, or the levels were so low that
they did not affect the functioning of the immune cells (data not
shown). Of the panel of inhibitors tested, we observed that selected
drugs alleviated the induction of immune suppression, with geldana-
mycin being most effective in this respect. This was followed by the
other hsp inhibitor, methylene blue, while occasional but less consistent
effects were seen for U-104. No significant effect was found for acet-
ylsalicylic acid or AG490. The effect of inhibitors was not the same for
all melanoma cell lines, but for geldanamycin an effect was observed in
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3 of 4 tested melanoma cell lines (EST-145, EST-152, EST-200,
Fig. 4B–D). This was followed by the less effective inhibitors methylene
blue and U-104 (Fig. 4B–D). The one exception to this trend was for the
cell line EST-41 (Fig. 4A). Here, the most effective inhibitor was me-
thylene blue, followed by geldanamycin and U-104 with similar effects.
Inhibitor-induced alleviation of T cell suppression induction was again
reflected by changes in monocyte phenotype; we observed increased
expression of HLA-DR when T cell suppression was reduced (Fig. 4D,
bottom panel). Again, this association was not observed with cell line
EST-41: there was no association between HLA-DR expression on mel-
anoma-educated monocytes and the degree of T cell proliferation when
monocytes and T cells were co-cultured with EST-41.
Fig. 2. Monocytes co-cultured with melanoma cells resemble MDSC cells in phenotype and function. Isolated monocytes and T cells were co-cultured with the melanoma cell line EST-200
for the time shown (A). The level of T cell suppression was determined using CFSE-stained autologous T cells. T cell suppression by melanoma-educated monocytes increased over time
with a maximum of suppression observed on or after 96 h. (B) Phenotypic changes (HLA-DR) of melanoma-educated monocytes (identified as CD14+) were analysed using flow
cytometry.
Fig. 3. Monocytes co-cultured with melanoma cells sup-
press T cell proliferation and show a phenotype resembling
MDSCs. Monocytes and T cells were co-cultured with the
established melanoma cell lines EST-41, EST-83, EST-145,
EST-152 or EST-200. T cell proliferation as well as pheno-
typic analysis of monocytes (CD14 and HLA-DR expression)
was analysed using flow cytometry (n= 6). T cell pro-
liferation was suppressed when monocytes were co-cultured
with melanoma cell lines EST-41, EST-83, EST-145 and EST-
200 (top panel) (relative degree of suppression obtained by
comparing proliferation of T cells and monocytes cultured
without melanoma cells). In line with the observed sup-
pressive capacity of monocytes co-cultured with melanoma
cells, phenotypic analysis revealed an up-regulation of
CD14 and down-regulation of HLA-DR expression on mel-
anoma-educated monocytes (bottom panel).
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To exclude the possibility that alleviation of T cell suppression in
inhibitor pre-treated co-cultures was related to the inhibitor affecting
the growth of melanoma cells, we performed experiments with double
the number of melanoma cells (4.0× 105). Here, we did not observe
differences related to the number of melanoma cells (data not shown).
Additionally, we also titrated drug concentrations so growth was not
adversely affected by the concentrations of these drugs used. Together
these results suggest that the effect of these drugs at alleviating T cell
suppression occurs through molecular pathways in melanoma cells, not
through indirect effects on the growth of melanoma cells.
Having shown that geldanamycin was most effective in reducing T
cell suppression induction, we then attempted to determine the time-
dependent effect of this drug on preventing the conversion of mono-
cytes into immune suppressive cells. To achieve this, the melanoma cell
line EST-200 was pre-treated for 18 h with geldanamycin as before, and
then co-cultured with monocytes and autologous CFSE-labeled T cells
from two healthy donors for 24–120 h. We observed a decrease in T cell
suppression over time when monocytes were co-cultured with gelda-
namycin pre-treated melanoma cells compared to co-cultures with un-
treated melanoma cells (Fig. 5, left panel). Changes in CD4+ and
CD8+ T cell proliferation across time are shown in Fig. 5 (right panel).
To investigate whether these observations are associated with changes
in monocyte phenotype over time, we also analysed the expression of
the myeloid maturation marker HLA-DR. In accordance with the ob-
servation of decreased T cell suppression over time, we found that HLA-
DR expression on monocytes cultured with geldanamycin pre-treated
melanoma cells was increased as well. Additionally, because several
soluble factors including GM-CSF have been shown to be involved in
the differentiation of monocytes into suppressive MDSCs, we analysed
the expression of GM-CSF in monocyte-melanoma co-cultures in pre-
liminary experiments. Here we observed decreased expression of GM-
CSF when melanoma cells were pre-treated with geldanamycin (data
not shown). Collectively, these results suggest that pre-treating mela-
noma cells with geldanamycin (blockade of HSP 90) results in a long
lasting effect at preventing the conversion of normal monocytes into
immune suppressive cells.
Having shown that geldanamycin and methylene blue were the
most effective drugs at preventing the induction of immune suppres-
sion, we investigated whether they are effective under conditions which
more closely mimic the tumour microenvironment. Many drugs are less
Fig. 4. Pre-treating melanoma cell lines with GA or MB alleviates T-cell suppression in melanoma-monocyte co-cultures. Melanoma cell lines EST-41, EST-145, EST-152 and EST-200
were pre-treated for 18 h with a panel of inhibitors targeting different molecular pathways (GA – HSP90, MB – HSP70 and U-104 – CA) (n= 6). Suppression of CD4+ and CD8+ T cells
was alleviated when melanoma cells were pre-treated with these inhibitors (upper two panels). GA and MB were most effective in reducing T cell suppression. Phenotypic analysis of
melanoma-educated monocytes agreed with functional analysis observed here; HLA-DR expression was up-regulated on monocytes co-cultured with pre-treated melanoma cells relative
to control monocytes co-cultured with untreated melanoma cells (bottom panel).
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effective due to the conditions found in the tumour microenvironment
[25,26]; however, because these two inhibitors target proteins which
are up-regulated under the stressful conditions of the tumour micro-
environment we hypothesised that they may be more effective under
these conditions. To achieve this, we utilised our established in vitro
model to induce MDSC-like cells under conventional culture conditions
and compared the results obtained under hypoxia (2% O2). As shown
above, we observed that geldanamycin and methylene blue reduced T
cell suppression in co-cultures performed under conventional culture
conditions. Comparing the effect of these drugs between the conven-
tional and 2% O2 conditions showed that the effect of alleviating im-
mune suppression was not lost under hypoxic conditions. On the con-
trary, a trend of greater activity under hypoxia was observed (Fig. 6).
Similar to GA, MB was found to be equally effective under hypoxic and
hyperoxic conditions (Fig. 6). This suggests that hypoxia in the tumour
microenvironment in vivo would not diminish the efficacy of drugs
against HSP90.
4. Discussion
Through their immune suppressive activity, MDSCs are thought to
represent one of the major barriers preventing effective cancer treat-
ment [5]. A number of mechanisms by which MDSCs suppress the
immune system have been elucidated, and several extracellular me-
chanisms of MDSC induction have been reported [16,18]. In contrast,
little is known about whether intra-cellular pathways in tumour cells
are responsible for converting monocytes into immune suppressive
cells. In the present study, using a new approach for in vitro generation
of tumour-associated human MDSCs, we describe the blocking of MDSC
induction by pretreating melanoma cells with hsp inhibitors. We report
that MDSC-like cells could be induced by co-culturing monocytes with
several melanoma cell lines, suggesting that melanoma cells are able to
direct monocytes from healthy individuals to differentiate into cells
capable of suppressing T cell proliferation. Furthermore, this observa-
tion suggests that tumour-induced MDSC differentiation is a mechanism
of immune suppression that could also occur in melanoma patients [1].
Although several soluble factors including GM-CSF, IL-6 and COX-2/
PGE2 have been shown to be involved in the differentiation of mono-
cytes into suppressive MDSCs [16], the molecular pathways in tumour
cells responsible for the induction of MDSC-like cells remain to be
elucidated. In preliminary experiments on isolated monocyte-mela-
noma cell co-cultures we observed reduced GM-CSF expression in co-
cultures pre-treated with geldanamycin, suggesting that Hsp90 is in-
volved in the production of GM-CSF. Because GM-CSF has been shown
to be involved in the differentiation of MDSCs, we pretreated melanoma
cells with a panel of inhibitors, in contrast to prior studies which di-
rectly treated melanoma-educated monocytes with inhibitors, in order
to identify pathways in the tumour cells themselves that were re-
sponsible for maintaining immunosuppressive networks. Lechner et al.
has shown that neutralisation of GM-CSF, IL-6 and IL-1beta in tumour
cell line-PBMC co-cultures abrogated induction of CD33+ suppressor
cell function and restored T cell proliferation to a level comparable to
controls [18]. Here, we have tested the potential of a panel of inhibitors
including those against hsps, pH regulatory proteins and inhibitors of
COX and JAK/STAT signaling. Co-culturing monocytes from healthy
individuals with melanoma cells pre-treated with geldanamycin (tar-
geting HSP90) or methylene blue (targeting HSP70/NO synthase) re-
sulted in increased HLA-DR expression on CD14+ monocytes and de-
creased suppression of T cell proliferation. Interestingly, comparing the
effect of the different drugs between melanoma cell lines, we observed
Fig. 5. Time-dependent effects of GA in co-cultures of monocytes, T cells and melanoma cells. The melanoma cell line EST-200 was pretreated with GA for 18 h before being removed and
co-cultured with isolated CD14+ cells plus activated CFSE-stained CD3+ T cells from 2 healthy individuals for either 24–120 h. We observed an increase in T cell proliferation of CD4+
and CD8+ cells over time when monocytes were co-cultured with GA pre-treated melanoma cells. In accordance with changes in T cell proliferation, we also found an increase in HLA-DR
expression on monocytes in GA-pretreated co-cultures (left panel). An example of CD4+ and CD8+ T cell proliferation according to CFSE is shown in the right-hand panel.
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differences in the capacity to alleviate T cell proliferation and this
differences in preventing melanoma cells from inducing MDSCs. This
suggests that different melanoma cell lines may use different me-
chanism to convert monocytes into suppressive MDSCs and thus re-
sulting in different effects of the drugs on alleviating T cell prolifera-
tion. However, the majority of cell lines were susceptible to treatment
with GA followed by less effective inhibitor methylene blue. Therefore,
these results show that targeting HSP70 and HSP90 within tumour cells
prevents the induction of monocyte differentiation into suppressive
immune cells on both at a phenotypic and functional level [27–30]. The
fraction of cell lines which did not respond to geldanamycin treatment
may use HSP90-independent mechanisms of MDSC differentiation, be-
cause every melanoma cell line examined to date has been shown to
express HSP90 [31]. HSP70 and HSP90 are two major types of mole-
cular chaperones that have central roles in cellular functioning by
maintaining the integrity of intracellular proteins [32]. These proteins
are highly conserved and present in all cells of every organism [33],
thus our results obtained in vitro using established cell lines are likely to
represent the roles that these proteins play in vivo. These molecules act
in a concerted fashion together with co-chaperones to assist in the
folding, function and degradation of a wide range of client proteins.
Furthermore, they play key roles in cancer; their up-regulation in re-
sponse to stress assists the functioning of cancer cells under the harsh
conditions of the tumour microenvironment, while their chaperoning
action maintains key signalling networks responsible for aberrant cell
division [34]. Because inhibiting the function of hsps alleviated tu-
mour-induced immune suppression, this suggests that there are over-
lapping networks between those traditionally thought to be responsible
for cancer maintenance (i.e. anti-apoptotic and signalling pathways)
and those more recently appreciated to influence cancer progression
such as immune suppression. Indeed this is reflected in the realisation
that traditional chemotherapeutic drugs exert much of their beneficial
effect through immune modulatory mechanisms [35]. Given that
MDSCs have been shown to be induced through pro-inflammatory
pathways, it seems plausible that inhibiting HSP70 and HSP90 in tu-
mour cells affects the production of pro-inflammatory cytokines. Sup-
porting this notion, preliminary results showed reduced GM-CSF pro-
duction in monocyte-melanoma cell co-cultures when melanoma cells
were pre-treated with the HSP90 inhibitor geldanamycin.
Because hypoxia is a widespread feature of the tumour micro-
environment that is also clinically important [25,26], culturing tumour
cells under high oxygen conditions (as is the case with cultures in air)
Fig. 6. GA is more effective in alleviating T cell suppression under hypoxic than under conventional culture conditions. The melanoma cell lines EST-152 and EST-200 were pretreated
with GA or MB and co-cultured with isolated monocytes and activated CFSE-stained CD3+ T cells for 120 h under either conventional (20% O2) or hypoxic (2% O2) conditions. GA
pretreated melanoma cells co-cultured with monocytes and T cells under hypoxic conditions were found to be more sensitive to GA treatment, resulting in less T cell suppression
compared to the conventional setting. The effect of MB was not inhibited by hypoxic either, and was found to be at least as effective under these conditions.
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may result in the generation of misleading results. The tumour mass
consists of areas with distinctive conditions when compared with sur-
rounding healthy tissue, including reduced oxygen tension, acidic pH
and aberrant angiogenesis which contributes to limited oxygen and
nutrient delivery. The major mechanism by which cells respond to
hypoxia is through modulation of the HIF transcription factor [36]. HIF
has been shown to regulate the expression of hsps, while HSP90 itself
stabilises HIF in melanoma cells under hypoxic conditions [37,38]. It
has been shown that hypoxia is capable of up-regulating the expression
of HSP70 and HSP90 [31,39]. Furthermore, Hsp90 is important for
hypoxic tolerance as measured by the growth rate and viability of
melanoma cells [31]. As such, given the importance of hsps under hy-
poxic conditions, hsp-inhibiting drugs may be relatively more effective
in hypoxic tumours, for which many standard therapies are known to be
less effective [25]. Considering this, we developed the hypothesis that
targeting these molecules in tumour cells under low oxygen tension will
not result in diminished efficacy that is associated with many drugs. On
the contrary we predicted that drugs against these molecules may be
more effective under low oxygen tension. Indeed, our results demon-
strate that drugs targeting HSP70 and HSP90 do not suffer from re-
duced efficacy under hypoxic conditions, while we observed a trend of
a more potent effect when inhibiting HSP90 under these conditions.
These results suggest that melanoma cells rely more heavily on these
molecules under hypoxic conditions, in turn resulting in a similar or
greater effect when measuring consequences of inhibiting their action
under these conditions. These observations suggest that targeting mo-
lecules such as hsps that tumour cells more heavily rely on under hy-
poxic conditions may avoid the issue of weakened activity under these
conditions.
Aside from the observation that the beneficial effects on preventing
immune suppression when targeting HSP70 and HSP90 in tumour cells
is not diminished by hypoxic conditions, further possible implications
of our results relate to the long duration of effect that we observed.
Tumour cells were exposed transiently to these drugs (18 h), before
being co-cultured for another 5 days in our co-culture model with im-
mune cells. We observed a maintenance of the effect for CD4+ cells
after 5 days post-exposure, while an increasing strength of alleviating
suppression of proliferation of CD8+ T cells was seen up until 5 days.
These results suggest that a single exposure to these drugs is sufficient
to result in a long-lasting therapeutic effect, potentially saving the pa-
tient from unnecessary drug side effects. Hsp inhibitors have been
trialed clinically, but not in dosing schedules similar to the conditions
used here in which sub-lethal doses that do not directly kill tumour cells
were employed followed by a long duration without exposure to the
drug.
5. Conclusion
Collectively, this study demonstrates a novel mechanism in tumour
cells responsible for the induction of MDSC-like cells in melanoma. A
single, sub-lethal dose was sufficient to provide protection against the
induction of immune suppression. Furthermore, unlike many standard
therapies the activity of these drugs was not diminished by hypoxic
conditions. This initial study into hsp-mediated immune suppression
warrants further investigation to validate the proposition of hsps as
immunomodulatory agents.
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CD3-A700  BD Biosciences (Franklin Lakes, USA) 
CD4-APC Milteny Biotec (Bergisch Gladbach, Germany) 
CD8-PB BD Biosciences 
CD14-APC-H7 BD Biosciences 
  
MDSCs  
CD33-PE eBiosciences (San Diego, USA) 
CD14-BV711 Bio Legend (San Diego, USA) 
CD15-FITC BD Biosciences 
CD86-PB Bio Legend 
CD34-APC BD Biosciences 
HLA-DR-PerCP-CY5.5 BD Biosciences 
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High levels of blood T cells identify breast cancer patients with HER2, MUC1 and 
SUR-reactive T cells 
Context: 
This study analysed blood leukocytes in order to identify surrogate 
markers for antigen-reactive T-cells for use in routine patient monitoring.  
Material and Methods: 
Using flow cytometry we assessed T-cells reactive to the HER2, MUC1 
and SUR antigens and determined the levels of T-cells, NK and B-cells in 
the blood of 50 breast cancer patients.  
Results: 
High levels of T-cells at various differentiation stages were associated 
with the presence of antigen-reactive T-cells. Combining leukocyte 
populations increased sensitivity and specificity up to 100% in identifying 
patients with antigen-reactive T-cells.  
Conclusion: 
We identified surrogate markers for antigen-reactive T-cells, which 
prevent the time-consuming and hard-to-standardise bioassays required to 
directly measure them. 
Keywords: tumour-associated antigen, T cells, NK cells, B cells, breast cancer, 
HER2, Survivin, MUC1, antigen-reactive T cells 
 
 
Introduction 
The most common treatments for breast cancer such as radio-, chemo- or hormone 
therapy are often sub-optimal, particularly for late-stage patients. As such, there is a 
need to optimise the therapeutic management and identify more effective therapies for 
breast cancer patients. One approach to improve treatment options may be the use of 
immunotherapies, which utilise the patient’s own immune system to control tumour 
growth. There are different forms of immunotherapy including monoclonal antibodies 
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such as “checkpoint inhibitors”, cancer vaccines or other methods that aim to harness 
the immune system. Immunotherapy may be used in combination with 
chemotherapeutic agents that act directly on tumour cells and which can induce the 
release of tumour-associated antigens (TAAs). The release of such cancer-associated 
proteins may allow the immune system to more effectively mount an immune response 
against tumour cells expressing them. However the efficacy of such approaches relies 
on the presence of immune cells which can recognise and kill tumour cells expressing 
relevant tumour antigens.  
We have previously shown that breast cancer patients who possess CD8+ T cells 
reactive to the HER2 TAA experience superior overall survival. This finding closely 
links TAA-reactive T cells with patient clinical outcome in breast cancer. However not 
every patient possesses tumour antigen-reactive T cells, making it important to identify 
these patients in order to optimise their therapeutic management. Lack of antigen-
reactive T cells could be due to the state of the immune system which inhibits the 
presence or function of such reactive T cells. For example, regulatory T, B and Natural 
Killer (NK) cells as well as myeloid-derived suppressor cells (MDSCs) have been 
shown to suppress antigen-specific T cell responses (Deniz et al., 2008, Bonertz et al., 
2009, van de Veen et al., 2013) and which may limit the potential clinical benefit of 
antigen-reactive cells to the patient. Given that TAA-reactive T cells are closely 
associated with a survival benefit for patients (Walter et al., 2012, Bailur et al., 2015, 
Rittig et al., 2016), understanding the immune contexts that permit the presence of such 
cells may allow superior prediction of patient survival, better treatment individualisation 
or the identification of new therapeutic targets.  
Our previous study (Janssen et al., 2016) investigated broad immunological 
features in breast cancer patients including HLA type, serum cytokines, tumour-
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infiltrating leukocytes and blood leukocytes, with the aim of identifying the features 
which most accurately select patients with tumour-antigen reactive T cells. The results 
from that study showed blood leukocytes to be the most informative parameter for 
identifying which patients possess antigen reactive T cells, and reciprocally for 
identifying the patients who lack these cells. Considering our prior studies, here we 
aimed to establish a more accurate method of identifying patients with TAA-reactive T 
cells by expanding on the relatively limited set of blood leukocytes previously 
examined. The identification of easily measurable blood-based surrogate markers that 
indicate the presence of antigen-reactive T cells may allow the individual prediction of 
clinical course by avoiding the time- and resource-intensive in vitro stimulation 
procedures required to directly measure TAA-reactive T cells. The protocols required to 
measure antigen-reactive T cells are complex and require a high degree of expertise; 
thus finding easily measurable surrogate markers might improve protocol 
standardisation to facilitate use in less-specialised laboratories. Furthermore, 
understanding the composition of the immune system that favours the generation of 
TAA-reactive T cells may uncover new therapeutic targets or allow the selection of 
patients more likely to benefit from therapies which rely on the presence of tumour 
antigen-specific T cells such as vaccines or checkpoint inhibitors. As such, this study 
aimed to take the first step towards the eventual clinical employment of blood 
leukocytes as markers for antigen-reactive T cells. To this end, we measured a number 
of B, NK, and T cell populations at different stages of maturation and differentiation in 
the peripheral blood of 50 non-metastatic breast cancer patients and investigated their 
association with T cells reactive to the HER2, MUC1 and SUR tumour-associated 
antigens. Ongoing clinical follow-up will reveal which of the blood leukocyte 
populations measured here are associated with patient prognosis. 
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Clinical significance 
• Understanding the composition of the immune system that favours the 
generation of TAA-reactive T cells may allow superior prediction of patient 
survival, better treatment individualisation, the selection of patients more likely 
to benefit from therapies or the identification of new therapeutic targets 
• The identification of easily measurable blood-based surrogate markers that 
indicate the presence of such cells may allow the use in routine clinical 
monitoring. 
 
Materials and Methods  
Patients 
Blood from 50 patients with non-metastatic invasive carcinoma of the breast were 
recruited at St. Savas Cancer Hospital in Athens between February 2014 and May 2015. 
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 All samples were collected one day prior to surgery. Peripheral blood mononuclear 
cells were isolated from whole blood using Ficoll-Hypaque gradient and stored in liquid 
nitrogen before being shipped to the Tübingen University Hospital for analysis. Written 
informed consent was obtained for all patients, and the study was approved by the ethics 
committee of St. Savas Cancer Hospital (4-11-2013). Study participants were diagnosed 
with non-metastatic invasive ductal carcinoma, including patients with tumours of any 
size but without extension to the chest wall (i.e. patients of AJCC stages 1, 2A, 2B, 3A 
and 3C (if no extension to the chest wall) were included but AJCC stages 3B and 4 were 
not). None of these patients were treated with neoadjuvant chemotherapy or were 
enrolled in other research protocols, nor did they have any history of cancer or other 
serious health problems. Tumour expression of hormone receptors (progesterone (PR) 
and oestrogen receptors (ER)), the HER2 oncoprotein and the marker of cell 
proliferation Ki67 was available for all patients. Expression of MUC1 and SUR were 
not available. See Table 1 for a detailed description of the patient cohort.  
Detection of antigen-reactive T cells 
T cell responses to HER2, Mucin1 (MUC1) and Survivin (SUR) were measured after 12 
days of in vitro culture. Detection of reactive T cells was performed as described in our 
prior study (Bailur et al., 2015) (see Additional File 1 for a full list of antibodies 
employed). Cytometer setup and tracking beads (BD Bioscience) were run before and 
after each sample measurement to ensure consistency in machine performance. The 
inclusion of a positive biological control (stimulation with influenza peptides,) was used 
to certify consistency in sample quality and the prevention of false negative results. 
Phenotypic analysis of T, B and Natural Killer cells 
For characterisation of T, B and NK cells, PBMCs were thawed and stained as 
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previously described (Bailur et al., 2015) using the antibody panels in Additional file 1. 
Antibody panels were established using fluorescence minus one controls. Cytometer 
setup and tracking beads were run before and after each sample measurement to ensure 
consistency in machine performance. The limited nature of patient material did not 
permit multiple testing of the same sample, but we performed multiple independent 
measurement of a healthy control donor (n = 3) in order to ensure consistency in 
measurement conditions. 
Flow cytometry data analysis 
Flow cytometry data were analysed by first excluding events not part of the main 
acquisition population using a time-vs-side scatter gate. Cell doublets were then 
removed before the exclusion of dead cells (EMA (ethidium monoazide)-positive 
events) and cell debris with the use of a morphological gate (see Additional file 2). The 
assessment of T cell responses to tumour-associated antigens was performed using the 
same method as in our previous study (Bailur et al., 2015); we compared control 
(unstimulated) and peptide-stimulated cultures as described in the methods section 
“Detection of antigen-reactive T cells” and assigned a positive response when the 
frequency of T cells producing one or more cytokines in the stimulated sample was at 
least twice that of the control sample (Additional file 3). Additionally, each response 
was visually assessed to ensure the presence of a clearly distinguishable population of 
positive events. This method allows the detection of multiple cytokines from each 
patient, but does not directly assess whether production is from the same or different 
population of cells. Antibody-stained leukocyte populations, including the assessment 
of T cell responses to TAAs, were gated according to the approaches shown in 
Additional file 2-7. 
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Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La 
Jolla, USA). Two independent groups were compared using the Mann-Whitney U test. 
Relationships across four grouping variables were assessed with Fisher’s exact test. 
Correlations were assessed using Spearman correlation analysis. A value of p < 0.05 
was considered statistically significant. Because this was an exploratory study we aimed 
to reduce the chance of obtaining false negative results. For this reason statistical 
analyses were not corrected using the Bonferroni method, and the results should be 
interpreted as such. 
Results 
Peripheral blood leukocytes are associated with clinical parameters of breast 
cancer patients 
We measured subsets of different peripheral blood leukocyte populations in the blood of 
50 non-metastatic breast cancer patients and assessed whether T cells (240 different 
populations assessed, including regulatory T cells), B cells (19 populations), NK cells 
(70 populations) or myeloid cells (15 populations) were related to clinical features of 
these breast cancer patients. We observed that all leukocyte types (T cells, B cells, NK 
cells and myeloid cells) were associated with certain clinical parameters including 
tumour grade, AJCC stage, Ki67 tumour expression and lymph node infiltration by 
tumour cells. In order to compare these leukocyte types on their relevance to patient 
clinical features, we calculated the proportion of identified clinical correlations relative 
to the number of phenotypes tested. We found that T cells were the most relevant to 
patient clinical features, followed by B, NK and myeloid cells, respectively (Fig. 1).  
Specifically, we found that patients of a higher AJCC stage and/or higher tumour grade 
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had lower levels of CD4+ T cells (AJCC stage: p = 0.02, tumour grade: p = 0.03) and 
NK cells (AJCC stage: p = 0.01) compared with patients with less advanced disease 
(Fig. 2A). Of note is that we could not identify such correlations for Tregs (data not 
shown), suggesting that these differences indicate a reduction in helper CD4+ T cells 
with disease progression. Higher tumour grade and/or AJCC stage was additionally 
found to be associated with higher levels of CD3hiCD56dim cells (tumour grade: p = 
0.003, AJCC stage: p = 0.03) and memory B cells (tumour grade: p = 0.02) (Fig. 2B). 
We also found that patients with a greater number of infiltrated lymph nodes had lower 
levels of total CD4+ cells (p = 0.02) (Fig. 2C) and CD4+ regulatory T cells (p = 0.04, 
data not shown). Similar relationships were observed for tumour Ki67 expression and 
NK cells; patients with a higher percentage of tumour cells expressing Ki67 had lower 
levels of NK cells (p = 0.04). This stands in contrast to B cells for which we observed 
an opposite trend with Ki67 expression (p = 0.06) (Fig. 2D). Other leukocyte 
populations were also observed to correlate with patient clinical parameters (data not 
shown). We also examined whether relationships between the major populations of T, 
B, NK or myeloid cells exist. Of these, we observed only one significant relationship; 
an increasing frequency of CD20+CD40+ B cells was associated with higher levels of 
CD4+ regulatory T cells (CD4+CD25+FoxP3+) (p = 0.02, Additional file 8). Other 
leukocyte phenotypes such as MDSCs were not found to correlate with any other 
leukocyte population. 
T cell responses to tumour-associated antigens in breast cancer patients 
We detected T cells reactive to HER2, MUC1 or SUR in this cohort of breast cancer 
patients using in vitro peptide stimulation. Our prior study (Bailur et al., 2015) showed 
that the presence of HER2-reactive T cells in breast cancer patients is associated with a 
more favourable prognosis. In the present study of prospectively recruited patients, we 
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have expanded the number of antigens tested to include MUC1 and SUR in addition to 
HER2. CD4+ or CD8+ T cells were considered reactive to an antigen if they produced 
any of the 6 cytokines that we measured (IL-2, IL-5, IL-10, IL-17, TNF and IFNγ). 
Antigen-reactive T cells were found to be common, with a high frequency of patients 
showing responses by either CD4+ or CD8+ cells to HER2 (96%), MUC1 (80%) and 
SUR (72%). We found that, in general, CD4+ reactive T cells were more common than 
CD8+ T cells. 
Although tumour antigen-reactive T cells are predictive of patient prognosis, the time- 
and resource-intensive culture protocols required for their detection limits their use as 
part of routine clinical monitoring. As previously mentioned, our prior study (Janssen et 
al., 2016) screened a broad set of patient features with the goal of finding those which 
are most capable of identifying patients with antigen-reactive T cells. Considering HLA 
type, serum cytokines, tumour-infiltrating leukocytes and blood leukocytes we found 
that the latter most accurately identified patients with antigen-reactive T cells. Based on 
these findings, we sought to extend blood leukocyte phenotyping beyond that 
previously examined with the goal of investigating if other populations of blood 
leukocytes can also be used to select patients with TAA-reactive T cells. If so, do they 
allow a more accurate selection of patients with these reactive T cells than was 
previously achieved? In the present study we have markedly increased the richness of 
the phenotyping analysis to encompass a total of 302 different blood leukocyte 
populations: 213 for T cells, 19 in the case of B cells, and 70 NK cell populations 
(Additional file 9). Regulatory T cells and myeloid cells including MDSCs were 
examined in our prior study and were therefore not considered again here. 
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Blood leukocytes identify patients with tumour antigen-reactive T cells 
NK cells are relevant for T cell responses to MUC1 and SUR but not HER2  
Assessing antigen-reactive T cells for relationships with NK cells showed that different 
NK cell populations were associated with T cell responses to MUC1 or SUR but not 
with HER2 (but note that because the vast majority of patients showed CD4+ HER2 
responses it was not possible to test for CD4+ associations to this antigen). We 
observed different populations of NK cells to be present at either higher or lower 
frequencies in patients with MUC1- or SUR-reactive T cells than in those without. For 
example, patients with CD4+ T cells reactive to MUC1 had higher levels of CD27+ NK 
cells compared to patients who did not possess these reactive T cells (p = 0.04) (Fig. 
3A). In contrast, another population of NK cells (CD56dimCD16-NKG2D+) was found 
to be lower in patients with MUC1-responsive T cells (p = 0.04) (Fig. 3A). A full set of 
correlations between NK cells and antigen-reactive T cells can be found in Additional 
file 10. 
High levels of B cells as a marker of patients with HER2-reactive T cells 
In contrast to NK cells, which were only associated with T cell responses to MUC1 and 
SUR, we found that B cells only correlated with HER2-reactive T cells. Of the 19 
populations of B cells examined, we found one which was associated with HER2 T cell 
responses; patients with CD8+ HER2-reactive T cells had higher levels of 
CD19+CD38-CD27+CD20- B cells (p = 0.04) (Fig. 3B). Apart from this, other 
relationships between B cells and CD4+ or CD8+ T cells reactive to any antigen were 
not found.  
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Blood T cells broadly correlate with HER2, MUC1 and SUR-reactive T cells  
Compared with NK and B cells, T cells were found to widely identify patients with 
HER2- MUC1- or SUR-reactive T cells. Of the total number of identified correlations 
between blood leukocytes and antigen-reactive T cells, 89% of these were with T cell 
populations, whereas NK cells and B cells accounted for only 10% and 1% of 
correlations, respectively. Interestingly, we observed that in the vast majority of cases 
(82/94), patients with TAA-reactive T cells had higher levels of blood T cells than 
patients without antigen-reactive T cells. This was true for CD4+ and CD8+ T cells of 
all differentiation stages. For example, high relative levels of CD8+CD27- T cells were 
associated with SUR-reactive T cells (p = 0.0007) (Fig. 3C), while high levels of 
CD8+TEMRA T cells were associated with MUC1-reactive T cells (p = 0.01) (Fig. 3C). 
In addition, a large number of other correlations between blood T cell populations and 
antigen-reactive T cells were found and appear in Additional file 11. 
A combination of multiple blood leukocyte populations improves the accuracy 
of predicting patients with TAA-reactive T cells  
In our prior study we combined immunological parameters in an attempt to more 
accurately select patients with TAA-reactive T cells. The results showed that the 
combination of different types of immunological parameters (such as tumour infiltrating 
leukocytes and blood leukocytes), but also the combination of multiple different blood 
leukocyte populations resulted in superior prediction of TAA responses (Janssen et al., 
2016). Based on this approach, we sought to determine more accurate markers of TAA-
reactive T cells than was previously possible with a relatively limited survey of blood 
leukocytes. By combining multiple populations of blood leukocytes, we were able to 
identify groups of patients who all possessed antigen-reactive T cells and therefore yield 
up to 100% sensitivity and specificity in the selection of patients with antigen-reactive T 
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cells. For example, a group of patients with above median levels of stem memory T 
cells (TSCM) and CD3-CD56- cells consisted exclusively of patients who possessed 
MUC-reactive CD4+ T cells (Fig. 4). Similarly, selecting patients on higher than 
median levels of NK (CD3-CD56hiCD16-CD27+) and NKT (NKG2D+ 
CD3+CD56dim) cells identified a group who all possessed CD8+ T cells reactive to 
SUR (Fig. 4). This approach therefore shows a high degree of accuracy in the selection 
of patients who possess antigen-reactive T cells. 
Discussion 
Our prior studies have shown that patients possessing TAA-reactive peripheral CD8+ T 
cells experience a more favourable prognosis, especially if they have lower than median 
levels of MDSCs (Bailur et al., 2015). Avoiding the complexity and extended duration 
of directly testing T cell reactivities and phenotyping MDSCs, assessing blood 
leukocytes is the most accurate method of identifying patients with these characteristics 
(Janssen et al., 2016). Considering this, the present investigation was designed to 
investigate blood leukocytes as markers of TAA-reactive T cells in greater detail. We 
had two primary aims in performing this study: by conducting an in-depth survey of 
peripheral immune cells in breast cancer, we sought to identify the leukocyte 
populations most relevant for clinical outcome, either alone or when combined with 
information regarding tumour antigen-reactive T cells. We continue to monitor this 
group of prospectively recruited patients regarding their clinical course, but the 
information available so far does not yet permit analysis. In addition, we aimed to 
identify surrogate markers for TAA-reactive T cells that may be used as part of patient 
clinical monitoring. The establishment of such surrogate markers will serve several 
purposes. Firstly, the measurement of blood leukocytes could replace the measurement 
of antigen-reactive T cells, for which a lengthy (12 day), expensive and labour intensive 
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in vitro stimulation period is required, as well as the additional resources and expertise 
needed to interpret the results. Furthermore, these culture protocols are complex and 
demand large numbers of leukocytes, often a limiting factor when dealing with material 
from cancer patients. Manufacturer- or batch-dependent differences due to the reagents, 
particularly the TAA peptides, are currently unknown but could likely influence the 
results. These aspects contribute to the difficulty of standardising the measurement of 
antigen-reactive T cells, while the considerable costs in time, labour and material have 
also proven prohibitive for the large-scale implementation of this approach in the 
clinical setting thus far. Given these limitations and the relative simplicity of directly 
measuring blood leukocytes, the latter may represent a viable alternative to indirectly 
allow the clinical monitoring of anti-tumour responses. Secondly, measuring blood 
leukocytes indirectly selects patients with a more favourable prognosis. Hence 
identifying these patients as part of routine clinical monitoring may spare them from 
unnecessary treatment or allow the administration of tailored forms of therapy. The 
rapid clinical implementation of immunotherapies including immunomodulatory 
antibodies and cancer vaccines means that optimising the use of these treatments will be 
increasingly important in future. The efficacy of such approaches is presumably through 
the stimulation, generation and amplification of tumour antigen-reactive T cells, and the 
downregulation of suppressive elements such as Tregs and MDSCs. Therefore, 
identifying patients with TAA-reactive T cells, or patients who show immune profiles 
favourable to the generation of such immune responses, may have implications for 
selecting patients more likely to respond to immunotherapy. The findings in this study 
allow the selection of patients with antigen-reactive T cells, but importantly they also 
identify patients who lack them. As such these results can be used to pinpoint 
differences in the immune system that are associated with either the presence or absence 
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of antigen-reactive T cells. These immune differences may thus represent novel 
therapeutic targets, whereby the immune systems of patients lacking antigen-reactive T 
cells can be altered to more closely resemble the immune systems of patients with 
TAA-reactive T cells. This form of therapy could potentially be used together with 
immunotherapies to enhance their activity. 
We found that peripheral B and NK cells allowed us to select patients with 
antigen-reactive T cells, but with these leukocyte types we could only identify patients 
with certain types of T cell responses. In contrast, blood T cells were found to widely 
correlate with both CD4+ and CD8+ T cells reactive to all antigens tested. Interestingly, 
the set of T cell phenotypes observed to correlate with antigen-reactive T cells did not 
share any definable features; we found that these phenotypes covered a range of 
differentiation stages from naïve to late-differentiated T cells. Despite this, we observed 
that in the vast majority of cases, patients with TAA-reactive T cells showed higher 
levels of blood T cells than patients without antigen-reactive cells, implying that the 
phenotypes found to correlate may directly participate or assist in the generation of 
antigen-reactive T cells. This is further supported by the observation that blood T cells 
accounted for 89% of all correlations with antigen-reactive T cells. In contrast B and 
NK cells together accounted for the remaining 11% of correlations, and unlike T cells, 
were not relevant to every type of T cell response. These findings suggests that 
therapies which alter the immune system of breast cancer patients to more closely 
mirror the immune system of patients with TAA-reactive T cells may result in enhanced 
anti-tumour responses by T cells. Because we found essentially all T cell phenotypes 
within both the CD4+ and CD8+ compartments to be higher in patients with TAA-
reactive T cells, elevating levels of T lymphocytes in general, such as with gamma-
chain cytokines, may result in more favourable conditions for the generation of antigen-
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reactive T cells. Underlining the clinical importance of peripheral T cells is that 
compared with NK and B cells, we found that T cells were most commonly associated 
with patient clinical parameters, adding further weight to their proposition as 
therapeutic targets. 
Conclusion 
The results f this study show that phenotypic assessment of blood leukocytes allows 
the accurate identification of breast cancer patients with functional TAA-reactive T 
cells. These findings are intended as the first step towards the possible clinical 
implementation of measuring blood leukocytes as part of routine monitoring to select 
patients with antigen-reactive T cells. Ongoing clinical follow-up will reveal which of 
the peripheral immune populations measured here are informative for patient outcome, 
and whether they more accurately predict survival when combined with the assessment 
of antigen-reactive T cells. 
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Table 1 Characteristics of the breast cancer patients 
Patient clinicopathological parameters (n = 50) 
Median Age (range in years) 56 (27-78) 
  
AJCC staging  
1 15 
2A 10 
2B 12 
3A 12 
3C 1 
  
Receptor status  
Triple negative 5 
Oestrogen receptor + 42 
Progesterone receptor+  33 
HER2+ 15 
  
Ki67  
<10% 7 
10% - 20% 21 
>20% 22 
  
T stage  
1 21 
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2 26 
3 3 
  
N stage  
0 21 
1 17 
2 11 
3 1 
  
Grade  
1 0 
2 26 
3 24 
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Figure 1. Relevance of T, B, NK and myeloid cells to patient clinical parameters. 
For each leukocyte type (T, B, NK and myeloid cells) the proportion of identified 
correlations with patient clinical features was calculated as a percentage relative to the 
number of phenotypes tested. We observed T cells to be the most relevant leukocyte 
type to patient clinical features, followed by B, NK and myeloid cells, respectively. 
Figure 2. Levels of blood leukocytes are associated with clinical features of breast 
cancer patients. 
T, B, NK and myeloid cells were measured in the blood of 50 breast cancer patients 
using flow cytometry and were tested for association with patient clinical parameters 
(Mann-Whitney U test). We found lower levels of CD4+ T cells and NK cells in 
patients with higher tumour grade or AJCC stage (A). Conversely, patients with a 
higher grade or AJCC stage showed higher levels of memory B cells or CD3hiCD56dim 
cells (B). We also found that patients with a greater number of infiltrated lymph nodes 
had lower CD4+ T cell frequencies (C), while tumour expression of Ki67 was 
associated with either lower levels of NK cells or showed a trend towards higher levels 
of memory B cells (D). Phenotypes given in square brackets indicate the reference 
population used to calculate the frequency of the respective leukocyte population. Bars 
indicate median values. *, p < 0.05; **, p < 0.01 
Figure 3. Levels of blood leukocytes differ in patients with HER2, MUC1 and SUR-
reactive T cells. 
T cell responses to HER2, MUC1 or SUR were measured in 50 breast cancer patients 
following 12 days of in vitro expansion. Levels of blood leukocytes were compared 
between patients with reactive T cells and those who lacked these cells. T cells were 
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considered responsive to an antigen if they showed a positive signal for any of the six 
measured cytokines (Mann-Whitney U test). This showed high or low levels of NK 
cells to be associated with the presence of MUC1-reactive T cells (A). High levels of B 
cells were found in patients with CD8+ HER2-reactive T cells (B), while high levels of 
CD8+CD27- T cells (C, left panel) and CD8+ TEMRA cells (C, right panel) were 
associated with the presence of SUR- or MUC1-reactive T cells. Phenotypes in square 
brackets indicate the reference population used to calculate the frequency of each 
leukocyte population. Bars indicate median values. HER2, Human Epidermal growth 
factor Receptor 2; MUC1, Mucin 1; NR, Non-Responder; R, Responder; SUR, 
Survivin; TAA, Tumour-Associated Antigen; TEMRA, terminally differentiated 
effector memory cells; *, p < 0.05; **, p < 0.01  
Figure 4. Combining blood leukocyte populations allows more accurate prediction of 
patients with anti-tumour reactive T cells.  
Selecting patients with >median levels of NKT and NK cells resulted in sensitivity and 
specificity of 90% and 100% in identifying patients with CD8+ SUR-reactive T cells. 
Similarly, the combination of >median levels of CD3-CD56- and TSCM resulted in 
75% sensitivity and 100% specificity in selecting patients with CD4+ MUC1-reactive T 
cells. MUC1, Mucin1; NK cells, Natural Killer cells; NKT cells, Natural killer T cells, 
SUR, Survivin; TSCM, stem memory T cells 
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Relevance of T, B, NK and myeloid cells to patient clinical parameters. For each leukocyte type (T, B, NK and 
myeloid cells) the proportion of identified correlations with patient clinical features was calculated as a 
percentage relative to the number of phenotypes tested. We observed T cells to be the most relevant 
leukocyte type to patient clinical features, followed by B, NK and myeloid cells, respectively.  
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Levels of blood leukocytes are associated with clinical features of breast cancer patients.  
T, B, NK and myeloid cells were measured in the blood of 50 breast cancer patients using flow cytometry 
and were tested for association with patient clinical parameters (Mann-Whitney U test). We found lower 
levels of CD4+ T cells and NK cells in patients with higher tumour grade or AJCC stage (A). Conversely, 
patients with a higher grade or AJCC stage showed higher levels of memory B cells or CD3hiCD56dim cells 
(B). We also found that patients with a greater number of infiltrated lymph nodes had lower CD4+ T cell 
frequencies (C), while tumour expression of Ki67 was associated with either lower levels of NK cells or 
showed a trend towards higher levels of memory B cells (D). Phenotypes given in square brackets indicate 
the reference population used to calculate the frequency of the respective leukocyte population. Bars 
indicate median values. *, p < 0.05; **, p < 0.01  
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Levels of blood leukocytes differ in patients with HER2, MUC1 and SUR-reactive T cells.  
T cell responses to HER2, MUC1 or SUR were measured in 50 breast cancer patients following 12 days of in 
vitro expansion. Levels of blood leukocytes were compared between patients with reactive T cells and those 
who lacked these cells. T cells were considered responsive to an antigen if they showed a positive signal for 
any of the six measured cytokines (Mann-Whitney U test). This showed high or low levels of NK cells to be 
associated with the presence of MUC1-reactive T cells (A). High levels of B cells were found in patients with 
CD8+ HER2-reactive T cells (B), while high levels of CD8+CD27- T cells (C, left panel) and CD8+ TEMRA 
cells (C, right panel) were associated with the presence of SUR- or MUC1-reactive T cells. Phenotypes in 
square brackets indicate the reference population used to calculate the frequency of each leukocyte 
population. Bars indicate median values. HER2, Human Epidermal growth factor Receptor 2; MUC1, Mucin 1; 
NR, Non-Responder; R, Responder; SUR, Survivin; TAA, Tumour-Associated Antigen; TEMRA, terminally 
differentiated effector memory cells; *, p < 0.05; **, p < 0.01  
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Combining blood leukocyte populations allows more accurate prediction of patients with anti-tumour reactive 
T cells.  
Selecting patients with >median levels of NKT and NK cells resulted in sensitivity and specificity of 90% and 
100% in identifying patients with CD8+ SUR-reactive T cells. Similarly, the combination of >median levels of 
CD3-CD56- and TSCM resulted in 75% sensitivity and 100% specificity in selecting patients with CD4+ 
MUC1-reactive T cells. MUC1, Mucin1; NK cells, Natural Killer cells; NKT cells, Natural killer T cells, SUR, 
Survivin; TSCM, stem memory T cells  
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Additional file 1 – Full list of antibodies employed 
The following table summarizes a full list of antibodies employed in this 
study 
TAA-reactive T cells   
Cell surface   
CD3-BV605 Bio Legend (San Diego, USA) 
CD4-Pacific Blue Bio Legend 
CD8-APC-H7 BD Biosciences (Franklin Lakes, USA) 
Intracellular  
IL-2-Alexa Fluor 700 Bio Legend 
IL-5-PE Bio Legend 
IL-10-APC Milteny Biotec (Bergisch Gladbach, Germany) 
IL-17-PerCP-Cy5.5 eBiosciences (San Diego, USA) 
IFNg-PECy7 BD Biosciences 
TNF-FITC Bio Legend 
  
  
B cells  
CD24-BV421 Bio Legend 
CD19-V500 BD Biosciences 
IgD-FITC BD Biosciences 
CD43-PE Bio Legend 
CD20-PerCP Bio Legend 
CD38-Pe-Cy7 Bio Legend 
IgG-APC Bio Legend 
CD40-APC-H7 BD Biosciences 
CD27-BV605 Bio Legend 
  
  
NK cells  
CD57-PB Bio Legend 
CD45-V500 BD Biosciences 
CD159a-PE Milteny Biotec 
CD161-FITC BD Biosciences 
CD314-PerCP-Cy5.5 BD Biosciences 
CD159c-PE-Vio 770 Milteny Biotec 
CD3-APC Bio Legend 
CD8-APC-H7 BD Biosciences 
CD27-A700 Bio Legend 
CD56-BV605 BD Biosciences 
CD16-BV711 BD Biosciences 
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T cells  
CD3-A700 BD Biosciences 
CD4-PerCP BD Biosciences 
CD8-APC-H7 BD Biosciences 
CD27-APC Bio Legend 
CD28-PE BD Biosciences 
CD45RA-V450 BD Biosciences 
CD57-FITC Immunotools (Friesoythe, Germany) 
CD95-PeCy7 eBiosciences 
CD279-PerCP-Cy5.5 Bio Legend 
  
unconjugated  
CCR7 R&D System (Minneapolis, USA)  
PO Invitrogen (Carlsbad, USA) 
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Reference population CD19+ 
Reference population CD38+ 
Additional file 2– Gating strategy B cells 
B cell gating strategy. Flow cytometry data were analysed first by excluding events not part of the main acquisition population using a time-vs-side scatter gate. Cell doublets were then  
removed before the exclusion of dead cells (EMA-positive events) and cell debris with the use of a morphological gate. Antibody-stained B cell populations, were gated according to  
the approaches shown here  using the antibody panel summarized in Additional file 1.  
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Unstimulated + HER2 peptide 
CD8 
IFNγ CD4 
0.08 % 0.53 % 
0.17 % 1.05 % 
Additional file 3- Assessment of TAA reactive T cells  
Control (left panels) and stimulated (right panels) CD4 (upper panels) and CD8 (lower panels) example  
showing a positive response for IFNγ  to HER2. We assigned a positive response when the frequency of T cells producing any cytokine in the 
stimulated sample was at least twice that of the control sample. Additionally, each response was visually assessed to ensure the presence of a 
clearly distinguishable population of positive events. T cell responses were considered categorically (present or absent) in addition to a 
quantitative assessment of the strength of response by calculating the ratio of the frequency of positive events in the stimulated sample by 
comparison with the unstimulated sample to give a stimulation index (SI). 
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Reference population CD45+ 
CD16- Bv711 
C
D
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- 
B
v6
05
 
Additional file 4 – Gating strategy NK cells 
NK cell gating strategy. Flow cytometry data were analysed first by excluding events not part of the main acquisition population using a time-vs-side scatter gate. Cell 
doublets were then removed before the exclusion of dead cells (EMA-positive events) and cell debris with the use of a morphological gate (see Additional file 2). 
Antibody-stained NK cell populations, were gated according to the approaches shown here using the antibody panel summarized in Additional file 1.  
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Additional file 5 – Gating strategy NKT cells 
NKT cell gating strategy. Flow cytometry data were analysed first by excluding events not part of the main acquisition population using a time-vs-side scatter gate. Cell 
doublets were then removed before the exclusion of dead cells (EMA-positive events) and cell debris with the use of a morphological gate (see Additional file 2). Antibody-
stained NKT cell populations were gated according to the approaches shown here using the antibody panel summarized in Additional file 1.  
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Reference population CD4+ 
Additional file 6– Gating strategy T cells 
T cell gating strategy. Flow cytometry data were analysed first by excluding events not part of the main acquisition population using a time-vs-side scatter gate. Cell doublets were then  
removed before the exclusion of dead cells (EMA-positive events) and cell debris with the use of a morphological gate (see Additional file 2).  Antibody-stained  T cell populations, were 
gated according to the approaches shown here  using the antibody panel summarized in Additional file 1.  
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Reference population CD8+ Page 36 of 44
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Additional file 7 – Gating strategy T cells (continued) 
T cell gating strategy. Flow cytometry data were analysed first by excluding events not part of the main acquisition population using a time-vs-side scatter gate. Cell doublets were then  
removed before the exclusion of dead cells (EMA-positive events) and cell debris with the use of a morphological gate (see Additional file 2).  Antibody-stained  CD4+ T cell populations, 
were gated according to the approaches shown here  using the antibody panel summarized in Additional file 1.  
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Additional file 8 – Correlation B cells and Tregs 
Frequency of B cells was positively associated with higher levels of CD4+ regulatory T cell.  
We examined whether relationships between the major populations of T, B, NK or myeloid cells exist. 
 Of these, we observed only one significant relationship; an increasing frequency of  
CD20+CD40+ B cells was associated with higher levels of CD4+ regulatory T cells (CD4+CD25+FoxP3+) (p = 0.02),  
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Additional file 9 - Total leukocyte populations tested 
T cell phenotypes  
CD4+ [CD3+] CD8+ [CD3+] 
CD3+ CD4+ CD27- [CD3+] CD8+ CD27- [CD3+] 
CD4+ CD28- [CD3+] CD8+ CD28- [CD3+] 
CD4+ CD57+ [CD3+] CD8+ CD57+ CD3+] 
CD4+ CD95+ [CD3+] CD8+ CD95+ [CD3+] 
CD4+CD45RA+ CCR7+ (Naive) |[CD3+] CD8+CD45RA+ CCR7+ (Naive) [CD3+] 
CD4+CD45RA+ CCR7+ (Naive)/CD27+ CD28+ [CD3+] CD8+CD45RA+ CCR7+ (Naive)/CD27+ CD28+ [CD3+] 
CD4+CD45RA+ CCR7+ (Naive)/CD27+ CD28+/CD57+ [CD3+] CD8+CD45RA+CCR7+(Naive)/CD27+CD28+/CD95+(TSCM)[CD3+] 
CD4+CD45RA+ CCR7- (TEMRA) [CD3+] CD8+CD45RA+ CCR7+ (Naive)/CD27- CD28- [CD3+] 
CD4+CD45RA- CCR7+ (CM) [CD3+] CD8+CD45RA+ CCR7+ (Naive)/CD27- CD28-/CD57+ [CD3+] 
CD4+CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM) [CD3+] CD8+CD45RA+ CCR7+ (Naive)/CD27- CD28-/CD95+ [CD3+] 
CD4+CD45RA-CCR7+ (CM)/CD27+ CD28+ (CM)/CD57+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA) [CD3+] 
CD4+CD45RA- CCR7+(CM)/CD27+ CD28+ (CM)/CD95+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27+ CD28+ [CD3+] 
CD4+CD45RA- CCR7+ (CM)/CD27- CD28+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27+ CD28+ /CD95+ [CD3+] 
CD4+CD45RA- CCR7+ (CM)/CD27- CD28+/CD95+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27+ CD28- [CD3+] 
CD4+CD45RA- CCR7- (EM)[CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27+ CD28-/CD95+ [CD3+] 
CD4+CD45RA- CCR7- (EM)/CD27+ CD28+  [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27- CD28- (E) [CD3+] 
CD4+CD45RA- CCR7- (EM)/CD27+ CD28+ /CD95+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27- CD28- (E)/CD57+ [CD3+] 
CD4+CD45RA- CCR7- (EM)/CD27- CD28+ [CD3+] CD8+CD45RA+ CCR7- (TEMRA)/CD27- CD28- (E)/CD95+ [CD3+] 
CD4+CD45RA- CCR7- (EM)/CD27- CD28+/CD95+ [CD3+] CD8+CD45RA- CCR7+ (CM) [CD3+] 
CD4+ CD27- [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM) [CD3+] 
CD4+ CD28- [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD57+ [CD3+] 
CD4+ CD57+ [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD95+ [CD3+] 
CD4+ CD95+ [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27+ CD28- [CD3+] 
CD45RA+ CCR7+ (Naive) [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27+ CD28-/CD95+ [CD3+] 
CD45RA+ CCR7+ (Naive)/CD27+ CD28+ [CD4+] CD8+CD45RA- CCR7+ (CM)/CD27- CD28+ [CD3+] 
CD45RA+ CCR7+ (Naive)/CD27+ CD28+/CD57+ [CD4]+ CD8+CD45RA- CCR7+ (CM)/CD27- CD28+/CD95+ [CD3+] 
CD45RA+ CCR7+ (Naive)/CD27+ CD28+/CD95+ (TSCM) [CD4] CD8+CD45RA- CCR7+ (CM)/CD27- CD28-/CD57+ [CD3+] 
CD45RA+ CCR7- (TEMRA)[CD4+] CD8+CD45RAint CCR7int [CD3+] 
CD45RA- CCR7+ (CM)[CD4+] CD8+CD45RAint CCR7int/CD27+ CD28+  [CD3+] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM) [CD4+] CD8+CD45RAint CCR7int/CD27+ CD28+ /CD95+ [CD3+] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD57+ [CD4+] CD8+CD45RAint CCR7int/CD27+ CD28- [CD3+] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD95+ [CD4+] CD8+CD45RAint CCR7int/CD27+ CD28-/CD57+ [CD3+] 
CD45RA- CCR7+ (CM)/CD27- CD28+ [CD4+] CD8+CD45RAint CCR7int/CD27+ CD28-/CD95+ [CD3+] 
CD45RA- CCR7+ (CM)/CD27- CD28+/CD95+ [CD4+] CD8+CD45RAint CCR7int/CD27- CD28- [CD3+] 
CD45RA- CCR7- (EM)/CD27- CD28+ [CD4+] CD8+CD45RAint CCR7int/CD27- CD28-/CD57+ [CD3+] 
CD4+CD27+ CD28+ [CD45RA+ CCR7+ (Naive)] CD8+CD45RAint CCR7int/CD27- CD28-/CD95+ [CD3+] 
CD4CD27+ CD28+/CD57+ [CD45RA+ CCR7+ (Naive)] CD8+ CD27- [CD8+] 
CD4+CD27+ CD28+ (CM) [CD45RA- CCR7+ (CM)] CD8+ CD28- [CD8+] 
CD4+CD27+ CD28+ (CM)/CD95+ [CD45RA- CCR7+ (CM)] CD8+ CD57+ [CD8+] 
CD4+CD27- CD28+ [CD45RA- CCR7+ (CM)] CD8+ CD95+ [CD8+] 
CD4+CD27- CD28+/CD95+ [CD45RA- CCR7+ (CM)] CD45RA+ CCR7+ (Naive) [CD8+] 
CD4+CD27+ CD28+ [CD45RA- CCR7- (EM)] CD45RA+ CCR7+ (Naive)/CD27+ CD28+ [CD8+] 
CD4+CD27+ CD28+ /CD95+ [CD45RA- CCR7- (EM)] CD45RA+ CCR7+ (Naive)/CD27+ CD28+/CD57+ [CD8+] 
CD4+CD27- CD28+ [CD45RA- CCR7- (EM)] CD45RA+ CCR7+ (Naive)/CD27+ CD28+/CD95+ (TSCM) [CD8+] 
CD4+CD27- CD28+/CD95+ [CD45RA- CCR7- (EM)] CD45RA+ CCR7+ (Naive)/CD27- CD28- [CD8+] 
CD4+CD45RA-CCR7+CD57+ [CD27+ CD28+ (CM)] CD45RA+ CCR7+ (Naive)/CD27- CD28-/CD57+ [CD8+] 
CD4+CD45RA-CCR7+CD95+ [CD27+ CD28+ (CM)] CD45RA+ CCR7+ (Naive)/CD27- CD28-/CD95+ [CD8+] 
CD4+CD45RA-CCR7+CD95+ [CD27- CD28+] CD45RA+ CCR7- (TEMRA) [CD8+] 
CD4+CD45RA-CCR7- CD95+ [CD27+ CD28+] CD45RA+ CCR7- (TEMRA)/CD27+ CD28+  [CD8+] 
CD4+CD45RA-CCR7-CD95+ [CD27- CD28+] CD45RA+ CCR7- (TEMRA)/CD27+ CD28- [CD8+] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM) [CD8+] CD45RA- CCR7+ (CM) [CD8+] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD57+ [CD8+] CD8+CD45RAint CCR7intCD95+ [CD27- CD28-] 
CD45RA- CCR7+ (CM)/CD27+ CD28+ (CM)/CD95+ [CD8+] CD3+ CD8+ CD57+ [CD3+ CD8+] 
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T cell phenotypes - continued  
CD45RA- CCR7+ (CM)/CD27- CD28+ [CD8+] CD3+ CD8+ CD57+ CD27- [CD3+ CD8+] 
CD45RA- CCR7+ (CM)/CD27- CD28+/CD95+ [CD8+] CD3+ CD8+ NKG2C+ [CD3+ CD8+] 
CD45RAint CCR7int [CD8+] CD3+ CD8+/CD56- CD27- [CD3+ CD8+] 
CD45RAint CCR7int/CD27+ CD28+  [CD8+] CD3+ CD8- CD57+ [CD3+ CD8-] 
CD45RAint CCR7int/CD27+ CD28+ /CD95+ [CD8+] CD3+ CD8- CD57+ CD27- [CD3+ CD8-] 
CD45RAint CCR7int/CD27+ CD28- [CD8+] CD3+ CD8- CD57- CD27+ [CD3+ CD8-] 
CD45RAint CCR7int/CD27+ CD28-/CD57+ [CD8+] CD3+ CD8- NKG2C+ [CD3+ CD8-] 
CD45RAint CCR7int/CD27+ CD28-/CD95+ [CD8+] CD3+ CD8-/CD56- CD27- [CD3+ CD8-] 
CD45RAint CCR7int/CD27- CD28- [CD8+] CD3+ [CD45+] 
CD45RAint CCR7int/CD27- CD28-/CD57+ [CD8+] CD3+ CD56dim [CD45+] 
CD45RAint CCR7int/CD27- CD28-/CD95+ [CD8+] CD3+ CD56dim CD8+ [CD45+] 
CD8+CD27+ CD28+ [CD45RA+ CCR7+ (Naive)] CD3+ CD56dim CD8+ [CD3+ CD56dim] 
CD8+CD27+ CD28+/CD57+ [CD45RA+ CCR7+ (Naive)] CD3hi CD56dim [CD45+] 
CD8+CD27+ CD28+/CD95+ (TSCM) [CD45RA+ CCR7+ (Naive)] CD3+ CD16+ [CD45+] 
CD8+CD27- CD28- [CD45RA+ CCR7+ (Naive)] CD3+ CD16+ [CD16+] 
CD8+CD27- CD28-/CD95+ [CD45RA+ CCR7+ (Naive)] CD161+ CD3+ CD56dim [CD45+] 
CD8+CD27+ CD28+ [CD45RA+ CCR7- (TEMRA)] CD161+ CD3+ CD56dim [CD161+] 
CD8+CD27+ CD28- [CD45RA+ CCR7- (TEMRA)] NKG2D+ CD3+ CD56dim [CD45+] 
CD8+CD27+ CD28-/CD95+ [CD45RA+ CCR7- (TEMRA)] NKG2D+ CD3+ CD56dim [NKG2D+] 
CD8+CD27- CD28- (E) [CD45RA+ CCR7- (TEMRA)] CD3+ CD8+ [CD45+] 
CD8+CD27- CD28- (E)/CD57+ [CD45RA+ CCR7- (TEMRA)] CD3+ CD8+ CD57+ [CD45+] 
CD8+CD27+ CD28+ (CM) [CD45RA- CCR7+ (CM)] CD3+ CD8+ CD57+ CD27- [CD45+] 
CD8+CD27+ CD28+ (CM)/CD57+ [CD45RA- CCR7+ (CM)] CD3+ CD8+ CD57- CD27+ [CD45+] 
CD8+CD27+ CD28+ (CM)/CD95+ [CD45RA- CCR7+ (CM)] CD3+ CD8+ /CD56- CD27- [CD45+] 
CD8+CD27+ CD28- [CD45RA- CCR7+ (CM)] CD3+ CD8- [CD45+] 
CD8+CD27+ CD28-/CD95+ [CD45RA- CCR7+ (CM)] CD3+ CD8- CD57+ [CD45+] 
CD8+CD27- CD28+ [CD45RA- CCR7+ (CM)] CD3+ CD8- CD57+ CD27- [CD45+] 
CD8+CD27- CD28+/CD95+ [CD45RA- CCR7+ (CM)] CD3+ CD8- CD57- CD27+ [CD45+] 
CD8+CD27- CD28- [CD45RA- CCR7+ (CM)] CD3+ CD8- NKG2C+ [CD45+] 
CD8+CD27- CD28-/CD57+ [CD45RA- CCR7+ (CM)] CD3+ CD8- / CD56+ CD27+ [CD45+] 
CD8+CD27- CD28-/CD95+ [CD45RA- CCR7+ (CM)] CD3+ CD8- / CD56- CD27- [CD45+] 
CD8+CD27+ CD28+  [CD45RA- CCR7- (EM)] CD3+ /CD3hi CD56lo [CD45+] 
CD8+CD27+ CD28+ /CD95+ [CD45RA- CCR7- (EM)] CD161+ CD3+ [CD45+] 
CD8+CD27+ CD28+ /CD95+ [CD45RAint CCR7int] CD161+ CD3+ CD8+ [CD45+] 
CD8+CD27+ CD28-/CD57+ [CD45RAint CCR7int] CD161+ CD3+ CD8- [CD45+] 
CD8+CD27- CD28- [CD45RAint CCR7int] NKG2D+ CD3+ CD8+ [CD45+] 
CD8+CD27- CD28-/CD57+ [CD45RAint CCR7int] NKG2D+ CD3+ CD8- [CD45+] 
CD8+CD27- CD28-/CD95+ [CD45RAint CCR7int] CD3+ CD8+ [CD3+] 
CD8+CD45RA+CCR7+ (naive)CD95+ (TSCM) [CD27+ CD28+] CD3+ CD8+ CD57+ [CD3+] 
CD8+CD45RA+CCR7+ (naive)CD57+ [CD27- CD28-] CD3+ CD8+ CD57+ CD27- [CD3+] 
CD8+CD45RA+CCR7+ (naive)CD95+ [CD27- CD28-)] CD3+ CD8+ CD57- CD27+ [CD3+] 
CD8+ CD45RA+ CCR7- (TEMRA)CD95+ [CD27+ CD28+] CD3+ CD8+ /CD56- CD27- [CD3+] 
CD8+CD45RA+ CCR7- (TEMRA)CD95+ [CD27+ CD28-] CD3+ CD8- [CD3+] 
CD8+CD45RA+ CCR7- (TEMRA)CD57+ [CD27- CD28- (E)] CD3+ CD8- CD57+ [CD3+] 
CD8+CD45RA+ CCR7- (TEMRA)CD95+ [CD27- CD28- (E)] CD3+ CD8- CD57+ CD27- [CD3+] 
CD8+CD45RA-CCR7+ (CM)CD95+ [CD27+ CD28+ (CM)] CD3+ CD8- CD57- CD27+ [CD3+] 
CD8+CD45RA-CCR7+ (CM)CD95+ [CD27+ CD28-] CD3+ CD8- NKG2C+ [CD3+] 
CD8+CD45RA-CCR7+ (CM)CD95+ [CD27- CD28+] CD3+ CD8- /CD56- CD27- [CD3+] 
CD8+CD45RA-CCR7+ (CM)CD57+ [CD27- CD28-] CD3hi CD56lo [CD3+] 
CD8+CD45RA-CCR7+ (CM)CD95+ [CD27- CD28-] CD161+ CD3+ CD8+ [CD161+ CD3+] 
CD8+CD45RA- CCR7- (EM)CD95+ [CD27+ CD28+ ] CD161+ CD3+ CD8- [CD161+ CD3+] 
CD8+CD45RAint CCR7intCD57+ [CD27+ CD28-] NKG2D+ CD3+ CD8+ [NKG2D+] 
CD8+CD45RAint CCR7intCD95+ [CD27+ CD28-]  
CD8+CD45RAint CCR7intCD57+ [CD27- CD28-]  
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B cell phenotypes  
CD19+ CD27+ IgD+ (unswitched (IgM) memory) [ref CD19+] CD19+ CD38- CD27+ CD24+ [CD19+CD38-CD27+] 
CD19+ CD27+ IgD- (switched memory) [CD19+] CD19+ CD38- CD27+ IgD+ [CD19+] 
CD19+ CD38+ CD27+ [CD19+ CD38+] CD19+ CD38- CD27+ IgD+ [CD19+CD38-CD27+] 
CD19+ CD38+ CD27+ CD20- [CD19+] CD19+CD38-CD27+CD20- [CD19+ CD38-] 
CD19+ CD38+ CD27+ CD20- [CD19+ CD38+] CD19+CD38-CD27+CD20- [CD19+CD38-CD27+] 
CD19+ CD38+ CD24+ CD27+ [CD19+CD38+CD24+] CD19+ CD38- CD24+ [CD19+ 
CD19+ CD38+ CD24+ IgD [CD19+CD38+CD24+] CD19+ CD43+ CD27+ [CD19+] 
CD19+CD38-CD27+ [CD19+] CD19lo CD20- CD27hi CD38hi [CD19+] 
CD19+ CD38- CD27+ CD24+ [CD19+] CD20+CD40+ [CD20+] 
CD19+ CD38- CD27+ CD24+ [CD19+ CD38-]  
  
NK cell phenotypes  
CD3- CD56+ [CD45+] CD3- CD56dim NKG2A- [CD45+] 
CD3- CD56+ CD27+ [CD45+] CD3- CD56dim NKG2A- [CD3- CD56+] 
CD3- CD56hi CD16- CD27+ [CD3- CD56+] CD3- CD56hi CD57- [CD3- CD56+] 
CD3- CD56hi CD16- CD27+ [CD3- CD56+ CD27+] CD3- CD56hi NKG2A+ [CD45+] 
CD3- CD56dim CD16+ (mature) [CD45+] CD3- CD56hi NKG2A+ [CD3- CD56+] 
CD3- CD56dim CD16+ (mature) [CD3- CD56+] CD3- CD56- [CD45+] 
CD3- CD56dim CD16+ CD8+ [CD45+] CD3- CD56- CD16+ (dysfunctional) [CD45+] 
CD3- CD56dim CD16+ CD8+ [CD3- CD56+] CD3- CD56- CD16+ (dysfunctional) [CD3- CD56-] 
CD3- CD56dim CD16+ CD8+ [CD3- CD56dim CD16+] CD161+ CD3- CD56+ [CD45+] 
CD3- CD56dim CD16+ CD8+ CD57+ [CD45+] CD161+ CD3- CD56+ [CD161+] 
CD3- CD56dim CD16+ CD8+ CD57+ [CD3- CD56+] CD161+ CD3- CD56dim CD16- [CD45+] 
CD3-CD56dimCD16+CD8+CD57+[CD3- CD56dim CD16+] CD161+ CD3- CD56dim CD16- [CD161+] 
CD3-CD56dimCD16+CD8+CD57+[CD3-CD56dimCD16+CD8+] CD161+ CD3- CD56dim CD16- [CD161+ CD3- CD56+] 
CD3- CD56dim CD16+ CD57+ [CD45+] CD161+ CD3- CD56hi CD16- [CD45+] 
CD3- CD56dim CD16+ CD57+ [CD3- CD56+] CD161+ CD3- CD56hi CD16- [CD161+] 
CD3- CD56dim CD16+ CD57+ [CD3- CD56dim CD16+] CD161+ CD3- CD56hi CD16- [CD161+ CD3- CD56+] 
CD3- CD56dim CD16+ CD57+ NKG2Chi [CD45+] CD161+ CD3- CD56lo CD16+ [CD45+] 
CD3- CD56dim CD16+ CD57+ NKG2Chi [CD3- CD56+] CD161+ CD3- CD56lo CD16+ [CD161+] 
CD3-CD56dimCD16+CD57+NKG2Chi[CD3-CD56dimCD16+] CD161+ CD3- CD56lo CD16+ [CD161+ CD3- CD56+] 
CD3- CD56dim CD16+ NKG2A+ [CD45+] NKG2A+ CD3- CD56+ [CD45+] 
CD3- CD56dim CD16+ NKG2A+ [CD3- CD56+] NKG2A+ CD3- CD56+ [NKG2A+] 
CD3- CD56dim CD16+ NKG2A+ [CD3- CD56dim CD16+] NKG2A+ CD3- CD56hi CD16- [CD45+] 
CD3- CD56dim CD16+ NKG2C+ [CD45+] NKG2A+ CD3- CD56hi CD16- [NKG2A+] 
CD3- CD56dim CD16+ NKG2C+ [CD3- CD56+] NKG2D+ CD3- CD56+ [CD45+] 
CD3- CD56dim CD16+ NKG2C+ [CD3- CD56dim CD16+] NKG2D+ CD3- CD56+ [NKG2D+] 
CD3- CD56dim CD16- [CD3- CD56+] NKG2D+ CD3- CD56dim CD16+ [CD45+] 
CD3- CD56dim CD16- CD8+ [CD45+] NKG2D+ CD3- CD56dim CD16+ [NKG2D+] 
CD3- CD56dim CD16- CD57+ [CD3- CD56+] NKG2D+ CD3- CD56dim CD16+ [NKG2D+ CD3- CD56+] 
CD3- CD56dim CD16- NKG2A+ [CD45+] NKG2D+ CD3- CD56dim CD16- [CD45+] 
CD3- CD56dim CD16- NKG2A+ [CD3- CD56+] NKG2D+ CD3- CD56dim CD16- [NKG2D+] 
CD3- CD56dim CD16- NKG2C+ [CD3- CD56dim CD16-] NKG2D+ CD3- CD56dim CD16- [NKG2D+ CD3- CD56+] 
CD3- CD56dim CD57+ [CD45+] NKG2D+ CD3- CD56hi CD16- [CD45+] 
CD3- CD56dim CD57+ [CD3- CD56+] NKG2D+ CD3- CD56hi CD16- [NKG2D+ CD3- CD56+] 
CD3- CD56dim CD57- [CD45+]  
CD3- CD56dim CD57- [CD3- CD56+]  
CD3- CD56dim NKG2A+ [CD45+]  
CD3- CD56dim NKG2A+ [CD3- CD56+]  
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Additional file 10 – Correlations between NK cells and TAA-reactive T 
cells 
NK cell phenotype P value  
CD3- CD56+ CD27+ [CD45+] 0.039 Higher in Responder 
   
   
CD3- CD56dim CD16+ CD8+ CD57+ [CD3-CD56dimCD16+CD8+] 0.021 Higher in Responder 
NKG2D+ CD3- CD56dim CD16- [NKG2D+] 0.038 Lower in Responder 
   
   
CD3- CD56dim CD16+ CD57+ NKG2Chi [CD45+] 0.037 Lower in Responder 
CD3- CD56dim CD16+ CD57+ NKG2Chi  [CD3- CD56+] 0.025 Lower in Responder 
CD3- CD56dim CD16+ CD57+ NKG2Chi  [CD3- CD56dim CD16+] 0.03 Lower in Responder 
CD3- CD56dim CD16- CD8+ CD57+ [CD3- CD56dim CD16-] 0.031 Lower in Responder 
CD3- CD56dim CD16- NKG2C+ [CD3- CD56dim CD16-] 0.013 Lower in Responder 
NKG2A+ CD3- CD56+ [NKG2A+] 0.025 Higher in Responder 
   
CD3- CD56hi CD16- CD27+ [CD3- CD56+ CD27+] 0.020 Higher in Responder 
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Additional file 11 – Correlations between blood T cells and TAA-
reactive T cells 
T cell phenotype P value  
CD8posCD45RApos CCR7neg (TEMRA) [CD3pos] 0.035 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27pos CD28neg [CD3pos] 0.045 Higher in Responder 
CD8posCD45RAint CCR7int/CD27pos CD28pos /CD95pos [CD3pos] 0.018 Higher in Responder 
CD45RApos CCR7neg (TEMRA) [CD8pos] 0.042 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27pos CD28neg [CD8pos] 0.041 Higher in Responder 
CD45RAint CCR7int/CD27pos CD28pos /CD95pos [CD8pos] 0.021 Higher in Responder 
CD4CD27pos CD28pos/CD57pos [CD45RApos CCR7pos (Naive)] 0.013 Lower in Responder 
CD4posCD27neg CD28neg (E)/CD57pos [CD45RApos CCR7neg 
(TEMRA)] 
0.038 Higher in Responder 
CD8posCD45RAnegCCR7pos (CM)CD57pos [CD27pos CD28neg] 0.033 Lower in Responder 
CD8posCD45RAnegCCR7pos (CM)CD95pos [CD27neg CD28pos] 0.036 Lower in Responder 
   
CD8posCD45RApos CCR7neg (TEMRA)/CD27pos CD28neg [CD3pos] 0.025 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27pos CD28neg/CD95pos 
[CD3pos] 
0.018 Higher in Responder 
CD8posCD45RAposCCR7pos (naive)CD57pos [CD27neg CD28neg] 0.031 Lower in Responder 
   
CD4posCD45RAneg CCR7pos (CM)/CD27neg CD28pos [CD3pos] 0.037 Higher in Responder 
CD4posCD45RAneg CCR7pos (CM)/CD27neg CD28pos/CD95pos 
[CD3pos] 
0.039 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27pos CD28neg [CD3pos] 0.016 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27pos CD28neg/CD95pos 
[CD3pos] 
0.036 Higher in Responder 
CD45RApos CCR7pos (Naive)/CD27pos CD28pos/CD95pos (TSCM) 
[CD4] 
0.046 Higher in Responder 
CD45RAneg CCR7pos (CM)/CD27neg CD28pos [CD4pos] 0.044 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27pos CD28neg [CD8pos] 0.013 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27pos CD28neg/CD57pos 
[CD8pos] 
0.034 Higher in Responder 
CD161pos CD3pos CD8neg [CD45pos] 0.013 Higher in Responder 
   
CD4posCD45RAneg CCR7pos (CM)/CD27neg CD28neg/CD95pos 
[CD3pos] 
0.030 Lower in Responder 
CD45RAneg CCR7pos (CM)/CD27neg CD28neg [CD4pos] 0.030 Lower in Responder 
CD45RAneg CCR7pos (CM)/CD27neg CD28neg/CD95pos [CD4pos] 0.030 Lower in Responder 
CD4posCD45RAnegCCR7neg CD95pos [CD27pos CD28pos] 0.044 Higher in Responder 
CD8posCD45RAneg CCR7neg (EM)/CD95pos [CD27neg CD28pos] 0.050 Higher in Responder 
NKG2Dpos CD3pos CD8pos [CD45pos] 0.029 Higher in Responder 
   
CD8posCD45RAneg CCR7pos (CM)/CD27neg CD28pos [CD3pos] 0.027 Higher in Responder 
CD8posCD45RAneg CCR7pos (CM)/CD27neg CD28pos/CD95pos 
[CD3pos] 
0.022 Higher in Responder 
CD8posCD27neg CD28pos [CD45RAneg CCR7pos (CM)] 0.018 Higher in Responder 
CD8posCD27neg CD28pos/CD95pos [CD45RAneg CCR7pos (CM)] 0.019 Higher in Responder 
CD161pos CD3pos CD56dim [CD161pos] 0.037 Higher in Responder 
CD161pos CD3pos CD8pos [CD45pos] 0.009 Higher in Responder 
CD161pos CD3pos CD8pos [CD161pos CD3pos] 0.001 Higher in Responder 
CD161pos CD3pos CD8neg [CD161pos CD3pos] 0.001 Lower in Responder 
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CD4posCD45RApos CCR7neg (TEMRA)/CD27neg CD28neg (E) 
[CD3pos] 
0.035 Higher in Responder 
CD4posCD45RApos CCR7neg (TEMRA)/CD27neg CD28neg 
(E)/CD95pos [CD3pos] 
0.027 Higher in Responder 
CD8pos CD27neg [CD3pos] 0.001 Higher in Responder 
CD8pos CD28neg [CD3pos] 0.001 Higher in Responder 
CD8pos CD57pos CD3pos] 0.002 Higher in Responder 
CD8pos CD95pos [CD3pos] 0.049 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA) [CD3pos] 0.005 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27neg CD28neg (E) 
[CD3pos] 
0.001 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27neg CD28neg 
(E)/CD57pos [CD3pos] 
0.003 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)/CD27neg CD28neg 
(E)/CD95pos [CD3pos] 
0.001 Higher in Responder 
CD8posCD45RAint CCR7int [CD3pos] 0.025 Higher in Responder 
CD8posCD45RAint CCR7int/CD27neg CD28pos/CD95pos [CD3pos] 0.018 Higher in Responder 
CD8posCD45RAint CCR7int/CD27neg CD28neg [CD3pos] 0.006 Higher in Responder 
CD8posCD45RAint CCR7int/CD27neg CD28neg/CD57pos [CD3pos] 0.009 Higher in Responder 
CD8posCD45RAint CCR7int/CD27neg CD28neg/CD95pos [CD3pos] 0.005 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27neg CD28neg (E) [CD4pos] 0.027 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27neg CD28neg (E)/CD57pos 
[CD4pos] 
0.043 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27neg CD28neg (E)/CD95pos 
[CD4pos] 
0.021 Higher in Responder 
CD8pos CD27neg [CD8pos] 0.002 Higher in Responder 
CD8pos CD28neg [CD8pos] 0.003 Higher in Responder 
CD8pos CD57pos [CD8pos] 0.018 Higher in Responder 
CD45RApos CCR7neg (TEMRA) [CD8pos] 0.011 Higher in Responder 
CD45RApos CCR7neg (TEMRA)/CD27neg CD28pos/CD95pos 
[CD8pos] 
0.033 Higher in Responder 
CD45RAint CCR7int/CD27neg CD28pos/CD95pos [CD8pos] 0.048 Higher in Responder 
CD45RAint CCR7int/CD27neg CD28neg [CD8pos] 0.014 Higher in Responder 
CD45RAint CCR7int/CD27neg CD28neg/CD57pos [CD8pos] 0.015 Higher in Responder 
CD45RAint CCR7int/CD27neg CD28neg/CD95pos [CD8pos] 0.013 Higher in Responder 
CD4posCD27pos CD28pos [CD45RAneg CCR7neg (EM)] 0.039 Lower in Responder 
CD8posCD27pos CD28pos [CD45RApos CCR7neg (TEMRA)] 0.001 Lower in Responder 
CD8posCD27neg CD28neg (E) [CD45RApos CCR7neg (TEMRA)] 0.008 Higher in Responder 
CD8posCD27neg CD28neg (E)/CD57pos [CD45RApos CCR7neg 
(TEMRA)] 
0.024 Higher in Responder 
CD8posCD27pos CD28pos /CD95pos [CD45RAint CCR7int] 0.045 Lower in Responder 
CD8posCD27neg CD28neg [CD45RAint CCR7int] 0.009 Higher in Responder 
CD8posCD27neg CD28neg/CD57pos [CD45RAint CCR7int] 0.034 Higher in Responder 
CD8posCD27neg CD28neg/CD95pos [CD45RAint CCR7int] 0.008 Higher in Responder 
CD4posCD45RAnegCCR7posCD95pos [CD27neg CD28neg] 0.050 Higher in Responder 
CD4posCD45RAnegCCR7negCD57pos [CD27pos CD28pos ] 0.031 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)CD95pos [CD27pos CD28neg] 0.016 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)CD95pos [CD27neg CD28pos] 0.042 Higher in Responder 
CD8posCD45RApos CCR7neg (TEMRA)CD95pos [CD27neg CD28neg 
(E)] 
0.000 Higher in Responder 
CD8posCD45RAneg CCR7neg (EM)CD95pos [CD27pos CD28neg] 0.037 Higher in Responder 
CD8posCD45RAint CCR7intCD95pos [CD27pos CD28neg] 0.003 Higher in Responder 
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CD8posCD45RAint CCR7intCD95pos [CD27neg CD28neg] 0.012 Higher in Responder 
CD3pos CD56dim [CD45pos] 0.027 Higher in Responder 
CD3pos CD56dim CD8pos [CD45pos] 0.015 Higher in Responder 
NKG2Dpos CD3pos CD56dim [CD45pos] 0.006 Higher in Responder 
NKG2Dpos CD3pos CD56dim [NKG2Dpos] 0.006 Higher in Responder 
CD3pos CD8pos CD57pos [CD45pos] 0.009 Higher in Responder 
CD3pos CD8pos CD57pos CD27neg [CD45pos] 0.010 Higher in Responder 
CD3pos CD8pos /CD56neg. CD27neg [CD45pos] 0.024 Higher in Responder 
CD161pos CD3pos CD8pos [CD45pos] 0.031 Higher in Responder 
CD3pos CD8pos CD57pos [CD3pos] 0.007 Higher in Responder 
CD3pos CD8pos CD57pos CD27neg [CD3pos] 0.006 Higher in Responder 
CD3pos CD8pos /CD56neg. CD27neg [CD3pos] 0.020 Higher in Responder 
CD161pos CD3p s CD8pos [CD161pos CD3pos] 0.023 Higher in Responder 
CD161pos CD3pos CD8neg [CD161pos CD3pos] 0.023 Lower in Responder 
CD3pos CD8pos CD57pos [CD3pos CD8pos] 0.018 Higher in Responder 
CD3pos CD8pos CD57pos CD27neg [CD3pos CD8pos] 0.013 Higher in Responder 
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Abstract: 
Introduction: 
A number of studies has shown that the “immune context” within the tumour plays a major 
role in cancer progression and responsiveness to immunotherapies. The efficacy of such 
immunotherapeutic approaches relies on the presence of immune cells that migrate into the 
tumour and subsequently kill tumour cells. Thus, a more comprehensive analysis of immune 
features in the tumour including cellular and soluble features may be required in order to 
better predict patient outcome or response to therapy. 
Methods: 
Here, we analysed multifaceted immune parameters in melanoma sections with the goal of 
identifying the immune factor(s) most relevant for patient outcome. Using fluorescence 
microscopy, we assessed T cells (CD3+) and myeloid cells (CD15+) in addition to a panel of 
soluble immune factors (IL-6, GM-CSF, TNF, IL-1Ra, IL-2, IL-10, GDF15, PGE2) as well as the 
transcription factor STAT3 in metastatic melanoma tissues of 76 patients.  
Results: 
We observed that tumour-infiltrating immune cells were present in the majority of patient 
samples, in which high relative levels of CD15+ but not CD3+ cells were found to be a 
potential prognostic marker for survival. Combining the assessment of CD15+ and CD3+ 
cells, we found that patients survived longer when their tumours contained high levels of 
CD3+ cells and low levels of CD15+ cells. No associations between patient clinical parameters 
and the level of a number of soluble factors were found, apart from high levels of TNF in 
patients with more advanced disease.  
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Conclusions: 
This pilot study proposes cellular but not soluble features as potential indicators of patient 
outcome in metastatic melanoma.  
Keywords:  
TILs, tumour microenvironment, metastatic melanoma, immune context 
 
Introduction 
Although malignant melanoma accounts for less than one percent of skin cancer cases (1), it 
is the most dangerous form, with an ever-increasing incidence worldwide. Despite recent 
therapeutic advances and sustained efforts at early diagnosis, the majority of metastatic 
melanoma patients still faces a poor prognosis. The recent introduction of 
immunomodulatory antibody therapies into the clinic has revolutionised treatment of 
metastatic melanoma and several other solid cancers. These therapies utilise the patient’s 
own immune system to control or suppress tumour growth. However, the efficacy of such 
approaches relies on the presence of immune cells which can migrate into the tumour and 
subsequently kill the cancer cells or otherwise suppress tumour development even when 
employing intratumoural immunotherapy (2). Supporting this notion, a number of recent 
studies has shown that the state of the immune system within the tumour plays a major role 
in cancer progression and patient outcome. The most intensively explored approach is based 
on investigations on the level of intra-tumoural lymphocytes and other immune cells in 
colorectal cancer, where the “immune context” had greater prognostic power than the 
standard staging system for predicting post-operative survival (3-5). Such associations 
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between the level of tumour-infiltrating lymphocytes and clinical outcome have also been 
reported in several other cancer types (6-9). As well as providing prognostic information on 
patient survival, the assessment of the intra-tumoural immune context could also assist in 
predicting which patients will respond to which forms of therapy, something of great 
importance in clinical patient management. Supporting this in the context of melanoma, 
Thume et al. has shown that high levels of infiltrating CD8+ cells are associated with 
responsiveness to therapeutic PD-1 blockade in these patients (10). Associations between 
the composition of the tumour microenvironment and the clinical efficacy of conventional 
therapies and immunotherapies have also been documented in several other cancer types 
(4, 11-18).  
However, tumour progression is still frequently seen even in the presence of substantial 
lymphocytic infiltration, suggesting that either an effective immune response cannot be 
generated, or that the immune response cannot always control tumour growth in every 
individual patient. This in turn suggests that a more comprehensive analysis of immune 
features in the tumour including cellular and soluble factors may be required in order to 
better predict patient outcome. This proposition is based on the notion that local immune 
cells are heavily influenced by signals received from soluble immune molecules such as 
chemokines or cytokines which can promote their migration and stimulate their anti-tumour 
activity but may also program them to become immunosuppressive. For example, Mlecnik et 
al. reported that the presence of certain chemokines and adhesion molecules is correlated 
with high levels of T cell infiltration into the tumour and with patient survival (19), while a 
separate study in uveal melanoma showed that intra-tumoural COX-2 expression was 
associated with the levels of Tregs and patient survival (20). These observational studies are 
supported by investigations which reveal interactions between soluble factors and cellular 
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immune features. For example, high levels of IDO and PGE2 inhibit T cell function, down-
regulate NK receptors and increase the frequency of tumour-infiltrating regulatory T cells 
(21-23). Furthermore, PGE2, IL-6 and a number of other soluble factors has been shown to 
drive the differentiation of monocytes into immunosuppressive “myeloid-derived suppressor 
cells” (MDSCs) (24-26). The levels of these molecules and their associated pathways in the 
tumour have also been shown to correlate with patient survival (27, 28). Collectively, these 
studies suggest that the soluble milieu in the tumour microenvironment influences the level 
and behaviour of local immune cells, and that both soluble and cellular immune features are 
important for patient prognosis. 
 
Considering the role of soluble signalling molecules in generating an efficient anti-tumour 
immune response, an immunological perspective of the tumour microenvironment would be 
incomplete without examining these soluble molecules. However, few studies have assessed 
the clinical importance of both cellular and soluble intra-tumoural immune features, and 
little is known about the prognostic value of cells infiltrating melanoma lesions. Because 
soluble factors influence leukocyte behaviour in pleiotropic or context-dependent ways, 
understanding what constitutes a “favourable” intra-tumoural environment is important for 
guiding the development of innovative therapies in future, as well as for optimal 
implementation of existing therapies. To take the first step towards this, the present study 
was designed to characterise multifaceted immune parameters in melanoma. We assessed T 
cells and myeloid cells in addition to a panel of soluble immune factors, with the goal of 
identifying immune factor(s) most relevant for patient outcome. 
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Materials and Methods 
Patients 
This study investigated 76 metastatic melanoma patients treated at the Dermatology 
Department of Tübingen University Hospital. Patients included in this study received diverse 
forms of anti-cancer therapies. Thus, this pilot study sought informative immune features 
common to all melanoma patients regardless of the type of treatment they received. The 
study population consisted of 44 men and 32 women with a median age of 63 (range 35 – 89 
years). See Table 1 for a detailed description of the patient cohort. This study was approved 
by the Ethics Committee of the University of Tübingen (017/2016BO2). Written informed 
consent was obtained from all patients for the storage and scientific analysis of tissue 
samples. 
Table 1: Description of patient cohort 
 
 
 
 
 
 
 
 
 
Patient clinicopathological parameters (n = 76) 
Median Age (range in years) 63 (35-89) 
  
Gender  
Men 44 
Women 32 
  
AJCC staging  
3 31 
4A 14 
4B 9 
4C 22 
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Immunofluorescence  
To detect proteins of interest, slide-mounted formalin-fixed paraffin-embedded tissue 
sections (5 µm thick) were first dewaxed for 15 min in xylene and then rehydrated in a series 
of graded ethanol solutions (100%, 96% and 70%, 5 min each), followed by incubation in 
distilled water for 30 min. Antigen retrieval was performed using an alkaline-based solution 
(1 mM EDTA, 25 mM Tris–HCl, 0.05% SDS, pH 8.5) (29) at 90°C for 45 minutes for all 
antibodies. Tissues were then rinsed with washing buffer (PBS, 0.025% Tween 20 and 
0.005% BSA) for 3 minutes before blocking non-specific binding with a 5% donkey serum 
solution (diluted in washing buffer) for 30 minutes at room temperature. This was followed 
by incubation with primary antibody (60 min at room temperature) before washing for 3 x 3 
min. After washing, secondary antibody was applied (incubated for 60 min at room 
temperature) before another round of 3 x 3 min washes. Cell nuclei were subsequently 
stained with 4′,6-diamidino-2-phenylindole (DAPI) (Roche, Mannheim, Germany) (diluted 
1:2000 in washing buffer) for 10 minutes before washing (3 x 3 min). Slides were then 
mounted with a glass coverslip (0.08–0.12 mm) using fluorescence mounting medium (Dako, 
Santa Clara, US). Stained slides were stored protected from light at 4°C before being 
measured with a Zeiss Axiophot fluorescence microscope using AxioVision 4.8 software. 
Soluble molecules were recorded at 20x magnification, whereas infiltrating cells were 
captured at 40x magnification. The following primary antibodies were used: rabbit 
polyclonal anti-CD3 (1:30, Abcam, Cambridge, UK ), goat polyclonal anti-CD14 (1:40 Novus 
Biologicals, Abingdon, UK), mouse monoclonal anti-CD14 (clone 5A3B11B5) (1:300 Santa 
Cruz Biotechnology, Dallas, Texas, USA) rabbit monoclonal anti-CD15 (1:80, Novus 
Biologicals), rabbit polyclonal anti-GM-CSF (1:20, Bioss, Woburn, Massachusetts, USA), 
rabbit polyclonal anti-TNF (1:40, Novus Biologicals), rabbit polyclonal anti-PGE2 (1:10, 
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Biorbyt, Cambridge, UK), rabbit polyclonal anti-GDF15 (1:35, BIOZOL, Eching, Germany), 
rabbit polyclonal anit-IL10 (1:10, BIOZOL), mouse polyclonal anti- IL-6 (1:20, Bioss), mouse 
anti- STAT3 (1:8, SantaCruz Biotechnology), mouse monoclonal anti-IL1Ra (clone OTI3B1) 
(1:45, ORIGENE, Rockville, MD, USA) and mouse monoclonal anti-IL2 (1:25, ACRIS, SanDiego, 
CA, USA). For the detection of the primary antibody, the following secondary antibodies 
were used: Alexa Fluor 488 donkey anti-rabbit IgG (H+L) (1:60), Cy3 donkey anti-mouse IgG 
(H+L) (1:150), Alexa Fluor 488 donkey anti-goat IgG (H+L) (1:60). All secondary antibodies 
were purchased from Jackson ImmunoResearch Laboratories, West Grove, PA, USA. Control 
sections omitting primary antibody were included for each sample. Primary antibodies were 
individually titrated and tested with different antigen retrieval methods in order to 
determine optimal staining conditions. 
Depending on tumour size, an average of 12 representative images was captured in a non-
biased manner covering all areas of the tissue, so that the tumour centre and margin were 
measured proportional to the tumour size. To determine relative differences in protein 
expression of different samples, fluorescence intensity was compared between the control 
(secondary antibody only) and primary antibody-stained tissue sections on the same slide. In 
order to standardise the measurement of different samples, signal intensity (exposure time) 
of the control tissue was adjusting in accordance with standard images. After determining 
comparable signal intensity in accordance with the standard images, an equivalent number 
of images from control and antibody-stained tissues was recorded. Fluorescence intensity 
for each image was measured with software designed in-house (created by Christof Zanke, 
Tübingen University Hospital, Tübingen, Germany) which was used to create a fluorescence 
index; mean pixel intensity of the antibody-stained tissue divided by mean pixel intensity of 
images from the control tissue. By including an internal control for each slide, this method 
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considers any potential differences in sample autofluorescence or in microscope settings or 
performance that may occur. Results obtained by software were confirmed visually. Tissues 
were considered to be positive for a protein if they showed fluorescence intensity of at least 
50% greater than the control slide (i.e. fluorescence index of 1.5). To quantify numbers of 
infiltrating cells, images were scored by two independent investigators and results compared 
to identify potential discrepancies. 
 
Statistical analysis 
Two independent groups were compared using the Mann-Whitney U test. Relationships 
across four grouping variables were assessed with Fisher’s exact test. Correlations were 
assessed using Spearman correlation analysis. Differences in disease-specific survival 
between two groups were compared using the Kaplan-Meier method with the log-rank test. 
Surviving patients or deaths not due to melanoma were censored. The patient cohort was 
dichotomised into two groups for survival analysis using two methods (1) following 
convention according to median values, or (2) the largest differences in survival between 
patient groups were determined by comparing all possible combinations of patient groups 
(group sizes accounted for at least 10% the entire cohort). To account for the additional 
number of statistical tests that this method requires, we adjusted the significance threshold 
considering this, whereas all other statistical relationships were considered using a threshold 
of 5%. Statistical analysis was performed with SPSS 22 (IBM, Ehningen, Germany) and Prism 
5 (Graph Pad, La Jolla, USA). 
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Results 
Metastatic melanomas are commonly infiltrated by T cells and granulocytic cells, and 
possess a diverse milieu of soluble factors 
 
To characterise the tumour microenvironment in melanoma, we assessed soluble factors 
and cellular features in the tumours of 76 metastatic melanoma patients. This 
characterisation included T cells, monocytes and granulocytic cells along with the soluble 
factors IL-6, GM-CSF, TNF, IL-1Ra, IL-2, IL-10, GDF15, PGE2 and the transcription factor 
STAT3. The presence of soluble molecules was very common, with a large fraction of 
tumours staining positive for most of the molecules (Fig. 1A). However, they were found to 
be present at different levels in different tumours, with IL-6, GM-CSF and IL-1Ra showing the 
greatest range (Fig. 1B). Similar to the soluble molecules, we observed that the majority of 
melanoma tissues contained CD3+ and CD15+ cells (Fig. 1C), but the latter were much less 
common (Fig. 1D) with substantially lower abundance compared to CD3+ cells (Fig. 1E). 
Further, there was no significant difference in the distribution of cells comparing center and 
margin of the tumour, neither for CD3+ nor for CD15+ cells (Fig. 1E), although there was a 
tendency towards greater CD15+ cell infiltration into the center of the tumour.  
We also attempted to quantify tumour infiltration by CD14+ cells using two commercially-
available antibodies (goat polyclonal anti-CD14 from Novus Biologicals and mouse 
monoclonal anti-CD14 from Santa Cruz (clone 5A3B11B5)). Despite the use of different 
staining protocols, we were not able to achieve staining quality that allowed quantification 
of CD14+ positive cells using either antibody.  
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Figure 1. Melanomas are commonly infiltrated by leukocytes and contain a range of different 
soluble molecules. Tumour infiltration by CD3+ and CD15+ cells (n = 56) and the presence of soluble 
molecules including IL-1Ra (n = 47), IL-2 (n = 56), IL-6 (n = 62), IL-10 (n = 56), GM-CSF (n = 45), TNF (n 
= 53), GDF15 (n = 47), PGE2 (n = 39) and STAT3 (n = 53) was determined using fluorescence 
microscopy. The presence of most soluble molecules was common in melanoma tumours (A), but 
differed in level (B). The majority of melanoma lesions was infiltrated by CD3+ (C, top image) and 
CD15+ cells (C, bottom image), with CD3+ cells being more common (D) and occurring at higher 
levels (E).  No significant difference between margin or center was observed for either CD3+ or 
CD15+ cells (E).  
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Levels of soluble molecules in the melanoma microenvironment correlate with each other 
and with infiltration by granulocytic cells  
We reasoned that a particular microenvironment might enhance or suppress the infiltration 
of immune cells into the tumour. We found that tumours more heavily infiltrated by CD15+ 
cells (which would be expected to suppress immunity) also showed lower expression of the 
immunosuppressive factor PGE2 (p = 0.02) (Fig. 2A). However, no other associations 
between immune cell infiltration and the level of soluble molecules were observed. Given 
that many of these soluble signalling molecules are known to act in concert, we next 
investigated whether the expression of the different molecules investigated here was 
related. Indeed, several factors were found to be positively associated with the presence of 
other factors. For example, levels of IL-6 and GM-CSF positively correlated with each other (p 
< 0.0001, r = 0.7) (Fig. 2B). Similar relationships were also seen between TNF and STAT3 (p < 
0.0001, r = 0.7), IL-2 and IL-10 (p < 0.0001, r = 0.5) as well as for other combinations of 
molecules. See supplementary data 1 for a full set of correlations. 
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Figure 2. The presence of soluble factors in melanoma tumours is correlated and can be associated 
with leukocyte infiltration. Intra-tumoural levels of CD3+ and CD15+ cells and the presence of 
soluble molecules (IL-1Ra, IL-2, IL-6, IL-10, GM-CSF, TNF, GDF15, PGE2, STAT3) was assessed in 
metastatic melanoma lesions from 76 patients. Patients were grouped according to their median 
expression level and cell counts, respectively. This revealed that patients with higher than median 
levels of CD15+ cells in tumours had lower levels of PGE2 (A). We also found that the amount of IL-6 
was positively correlated with GM-CSF, with similar relationships observed between STAT3 and TNF 
and between IL-2 and IL-10 (B). FI, Fluorescence Index 
 
High intra-tumoural levels of TNF are present in patients with more advanced disease  
We next investigated whether the presence of soluble factors or tumour infiltration by T 
cells or granulocytic cells was associated with clinical parameters in these melanoma 
patients. We investigated whether the immune parameters measured here were associated 
with clinical features including disease stage, progression time (stage III to stage IV), age and 
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gender. This analysis showed that patients with stage IV disease had tumours with higher 
levels of TNF relative to stage III patients (p = 0.02) (Fig. 3A). No other association between 
stage and any other immune features were found here; neither STAT3 nor CD3+ or CD15+ 
cells in the margin were associated with tumour stage (Fig. 3A). Older patients were 
additionally found to have lower numbers of CD15+ cells infiltrating into the tumour margin 
(p = 0.046) (Fig. 3B), while CD3+ infiltration into the margin, TNF and STAT3 expression 
where not influenced by age. No other associations between patient clinical parameters and 
the immune features measured here were found (Fig. 3, selected results shown).  
 
 
Figure 3. Levels of tumour-infiltrating leukocytes and intra-tumoural soluble factors are associated 
with some patient clinical parameters. Tumour-infiltrating cells (CD3+ and CD15+) and soluble 
factors (IL-1Ra, IL-2, IL-6, IL-10, GM-CSF, TNF, GDF15, PGE2 and STAT3) were measured in the tissue 
of 76 melanoma patients using fluorescence microscopy and tested for association with patient 
clinical parameters. Patients with more advanced disease had tumours with higher levels of TNF (A). 
We also found that older patients had lower levels of CD15+ cells infiltrating the tumour margin 
(young group: median age 53 (range 35 - 63 years); old group: median age 73 (range 64 - 89) (B).  
 
  
15 
 
Tumour-infiltrating leukocytes are associated with patient survival  
 
Based on recent findings suggesting that the makeup of the tumour microenvironment can 
accurately predict patient prognosis in certain types of cancer (6-9), we investigated 
whether the amounts of soluble factors or the infiltrating immune cells investigated here 
were associated with patient survival. To achieve this, we first stratified the patients into 
two groups according to median values and performed Kaplan-Meier survival analysis. Using 
this approach, we were unable to identify any single soluble or cellular factor which was 
associated with patient survival (data not shown). Because the aforementioned approach is 
based on an arbitrary method of dividing a single patient cohort into two groups, we next 
investigated whether separating the cohort according to different criteria would reveal 
discrete groups of patients showing differences in survival. To achieve this we compared the 
survival of two patient groups according to different cut-off values to determine the 
threshold with the minimum p value and thus the greatest differences in survival. This 
analysis surprisingly showed that lower intra-tumoural levels of GM-CSF and IL-10, as well as 
high levels of PGE2, were associated with better patient survival (Fig. 4A, and B). At the same 
time, patients with higher levels of intra-tumoural T cells or lower levels of granulocytic cells 
had better survival (Fig. 4C). To account for the additional number of statistical tests that this 
method requires, we adjusted the significance threshold accordingly. After this adjustment, 
only the association between survival and CD15+ infiltration into the margin of the tumour 
remained significant (p = 0.0006, adjusted significance threshold p = 0.0009) (Fig. 4C). These 
results therefore identify soluble and cellular factors in the tumour microenvironment as 
potential prognostic markers, but they require validation in an independent cohort to 
confirm these initial findings. 
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Figure 4. Levels of intra-tumoural leukocytes and soluble molecules are associated with the 
survival of melanoma patients. We compared the survival of two patient groups according to 
different cut-off values to determine the largest differences in the survival between patients showing 
high or low levels of soluble molecules and tumour-infiltrating leukocytes. This showed that low 
levels of GM-CSF and IL-10 (A) and high levels of PGE2 (B) were associated with longer patient 
survival. Similarly, patients with high levels of CD3+ or low levels of CD15+ cells in the tumour were 
found to have a survival benefit (C). When considering the number of statistical tests performed, 
only intra-tumoural levels of CD15+ cells were found to be associated with survival (adjusted 
significance threshold p = 0.0009).  
GM-CSF (n = 45): 27% of patients in the high group (>), 73% of patients in the low group (<); IL-10 (n = 
56): > 46%, < 54%; PGE2 (n = 39): > 74%, < 26%; CD3+ centre (n = 56): > 29%, < 71%; CD15+ margin (n 
= 56): > 30%, < 70%.  
Green lines in survival curves, patients with high levels of indicated feature; red lines, patients with 
low levels of indicated features; FI, Fluorescence Index  
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A combination of different types of immune parameters as prognostic markers for 
metastatic melanoma  
Considering our results which suggested that single immune parameters measured in this 
study might act as prognostic markers, we hypothesised that combinations of different 
immune features would correlate more closely with clinical outcome. This analysis revealed 
a survival advantage for patients with high levels of tumour-infiltrating CD3+ cells combined 
with low levels of CD15+ infiltration, compared to patients with other combinations of these 
parameters (p = 0.03) (Fig. 5A). A trend was observed for patients with high levels of CD3+ 
cells and low levels of IL-10 (p = 0.1) as well as for patients with low levels of both CD15+ cell 
infiltration and IL-10 (p = 0.08) (Fig. 5B). This combinational analysis reduces the number of 
patients that can be considered, and for this reason these results must be considered 
preliminary until such time as they are validated. 
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Figure 5 Combinations of multiple immune parameters are more closely associated with survival in 
melanoma patients. Patients were grouped according to combined immune parameters, and 
survival between these groups was compared using Kaplan-Meier analysis. This showed that high 
levels (>median) of tumour-infiltrating CD3+ and low levels (<median) of CD15+ cells were associated 
with better patient survival (A). Patients with high (> median) levels of tumour-infiltrating CD3+ cells 
and low (< median) tumour expression of IL-10, or patients with low levels (< median) of tumour-
infiltrating CD15+ cells and low (< median) expression of IL-10 were also found to have better survival 
(B). 
CD3hiCD15lo: n = 9, CD3loCD15hi: n = 12, CD3hiCD15hi: n = 16, CD3loCD15lo: n = 15: CD3hiIL-10low: 
n = 10, CD3lowIL-10hi: n = 11; CD15hiIL-10hi: n = 12, CD15loIL-10lo: n = 15; 
Green lines, patients with combined features associated with a better survival; red lines; patients 
with combined features that are associated with short survival 
 
Discussion 
It has been widely reported across different cancer types that high levels of tumour-
infiltrating immune cells can be associated with superior patient survival (4, 30). However, 
tumour progression is frequently seen despite the presence of high levels of such intra-
tumoural immune cells, suggesting that there are factors within the tumour 
microenvironment that impair the function of these cells and/or that these cells lack anti-
tumour activity. Therefore, factors providing additional information on the phenotype of 
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infiltrating cells as well as on the makeup of the tumour microenvironment may be used as 
biomarkers that can more accurately predict patient survival compared with other 
approaches that only assess the level of infiltrating immune cells. In support of this, prior 
investigations have shown that soluble immune molecules in the tumour microenvironment 
such as PGE2, COX or IL-6, correlate with patient survival (27, 28) and influence the 
migration, differentiation and functional state of infiltrating immune cells (19, 24, 25) 
including innate immune cells particularly for TNF (31). These observations support the 
proposition that the soluble and cellular makeup of the tumour microenvironment plays a 
fundamental role in the generation of effective anti-tumour immune responses, and thus 
may more accurately predict patient outcome when compared to the assessment of intra-
tumoural leukocytes alone. As the majority of studies on the tumour microenvironment 
focus on tumour-infiltrating leukocytes, the present study is one of the few to characterise 
both soluble and cellular intra-tumoural immune features at the same time, with the goal of 
defining an intra-tumoural immune context linked with favourable patient outcome. To 
achieve this, we studied tumour-infiltrating T cells (CD3+) and granulocytic cells (CD15+) 
along with a broad range of soluble molecules (GDF15, PGE2, IL-1Ra, IL-2, IL-6, IL-10, GM-
CSF, TNF) and the transcription factor STAT3. Tumour-infiltrating immune cells were present 
in the majority of patient samples, but CD3+ cells were not associated with any prognostic 
feature. Only CD15+ cells may be a potential prognostic marker depending on the method of 
analysis. This result is in contrast to a number of other studies that report an association 
between CD3+ infiltration and patient prognosis in several other types of cancer (4, 5, 30, 
32-38). However, the finding here that intra-tumoural T cells are not related to patient 
survival adds to the disparate results for the role of tumour-infiltrating T cells in melanoma. 
Hillen et al. reported that high levels of intra-tumoural T cells were associated with poor 
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survival (39), whereas other studies report the opposite relationship; high levels of intra-
tumoural T cells or one study considering peri-tumoural T cell activation markers were found 
to correlate with longer patient survival (40, 41). Furthermore, a recently published study 
reported no significant association between the level of intra- or peri-tumoural CD3+ cells 
and overall survival, in line with the results presented here (42). These discrepancies might 
be explained by variations in the broad populations of CD3+ T cells, which include helper 
cells, exhausted or anergic cells, regulatory T cells as well as cytotoxic cells. Thus, CD3 is 
present on cells with very different functional properties and activation states. Prior studies 
and the present work suggest that information about the level and distribution of T 
lymphocytes in the melanoma microenvironment can be associated with patient prognosis, 
but only in certain contexts. Combining markers providing information on the subsets of 
infiltrating T cells together with an assessment of the activation state of these cells (eg. 
measuring markers of exhaustion or activation) may increase the accuracy of this feature to 
predict patient prognosis. The potential prognostic differences associated with different 
populations of T cells are highlighted by one study in melanoma which showed an inverse 
association with patient survival for T lymphocytes, whereas longer survival was found when 
considering the degree of cells expressing the T cell activation marker CD69 (39). These 
findings highlight potential limitations in the widespread applicability of studies which 
propose TILs as markers of patient prognosis. For example, in the “immunoscore” studies 
performed in colorectal cancer, infiltration by CD3+ T cells alone were sufficient to use as a 
prognostic marker (8), but despite claims that melanoma is an immunogenic tumour type 
(43) no such associations were found in the present study. 
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Many mechanisms inducing T lymphocyte dysfunction have been identified, including 
suppression by regulatory T cells or through the expression of inhibitory ligands like PD-L1 on 
tumour cells or APCs (44, 45). These mechanisms have the potential to prevent optimal T cell 
function within the tumour microenvironment, suggesting that the prognostic value of such 
TILs is limited by the entire immunological context (both soluble and cellular) which 
influences the functional state of those cells. In accordance with this, we observed better 
survival in patients, whose tumours contained high levels of CD3+ cells in addition to low 
levels of CD15+ cells, suggesting that interactions between intra-tumoural leukocytes are 
important for their function and activation state. This notion is supported by a study 
showing that high levels of tumour-infiltrating CD8+ T cells are followed by recruitment of 
regulatory T cells into the tumour microenvironment, which might serve as a negative 
feedback mechanism following infiltration by cytotoxic T cells and thus may limit the 
prognostic accuracy of assessing cytotoxic T cells in isolation (46). In addition to the cellular 
context, we also observed a trend towards better survival in patients with high levels of 
CD3+ cells and low expression of the potentially immunosuppressive cytokine IL-10. 
Considering these data and the increasing clinical use of immunotherapies, more 
comprehensive analysis of the tumour microenvironment may be required to better predict 
patient outcome - especially as the clinical efficacy of immunotherapies has been shown to 
be associated with immune features of the tumour microenvironment in several cancer 
types (4, 11-18). In the context of immunomodulatory antibodies such as “checkpoint 
inhibitors”, the level of infiltrating lymphocytes and the expression of the target molecule 
has been shown to be important. For example Taube et al. found an association between 
the expression of PD-1 on tumour-infiltrating T cells and clinical response to PD-1 antibodies 
(47), which is in line with the observations by Chen et al.  who found higher expression of 
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PD-1 in patients responding to anti-PD-1 therapy as well as higher CD8+ infiltration in 
responder to CTLA-4 blockade at early on-treatment (48). As such, there is a need to 
understand the immune context in order to allow better treatment individualization or even 
the identification of new therapeutic targets. 
 
This was a pilot study investigating soluble and cellular immune parameters as potential 
combinatorial indicators of patient outcome in metastatic melanoma. The results of this 
study suggest that certain immune features either alone or in combination may be 
informative for patient prognosis in this cancer, regardless of the nature of patient pre-
treatment. Unlike commonly reported scenarios for other cancer types, T cell infiltration was 
not strongly associated with patient outcome, whereas granulocytic cells appear to be a 
more promising factor for the prediction of patient survival in melanoma. 
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Supplementary Data  1: Full set of correlations between soluble, cellular and transcription factors 
IL-6 GM-CSF r=0.733, p=0.000 
 TNF r=0.489, p=0.000 
 STAT3 r=0.462, p=0.001 
   
GM-CSF TNF r=0.444, p=0.007 
 STAT3 r=0.395, p=0.017 
 IL-1Ra r=0.475, p=0.014 
   
PGE2 Ratio CD15 margin/centre r=-0.408, p=0.031 
   
TNF STAT3 r=0.688, p=0.000 
 CD15 evenness r=0.32,  p=0.034 
   
STAT3 IL-2 r=0.421, p=0.008 
 IL-10 r=0.364, p=0.023 
 CD15 evenness r=0.349, p=0.02 
   
GDF15 IL-1Ra r=0.41, p=0.004  
   
IL-2 IL-10 r=0.503, p=0.000 
   
CD3 margin CD3 centre r=0.765, p=0.000 
 CD3 total r= 0.959, p=0.000 
 CD3 ratio margin/centre r=0.362, p=0.026 
 CD3 evenness r=0.913, p=0.000 
 CD15 evenness r=0.296, p=0.033 
   
CD3 centre CD3 total r=0.89, p=0.000 
 CD3 ratio margin:centre r=-0.52, p=0.001 
 CD3 evenness r=0.874, p=0.00 
 CD15 margin r=0.312, p=0.025 
 CD15 evenness r=0.293, p=0.035 
   
CD3 total CD3 evenness r=0.935, p=0.000 
 CD15 margin r=0.294, p=0.034 
 CD15 centre r=0.276, p=0.047 
 CD15 evenness r=0.308, p=0.026 
   
CD3 evenness CD15 margin r=0.284, p=0.041 
 CD15 centre r=0.275, p=0.048 
 CD15 evenness r=0.307, p=0.027 
   
CD15 margin CD15 centre r=0.600, p=0.000 
 CD15 total r=0.847, p=0.000 
 CD15 ration margin/centre r=0865, p=0.000 
 CD15 evenness r=0.830, p=0.000 
   
CD15 centre CD15 total r=0.880, p=0.000 
 CD15 ratio margin/centre r=0.528, p=0.000 
 CD15 evenness r=0.792, p=0.000 
   
CD15 total CD15 ratio margin/centre r=0.740, p=0.000 
 CD15 evenness r=0.914, p=0.000 
   
CD15 ratio margin/centre CD15 evenness r=0.729, p=0.000 
 
